University of Mississippi

eGrove
Electronic Theses and Dissertations

Graduate School

2011

Use of Structure-And Ligand-Based Drug Design Tools for the
Discovery of Small Molecule Inhibitors of Cysteine Proteases for
the Treatment of Malaria and Sars Infection
Falgun Shah

Follow this and additional works at: https://egrove.olemiss.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Shah, Falgun, "Use of Structure-And Ligand-Based Drug Design Tools for the Discovery of Small Molecule
Inhibitors of Cysteine Proteases for the Treatment of Malaria and Sars Infection" (2011). Electronic
Theses and Dissertations. 260.
https://egrove.olemiss.edu/etd/260

This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more
information, please contact egrove@olemiss.edu.

USE OF STRUCTURE-AND LIGAND-BASED DRUG DESIGN TOOLS FOR THE
DISCOVERY OF SMALL MOLECULE INHIBITORS OF CYSTEINE PROTEASES FOR
THE TREATMENT OF MALARIA AND SARS INFECTION

A Dissertation
Presented for the
Doctor of Philosophy
In
Pharmaceutical Sciences
The University of Mississippi

Falgun Shah
November 2011

Copyright © 2011 by Falgun Shah
All rights reserved

ABSTRACT
A wide array of molecular modeling tools were utilized to design and develop inhibitors
against cysteine protease of P. Falciparum Malaria and Severe Acute Respiratory Syndrome
(SARS). A number of potent inhibitors were developed against cysteine protease and
hemoglobinase of P. falciparum, referred as Falcipains (FPs), by the structure-based virtual
screening of the focused libraries enriched in soft-electrophiles containing compounds. Twenty
one diverse, non-peptidic, low micromolar hits were identified. A combined data mining and
combinatorial library synthesis approach was performed to discover analogs of virtual screening
hits and establish the structure-activity relationships (SAR). However, the resulting SAR of the
identified hits was unusually steep in some cases and could not be explained by a traditional
analysis of the interactions (electrostatics, van der Waals or H-bond). To gain insights, a
statistical thermodynamic analysis of explicit solvent in the ligand binding domain of FP-2 and
FP-3 was performed that explained some of the complex trends in the SAR. Furthermore, the
moderate potency of a subset of FP-2 hits was elucidated using quantum mechanics calculations
that showed reduced reactivity of the electrophilic center of these hits. In addition, solvent
thermodynamics and reactivity analysis also helped to elucidate the complex trends in SAR of
peptidomimetic inhibitors of FP-2 and FP-3 synthesized in our laboratory. Multi nanosecond
explicit solvent molecular dynamics simulations were carried out using the docking poses of the
known inhibitors in the binding site of SARS-3CLpro, a cysteine protease important for
replication of SARS virus, to study the overall stability of the binding site interactions as well as
ii

identify important changes in the interaction profile that were not apparent from the docking
study. Analysis of the simulation studies led to the identification of certain protein-ligand
interaction patterns which would be useful in further structure based design efforts against
cysteine protease (3CLpro) of SARS.
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LIST OF ABBREVIATIONS
3Clpro = 3C-like protease, C=Chymotrypsin
ADME = Absorption, Distribution, Metabolism, Elimination
Boc = t-butyloxycarbonyl
Cat = Cathepsins
Cbz = Carboxybenzyl
DMF = Dimethylformamide
EDCI = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
FCPI = Focused cysteine protease inhibitor library
Gscore = Glide score
HOBT =Hydroxybenzotriazole
HOMO = Highest occupied molecular orbital
HRMS = High resolution mass spectroscopy
HTS = High throughput screening
FMK = Fluoro methyl ketone
FP-2 = Falcipain-2
FP-3 = Falcipain-3
LBD = Ligand binding domain
LUMO = Lowest unoccupied molecular orbital
MD = Molecular dynamics
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M pro = Main protease
MLR = Multiple linear regression
MM-GBSA = Molecular mechanics Generalized Born surface area
MM-PBSA = Molecular mechanics Poission-Boltzmann surface area
NMR = Nuclear magnetic resonance
ORF = Open reading frames
OPLS = Optimized potential for liquid simulation
PDB = Protein data bank
P. falciparum = Plasmodium falciparum
PP = polyprotein
QSAR = Quantitative structure activity relationships
RMSD = Root mean square deviation
SAR = Structure-activity relationships
SARS = Severe acute respiratory syndrome
SBVS = Structure-based virtual screening
TEA = triethylamine
W2 = Chloroquine-resistant strain of P. falciparum
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Chapter 1

Targeting Cysteine Protease of P. Falciparum
Malaria and SARS for Drug Discovery

Content of this chapter is published in: Shah, F., Mukherjee, P., Desai, P., Avery M. A.,
Computational approaches for the discovery of cysteine protease inhibitors against Malaria and
SARS. Current Computer Aided Drug Designing, 2010, 6, 1.
1

1.1. Introduction
Proteases are an important class of enzymes involved in the hydrolysis of peptide bonds
in protein. Proteases can be subdivided into five major categories based on their mechanism of
peptide hydrolysis: Aspartic, Serine, Cysteine, Threonine and Metalloprotease 2. They play a
vital role in a variety of cellular and physiological events in lower order, viruses extending up to
higher organisms including humans, making them attractive targets for further considerations 3.
Among these proteases, cysteine proteases, with their unique mechanism and diverse array of
functions, have become important targets for drug design.
Cysteine proteases are classified in three structurally distinct groups, namely papain-like
(e.g., clan CA, the cathepsins, falcipain), ICE-like (e.g., clan CD, the caspases) and picornainlike (e.g. clan PA (C), SARS 3CLpro) 4. Different cysteine proteases are associated with a variety
of clinical conditions in humans, for example, Caspase-I (psoriasis, inflammation), Cathepsin S
(autoimmune or inflammatory disorders) and Cathepsin K (osteoporosis) 5. They are also present
in the life cycle of protozoa, for example, falcipain from P. falciparum (malaria) and cruzain
from T. cruzi (chaga‟s disease), as well as in viruses such as HRV 3CLpro from the rhinovirus
(common cold)

6

and SARS 3CLpro, an etiological agent responsible for the Severe Acute

Respiratory Syndrome (SARS) infection 7.
The proteolytic mechanisms of cysteine proteases involve a nucleophilic attack of the
thiolate anion from the catalytic cysteine on the carbonyl carbon of the labile peptide bond. This
leads to the formation of an acyl-enzyme (tetrahedral) intermediate, stabilized by the hydrogenbonding to the residues of the oxyanion hole. Subsequent hydrolysis of the tetrahedral
intermediate releases the free enzyme 3. Although, selectivity among the members of cysteine
protease from the same family is of great concern, some inhibitors have now entered into various
2

phases of pre-clinical or clinical development 5, which has attracted the attention of researchers
for further drug design against this target.
The present chapter highlights various rational approaches adopted for the discovery of
peptidic and non-peptidic inhibitors against parasitic cysteine proteases: falcipains, a papain-like
protozoal cysteine protease, and SARS 3CLpro, a chymotrypsin-like viral cysteine protease.
Although these two proteases are quite different from each other in structure and specific
biological functions they exhibit in protozoa or virus, similarity exist in drug design approaches
against both proteases. The drug design approaches discussed below include knowledge-based
drug

design,

structure-guided

drug

design,

virtual

and

high-throughput

screening,

peptidomimetic design and natural product-based drug discovery that provide an absolute
understanding of drug discovery process against both the targets. Particular emphasis has been
given to the computational approaches adopted for the design of inhibitors or understanding the
mechanism of inhibitor binding. The drug design strategies discussed in the next sections are
introduced here briefly in the context of cysteine proteases.
Knowledge-based drug design initiates drug discovery efforts based on the similarity of a
cysteine protease under consideration with other members of the same or different protease
family. This approach merges information obtained from the knowledge of the substrate
requirement of a given protease with the known inhibitors of the homologous proteases while
design of inhibitors against the protease under consideration. Knowledge-based drug design is
particularly important when only a limited option exists for the treatment against a particular
disease. For example, during the outbreak of SARS, in the absence of efficacious drugs,
analogues of rupintrivir (a rhinovirus

protease inhibitor belonging to the C3 family and

3

approved for the clinical trials in humans for treatment of cold) served as a starting point for the
drug design against SARS-CoV Mpro (member of the C30 family of cysteine proteases) 8.
Structure-guided drug design considers the design of the inhibitors based on the X-ray
crystal structure 9-11 or homology model of the given protease

12, 13

taking into consideration the

nature of the specificity subsites and interactions with the key residues of the active site.
Rupintrivir developed by Pfizer Inc. is the best example of the application of structure-guided
drug design in lead discovery

14

. Peptidomimetics design against cysteine protease usually

involves an address element that mimics the natural peptide sequence and sometimes the
secondary structures of protein such as β-turn 15. The addressing element is important for subsite
recognition and binding to the target enzyme. A warhead group or electrophilic deficient center
is present in addition to the addressing element, which replaces the scissile amide bond of the
substrate and is capable of reacting in reversible or irreversible fashion with the active site thiol
16

. Improved pharmacokinetics properties of the peptidomimetics due to their stability against

hydrolytic enzymes as well as reduced toxicity to the human host suggest the preference of
peptidomimetics design over the natural peptide 17.
Highthroughput screening (HTS) provides an opportunity to simultaneously screen a
large number of compounds originated from the diverse chemotypes with the help of a sensitive
and robust assay method18. Structure-based virtual screening involves in silico evaluation of a
database of molecules against an experimentally determined structure or a homology model of
protein target using a docking program. The docking poses thus obtained are ranked based on a
scoring function to identify putative binders. Thus, only a small set of compounds are selected
and evaluated in a biological assay as compared to the high throughput screening of an entire
compound library 19.
4

The following sections describe comprehensive drug discovery efforts conducted against
FPs and SARS-3CLpro based on rationale drug design approaches discussed above. The drug
development strategies described below could also be applied for the design of inhibitors of
cysteine protease present in existing and future emerging pathogens, humans or design of
inhibitors for all cysteine proteases in general.
1.2. Malarial cysteine protease “falcipain”: genesis, function and structural requirements
Malaria is a global health issue, causing close to a million deaths annually according to recent
death statistics from the World Health Organization (WHO) 20. It is caused by four major species
of the Plasmodium (P) genus in humans: P. falciparum, P. vivax, P. ovale, and P. malaria. The
most virulent strain of malaria-causing pathogen is P. falciparum, responsible for the highest
morbidity, mortality and spread of the disease 21. The regions where malaria is endemic include
tropical and subtropical regions of Africa, Asia and South America.22. Falciparum malaria is a
particular threat for Africans, especially children under the age of five. Approximately 90% of
malaria cases are reported from developing countries in Asia, South America, and Sub-Saharan
Africa, and so there is a particular need for inexpensive, easy to use, and well-tolerated malaria
treatments23. A number of drugs are currently available to treat malaria24, however, treatment is
complicated by the toxicity, high cost, and diminishing efficacy of different agents. The first
known treatment of malaria occurred in 1631 with the bark of the cinchona tree, from which
quinine was later purified25. As quinine is not well tolerated, new therapeutics were developed,
including chloroquine and related aminoquinolines, antifolates, and mefloquine. However,
strains of P. falciparum resistant to all these therapeutics have been observed.26-28 Artemisinin, a
natural product from Artemisia annua, and its derivatives have been identified as rapidly active
5

and highly efficacious antimalarials28. In recent years the standard of care for the treatment of
uncomplicated falciparum malaria has moved to artemisinin-based combination therapy,
including an artemisinin component (artesunate, artmether, or dihydroartemisinin) combined
with a longer acting agent29. However, P. falciparum strains have been found showing decreased
responsiveness to artemisinin therapy, in particular near the Thailand-Cambodia border26. This
finding validates a continued need for effective alternative therapeutics targeting key pathways in
the life-cycle of malaria parasites.
Several proteases play an essential role in the life cycle of the P. falciparum, which
includes aspartic protease “plasmepsins”, cysteine protease “falcipains” and the metalloprotease
“falcilysin” 30-32. Among these proteases, falcipains have gained increasing attention due to their
critical roles in the survival of protozoa. The P. falciparum genome contains 33 open reading
frames (ORFs) expressing four different cysteine proteases of the papain family (clan CA),
collectively known as falcipains

33-36

. These include falcipain-1 (FP-1), falcipain-2 (FP-2),

falcipain-2‟ (FP-2‟) and falcipain-3 (FP-3) 37.
The biological roles of falcipains are reviewed elsewhere in detail38. In brief, their
suggested roles involve erythrocytic invasion, hydrolysis of hemoglobin and erythrocytic
rupture. Among FPs, FP-2 and FP-3, encoded by nearby genes, are localized to the P. falciparum
food vacuole, the site of hydrolysis of large quantities of hemoglobin by erythrocytic parasites.
FP-2 and FP-3 have been shown to be hemoglobinases38, and they appear to be responsible for
the hydrolysis of the host erythrocyte hemoglobin to provide amino acids required for protein
synthesis in protozoa34,

36, 39

. Knockout of FP-2 led to parasites with diminished hemoglobin

hydrolysis39. Knockout of FP-3 was not possible, strongly suggesting that this protease is
6

essential for erythrocytic parasites37. Functions of the other falcipains are less well understood.
FP-1 activity was associated with erythrocyte invasion by P. falciparum merozoites40, but
knockout of the protease did not alter erythrocytic parasites41, and its primary function is more
likely in mosquito-stage parasites42. FP-2' is a near-identical copy of FP-2, but knockout of FP-2'
had no apparent phenotype, indicating that the protease is not essential37. In particular, inhibition
of FP-2 and -3 by covalent irreversible cysteine protease inhibitors blocked hemoglobin
hydrolysis and formed characteristic swollen, dark-stained food vacuoles due to accumulation of
unhydrolysed globin43,

44

. These morphological abnormalities are typical characteristics of

cysteine protease inhibition not elicited by inhibitors of other food vacuole proteases such as
aspartic protease45. In any events, inhibition of FP-2 and FP-3, blocks parasite development,
enabling these enzymes as viable targets for the development of antimalarial chemotherapy.
During the early phases of the drug discovery against these plasmodial hemoglobinase in
the absence of the X-ray crystal structure, several homology models were reported
Multiple crystal structures of FP-2 and FP-3 became available later on

49-52

13, 46-48

.

which not only

revealed the overall topology of FP-2 and FP-3 but also provided an opportunity to rationally
explore the structural determinant of falcipains

49

. The crystal structure of FP-2 (3BPF, protein

data bank (PDB) code) shown in Figure 1.2.1a) has been discussed briefly here. FP-2 has a
distorted ellipsoidal shape, a typical attribute of the papain-like cysteine proteases. In addition to
a classic papain-like fold, FP-2 has two distinct domains, left domain (L) and right domain (R)
(Figure 1.2.1a). The L domain is made up of α-helices whereas the R domain is mainly
composed of antiparallel β-sheets

49

. Both FP-2 and FP-3 have two unique structural features

designated as N-terminal extension and hemoglobin binding insert that distinguish them from all
7

other structurally characterized papain family enzymes

50

. N-terminal extension is involved in

the folding of enzyme into its mature form whereas hemoglobin binding insert captures the host
erythrocyte hemoglobin

49

. The substrate-binding site is located at the junction of these two

domains bearing a catalytic triad formed by Cys-42, His-174 and Asn-204. Figure 1.2.1b
displays a magnified view of the substrate-binding site of FP-2 in complex with an irreversible
epoxysuccinate (E-64) inhibitor. Subsites S1, S1‟, S2, S3 and the P1, P1‟, P2 and P3 side chain
of E-64 are shown in Figure 1.2.1b.
Both FP-2 and FP-3 share a high sequence identity of 66.7%

50

. The homology models

and the X-ray crystal structures of FP-2 and FP-3 revealed major differences in the S2 pocket of
the active site with more flexible Glu 243 in FP-3 as compared to Asp 234 in FP-2 as well as
bulkier Tyr 93 in FP-3 with corresponding Leu 84 in FP-2

13, 50

. The presence of the bulkier

residues narrow down the S2 binding pocket of FP3 as compared to FP2 and might be
responsible for the kinetic difference between these closely related enzymes

50

. These two

proteases contribute almost equally to the hemoglobin degradation with the former expressing at
the earlier stages in the life cycle of protozoa 36. The similarity in the functions exhibited by FP2, FP-2‟ and FP-3 point towards the combined drug discovery efforts against these subtypes 35, 53.
Substrate-cleavage assays suggest marked preference for hydrophobic residue, particularly Leu
at P2 for FP-2

34

and FP-3

36

. These studies gave important insights for the designing of

inhibitors against both the enzymes.
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Fig. 1.2. (a) Overall topology of FP-2; (b) Magnified view of the substrate-binding pocket of FP2 with co-crystallized ligand E-64. Subsites S1, S1‟, S2 and S3 of the enzyme (black), the P1,
P1‟, P2 and P3 side chains of E-64 (red) and residues of FP-2 binding sites (white) are shown.
1.3. Drug Design Approaches Against FPs
1.3.1. Knowledge-Based Drug Design
The drug design efforts were initiated against FPs with the previous knowledge of
inhibitors of other cysteine proteases such as papain, cathepsins, calpain, and cruzain having
reversible electrophilic isostere such as peptidic aldehyde

54

, α-keto carbonyl

well as irreversible warhead groups such as halo methyl ketones

58

55, 56

, nitriles

, epoxysuccinyl

59

57

as

and

vinylsulphones 60 etc.
Early efforts for the validity of FP-2 (formerly known as trophozoite cysteine proteinase
or TCP) by Rosenthal and colleagues as a possible chemotherapeutic target led to the evaluation
of a panel of peptidyl fluoromethyl ketones (FMKs) against TCP. Benzyloxycarbonyl (Z)-PheArg-CH2F (1, Figure 1.3.1), was found to inhibit TCP proteolytic activity in the sub-nanomolar
concentration (IC50 = 0.36 nM) and parasite killing (IC50 = 64 nM) in the nanomolar range 43. In
addition, Morpholine urea (Mu)-Phe-Homophe(HPhe)-CH2F (2), one of the FMK inhibitors,
cured 80% of P. vinckei-infected mice under test conditions having biochemically similar
9

cysteine protease as P. falciparum 61. However, severe toxicity associated with the use of FMKs
in animal models restricted their further development 62.
Epoxysuccinyl peptides derived from E-64 (3, Figure 1.3.1) containing transepoxysuccinic acid as electrophilic element are selective inhibitors of cysteine proteases from the
papain superfamily and involve the irreversible activation of the enzyme by alkylation of the
active site cysteine 63. Several groups have reported the efficacy of E-64 and its derivatives as an
antiplasmodial agent with activities in the nanomolar range against falcipains as well as cultured
parasites

34, 43, 64, 65

. However, their lack of selectivity against different members of the papain

family limits their further development as drugs.
Various mechanism-based vinylsulphone inhibitors were reported against closely related
cysteine proteases during the late 90‟s 60. Rosenthal et al. performed the synthesis of a previously
identified potent cysteine protease inhibitor 4 as well as closely related compounds with different
side chains of P1 and P2 amino acids and evaluated the antimalarial potential of vinyl sulphones
62

. Among the synthesized compounds, compound 4 effectively inhibited the P. falciparum

(IC50= 3 nM) cysteine protease as well as blocked hemoglobin hydrolysis and development of
parasites at nanomolar concentration. Further, orally bioavailable derivatives of vinyl sulphones
were reported by replacing the morpholine urea group with the N-methyl piperazine urea

66

.

Also, the phenyl vinyl sulphone was replaced with a naphthalene vinyl sulphone. Compound 5
(IC50 of 5 nM for P. falciparum cysteine protease) was active in-vivo against murine malaria
(cured 40% of infected mice after oral doses of 50mg/kg twice a day)

66

. Shenai et al.

synthesized 39 new compounds having vinyl sulphones, vinyl sulfonamide and vinyl sulfonate
esters as warhead groups to establish the structure activity relationships 67. Inhibitors with Leu at
10

the P2 position and homophenylalanine (HPhe) at the P1 position displayed potent inhibitory
activity against both the enzymes as well as cultured parasites, which point towards importance
of these residues for substrate specificity against FP-2. Vinyl sulphonate esters were the most
active (compound 6, FP-2 IC50 = 0.9 nM, W2 IC50 = 9.7 nM), followed by vinyl sulfonamides
(compound 7, FP-2 IC50 =2.3, W2 IC50 = 4.4 nM), and finally phenyl vinyl sulfones (compound
8, FP-2 IC50 = 6.9 nM, W2 IC50 = 3.9 nM) among the synthesized series of compounds 67 (Figure
1.3.1). (Note: W2 and D6 stand for chlorquine resistant and chloroquine sensitive strains of the
P. falciparum, respectively).
Further, conformationally restricted analogues of sulfones were designed with vinyl
sulfone attached to the dipeptide sequence in order to improve their potency and metabolic
stability. Compound 9 with trans (E) geometry of the double bond inhibited the enzyme as well
as cultured parasite in micromolar range (FP-2 IC50 = 13.7 μM, W2 IC50 = 7.8 μM)

68

. The

substantial reduction in the activity of these compounds compared to corresponding acyclic
analogs (for example 4) prompted the authors to predict the binding mode of 9 in the active site
of the homologous enzyme, cruzain. The predicted conformation of compound 9 disfavored the
Michael addition of cysteine to the β-carbon of the vinyl-sultam due to interference of the ring
substitution on the α–carbon of the Michael acceptor and, therefore, could be responsible for a
lower activity 68 (Figure 1.3.1).
The most concerning drawback of vinyl sulphone inhibitors includes irreversible
alkylation of the active site cysteine residue by conjugate addition. To encounter these issues,
closely related peptides bearing reversible warhead groups such as aldehyde and α-ketoamide
were developed 69. Representative compounds from the aldehyde (compound 10 native FP-2 IC50
11

= 1 nM, W2 IC50 = 1.1 nM) and ketoamide series (compound 11 native FP-2 IC50 = 1 nM, W2
IC50 = 2.9 nM) are shown in Figure 1.3.1. Both of these compounds were active against multiple
strains of P.falciparum 69.
Phenolic Mannich bases were previously reported to possess anticancer as well as
antimalarial properties

70

. The bioactivities of these compounds were thought to involve in situ

generation of α, β-unsaturated ketones possessing a higher affinity for cysteine thiols. Also,
thiosemicarbazone scaffold-bearing compounds were reported to have a broad spectrum of
chemotherapeutic activity including anti-malarial activity 70. These compounds are Schiff bases,
having iron-chelator properties as well as acting as electrophilic warheads to attract cysteine
thiol. Chipeleme et al. appended the phenolic mannich base group to various (thio)
semicarbozaone entities and linked them with aminoquinolines (known to inhibit hemazoin
formation). Compound 12 from this series exhibited potent inhibition of FP-2 (IC50 = 0.63 μM)
and W2 strain of P. falciparum (IC50 = 0.27 μM, Figure 1.3.1) in the lower micromolar range 70.
Aziridines compounds are selective and irreversible inhibitors of cysteine protease. They
are aza analogues of epoxides

71

. These compounds were previously evaluated against the

cysteine protease of SARS, Leishmania, and Trypanosoma brucei, as well as cathepsin K, and
they inhibited the protease by covalent adduct formation with cysteine thiol of the active site.
Schulz et al. evaluated three class of aziridines, aziridine-2-carboxylic acid derivatives, Nacylated aziridine-2, 3-dicarboxylic acid derivatives and aziridines-2-carboxylate containing a
lysine residue, against FP-2 and FP-3 72. Two of the most active compounds, compound 12 from
the aziridines 2-carboxylate series (FP2 IC50 = 2.5 µM, FP3 IC50 = 3.8 µM, W2 IC50 = 9.7 µM)
and compound 13 from the N-acylated aziridine-2, 3-dicarboxylic acid series (FP2 IC50 = 0.079
12

µM, FP-3 IC50 = 0.25 µM, W2 IC50 = 0.43 µM) are shown in Figure 1.3.1 72.
Recently, a multiple ligand approach was reported against FP-2, which involved the
combination of artemisinin, a sesquiterpene lactone, and a potent antimalarial compound with
dipeptidyl vinyl sulphones via a linker to combat multi-drug resistance in P. falciparum malaria
73

. The compound 15 exhibited potent inhibitory activity of FP-2 (FP2 IC50 = 0.21 nM). Also, it

had a superior activity profile against multiple strains of malaria as compared to artemisinin and
chloroquine 73.

13

Figure 1.3.1. Representative peptidic inhibitors developed by knowledge-based drug design.
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1.3.2. Structure-Guided Drug Design
Sabnis et al. developed homology models of FP-2 and FP-3 and validated these models
with the help of various structures/geometry tools as well as by the docking of substrate/known
vinyl sulphone inhibitors

13, 46

. The validated model was used to design novel non-peptidic

analogs having clinically validated isoquinolines core. Two compounds were designed based on
the intuitions from the docking studies. In-vitro evaluation of these compounds against FP-2
showed activity in the micromolar range (most active compound 16 with FP-2 IC50 of 8 μM)13.
Several isoquinolines and dihydroisoquinolines analogs were designed to further optimize the
activity of compound 16, considering the interaction of designed analogs with Asp234 of the S2
pocket as essential

12

. The synthesized compounds vary in the IC50 range from 3 to 10 μM

(representative compound 17, FP2 IC50 = 3μM, Figure 1.3.2). Docking predictions of the
compounds from these series were in an excellent agreement with the in-vitro activity, having
correlation coefficient of 0.94.
Goud et al. addressed the de-novo design of novel non-peptidic inhibitors bearing the
thiazoline scaffold 74. The thiazoline core was chosen because of the favored key interactions and
the spatial arrangement of the designed trisubstituted thiazoles in the active site of FP-2. Also,
the thizaole core was able to gain a planar conformation and could mimic the amino acid portion
of the peptide bond in the molecular modeling studies. In addition to this, docking studies
predicted a similar binding mode and interaction energies of these designed thiazole compounds
to the known vinyl sulphone inhibitors. This led to the dedicated synthesis and biological
evaluation of a series of trisubstituted thiazole analogs against FP-2 and FP-3

74

. Compound 18

was a dual inhibitor of both enzymes (FP-2 IC50=6.6 μM, FP-3 IC50=29.4 μM) as well as
15

showing activity against cultured malarial (W2 EC50= 13.8) and leishmanial parasites (EC50= 4.5
μM) (Figure 1.3.2).

Fig.1.3.2. Representative non-peptidic inhibitors developed by structure-guided drug design.
1.3.3. Peptidomimetics Design
Verissimo et al. undertook modeling studies to compare the low energy conformations of
their proposed peptidomimetics with vinyl sulphone inhibitor 4 by substituting leucine at P2 of
vinyl sulphone with pyridone75. Their designed molecules adopted a similar low energy
conformation to that of a vinyl sulphone inhibitor in 3D space. Synthesis of the designed
peptidomimetics with pyridone as a P2 recognition element and different electrophilic isostere at
P1‟ positions were performed. Compounds 19 and 20 with aldehyde and vinyl sulphone warhead
groups showed an IC50 value of 10.9 μM and 19.0 μM, respectively, against FP-2

75

(Figure

1.3.3). Although molecular modeling studies showed an excellent overlay of the peptidic
counterparts of these compounds, the lower activity of the designed compounds suggested that
the rigid pyridone moiety chosen was not suitable for the backbone modifications.
Nicola et al. designed aldehyde-based peptidomimetics with benzodiazepines (BDZ)
scaffold as a mimetic of the fragment D-Ser-Gly of peptide and the aspartic aldehyde building
block at C-terminal that was known to form a reversible covalent bond with the enzyme active
16

site

76

. They also considered the excellent bioavailability, tolerability and β-turn mimetic

properties of BDZ scaffold in their peptidomimetics design. Effort towards the synthesis of the
designed peptidomimetics discovered compound 21 with IC50 of 10.29 μM and 19.31 μM against
FP-2 and FP-2‟, respectively. Also, these compounds were selective to malarial protease as
evident by their inactivity against recombinant human caspases 1-9 for up to 50 μM
concentration 76.
Further, the P1 and P1-P1‟ positions of the most active compound 21 were modified to
explore the structural requirements for this class of peptidomimetics. The aspartic aldehyde
building block at the P1 position of 21 was replaced with an electrophilic vinyl sulphone moiety
spanning the P1-P1‟ position (for covalent trapping of cysteine thiol of the active site) with
different aromatic substitution (to explore the size and characteristics of the lipophilic P1‟
pocket)

15

. A second modification involved HPhe at the P1 position (a residue known to boost

the potency of FP-2 inhibitors) and, finally, the placement of glycine (Gly) at the same position
(to evaluate the process of ligand recognition as well as its impact on inhibitory kinetics by the
enzyme) 15. As expected, compounds with the HPhe at P1 position showed higher second order
rate constant as compare to glycine at the same position

15

. The representative compound (22,

Figure 1.3.3) from this series showed the highest inhibition of FP-2 coupled with good inhibition
potency against the cultured parasites (W2 IC50 = 9.1 μM). Attempts were made to replace the
vinyl sulphone moiety with vinyl phosphates, but only resulted in compounds exhibiting poor
activity and selectivity profile 77. Recently, another strategy presented by the same group focused
on the evaluation of the strength and efficacy of different α, β–unsaturated electrophilic
withdrawing groups such as vinyl-ketones, amides, esters and nitriles against cysteine thiol
17

77

.

Among the synthesized compounds, vinyl ester 23 displayed potent inhibition of FP-2 (Ki = 17
nM) as well as significant inhibition of the P. falciparum FCBR strain (IC50 = 12 μM). However,
this compound was also selective towards human cysteine protease, cathepsin B and L.

Fig.1.3.3. Representative peptidomimetics developed against FP-2 and FP-3.
1.3.4. Structure-Based Virtual Screening
This section will review the discovery of the non-peptidic inhibitors developed against
FP-2 and FP-3 by a structure-based virtual screening approach. Table 1.3.4 summarizes the
commercial databases, methods, softwares and scoring functions used for virtual screening, hit
ratio along with chemical structures of hits obtained.
Ring et al. initiated the structure-based virtual screening efforts against cercarial elastase
(a serine protease responsible for schistosomiasis) and TCP using a developed homology model
78

. An earlier version of DOCK was used to screen the fine chemical directory of ~50,000

compounds. A total of 8800 molecules were retained after the initial phase of docking,
considering the shape complementary and force field-based scoring scheme. In the final stage of
visual inspection, compounds exhibiting good fitness as well as potential H-bonding and
electrostatic interactions were retained with reduced priority on the scoring scheme. A total of 31
18

compounds were biologically evaluated against TCP. All four inhibitors identified against TCP
and cercarial elastases were from the shape-based and force field-based scoring scheme,
respectively. The shape-based scoring functions worked well for the hydrophobic site of TCP
whereas force-field based scoring performed well for the charged amino acid cavity (polar) of
cercarial elastase. Compound 24, obtained with the shape-based scoring scheme, was found to
have an IC50 value of 6 μM against TCP (Table 1.3.4, raw 1). The docking pose of 24 showed
one naphthol group occupying the S2 pocket whereas another naphthol group was found to
interact with the Trp173 of the S1‟pocket

78

. Further, structural modifications of compound 24

were carried out to reduce the conformational flexibility, enhance water solubility and
electrostatic interactions, improve overall chemical/metabolic stabilities and to analyze the size
and electronic characters of the subsite specificity pocket

79

. The structural modifications

resulted in a synthesis of a series of novel chalcone derivatives with good potency against the
W2 and D6 strains of P. falciparum. (Representative compound 25, W2 IC50 = 0.24 μM, D6 IC50
= 0.19 μM). Molecular modeling tools as well as experimental assay revealed the inhibitory
action of this compound by the inhibition of TCP 79 (Table 1.3.4, raw 1).
Joachimiak et al. developed a homology model of FP-2 using the X-ray crystal structure
of cathepsin K zymogen (PDB code: 1BY8) as a template for virtual screening of compounds
from the Available Chemical Library (ACD) using DOCK 4.0 47. 5000 compounds were retained
from the energy and shape-scoring schemes implemented in DOCK after initial docking. The
final selection of the set of compounds was based on the knowledge of the specificity sites of FP2 along with the consideration of drug-like properties of small molecules (such as
hydrophobicity, molecular weight and absence of reactive chemical functionalities with the
tendencies to form covalent bond). A set of selected compounds were evaluated in a
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fluorescence-based assay using a recombinant FP-2 enzyme. Eight inhibitors 26-33 were
identified (IC50 of 1 to 7 μM. Table 1.3.4, raw 2) in the enzyme assay, three of which 28, 29, 33
were also active against the chloroquine resistant (W2) strain of P.falciparum (IC50 range < 26
μM) 47.
FP-2, FP-3, cruzain and cysteine protease from Leishmania donovani (L. donovani) share
more than 40% homology in their mature domain and about 90% in the binding sites

33

. To

identify a broad spectrum inhibitor against these protozoa, Desai et al., screened the
CHEMBRIDGE database against homology models of FP-2 and FP-3 developed in their
laboratory

13, 46, 80, 81

. Protein preparation for screening was carried out at pH 5 to mimic the

acidic environment of the food vacuole of P. falciparum, where the enzyme is located. Prior to
the docking studies, the database was processed to eliminate metal and counter ions, neutralize
charged molecules, eliminate compounds with poor ADME properties and identify compatibility
with the Lipinski rule. The docking protocol was pre-validated by predicting the experimental
pose of a vinyl sulphone inhibitor in the available crystal structure of cruzain (1F2A, PDB code).
The filtered databases were subjected to docking using GOLD software in three different
settings: 7-8 times speed up mode, 2 times speed up mode and standard mode. As docking of the
large databases can be computationally expensive, multispeed docking protocol was adopted to
discard the compounds quickly in the initial stages, retaining only those which were
complementary to the binding site topology. In the consequent stages (with the standard docking
mode), more exhaustive docking runs were performed for predicting the binding modes and
interactions of the remaining compounds with the active site. Considering the high sequence
similarity in the active sites of these two enzymes with major differences in the size of S2 pocket
20

(narrower in FP-3 as compared to FP-2), it was thought that the compounds binding to FP-3
would most likely fit into FP-2. Hence, the initial two rounds of docking were only conducted in
FP-3 to reduce the computational time. The top 10% of compounds at the end of the second run
were docked in both homology models using more rigorous standard mode of GOLD. Ten vinyl
sulphone inhibitors were seeded as a positive control for periodic measure of the docking
procedure efficiency at each stage. Finally, the top common hits for the two enzymes were
visually inspected based on the geometry of the binding pose, proximity of the electrophilic
center of the ligand to the catalytic cysteine and complementarity between ligand and protein
surfaces in terms of spatial occupancy and hydrophobic/hydrophilic contacts. After visual
inspection, eighty four compounds were biologically evaluated, twenty four of which showed
inhibition against one or more cysteine protease. Twelve compounds were found as dual
inhibitors of FP-2 and FP-3 (for example: 34-41, IC50 range: 1 to 63.4 μM for FP-2, 4.9 to 62.2
μM for FP-3, Table 1.3.4, raw 3), with compound 34 having the highest dual activity. Compound
40 showed an excellent profile against the chloroquine-sensitive (D6) and chloroquine resistant
(W2) strains of P. falciparum, (W2 IC50 = 6.6 μM, D6 IC50 = 6.9 μM), falcipains (FP-2 IC50 =
4.6 μM, FP-3 IC50 = 5.8 μM), L. donovani cysteine protease and L. donovani promastigotes with
IC50 values of 112.9 and 8.8 µM, respectively. Compound 40, along with other compounds (for
example, 34 and 35), suggested the possibility of developing broad spectrum antiprotozoal drugs
80

(see Table 1.3.4, raw 3).
Desai et al. adopted similar protocol as described before using the ACD in their second

attempt of virtual screening against parasitic cysteine proteases

81

. Additionally, a toxicity filter

was added in the initial processing of the database to remove potentially toxic functionalities
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such as N-oxides, aldehydes, nitrogen and sulfur mustards, chloramines and isocyanides. The
study led to the identification of 22 non-peptidic small molecule inhibitors of the parasitic
cysteine protease, 18 were active against falcipains (representative examples 41-47 in Table
1.3.4, raw 3, IC50 range: 1.4-54.3 μM), out of which eight compounds were common inhibitors
of FP-2 and FP-3 (the most active compound 41, FP-2 IC50= 1.4 μM, FP-3 IC50= 11.4 μM). Four
compounds inhibited L. donovani cysteine protease in micromolar concentration, and six
compounds exhibited in-vitro inhibition of both P. falciparum and L. donovani promastigotes in
the micromolar range (the most active compound 48, W2 IC50 = 0.44 μM,

L. donovani

promastigotes IC50= 7 μM). Further, to identify common features of the diverse hits active
against FP-2, a pharmacophore model was proposed using a Hip-Hop module of Catalyst. A
four-feature hypothesis, which correlated well with the ligand-receptor interactions observed in
the docking studies, was selected. The pharmacophoric features include two hydrogen bond
acceptors and two hydrophobic regions. Mapping of the chemical features of previously
identified FP-2 hits (from the chembridge database) on the developed model showed good fitting
for more than 60% of the FP-2 inhibitors identified from the previous study. However, the
developed model was unable to distinguish compounds with dual inhibitory (FP-2 and FP-3)
activity from the exclusive inhibitors of FP-2 81 (Table 1.3.4, raw 4).
Recently, a successful application of virtual screening was reported by Li et al. using two
parallel docking routes with Glide and GAsDock docking programs to screen the SPECS
database against the crystal structure of FP-2 (2GHU, PDB code)

82

. The rationale behind the

screening of the database with two different docking programs was to highlight and explore the
different aspects of the ligand binding. All the compounds were initially subjected to drug-like
22

filters

83

. The top thousand compounds were selected from both routes after ranking the

compounds with the Glide score (GScore) in case of Glide standard precision (SP) docking and
with the energy score in GAsDock. Redocking of the compounds obtained after the first step in
Glide docking was carried out with the more accurate Glide extra precision (XP) mode. The top
200 compounds selected based on the GScore were visually inspected for complementarity
between ligands and the hydrophobic S2 pockets and H-bond networks of ligands within the
active site. 53 compounds retrieved from the Glide docking run were evaluated against FP-2.
Similarly, after initial evaluation of the compounds with energy score of GAsDock, compounds
were reranked based on the consensus scoring function (CScore) of five. The top 154 compounds
thus selected were visually inspected using the criteria mentioned above. A total of 56
compounds obtained from the GAsDock route were purchased from SPECS. 28 non-peptide
molecules were identified from the pool of 81 compounds tested as non-peptidic inhibitors of
FP-2 with IC50 ranging from 2.7 to 52.4 μM (see representative compounds 49-54 in Table 1.3.4,
raw 5). The GAsDock outperformed the Glide in terms of hit ratios (38.8% for GAsDock and
31% for Glide) in this study. The authors concluded that GOLD and DOCK scores performed
well for apolar binding sites such as of FP-2 whereas FlexX and Chemscore-based GScore work
well for polar binding sites. Their conclusion was based on the previous reports by Desai et al. 80,
81

in conjunction with the analysis of binding site and the results obtained in their screening

82

.

Similarity analysis of the 28 active hits, calculated using the Tanimoto similarity index (average
value= 0.25), showed structural diversity in identified hits. The shape analyses of each pair of the
docked poses calculated using Ultrafast Shape Recognition (USR, which consider the shape of
the molecules based on the relative position of its atoms) showed an average similarity score of
23

0.73. This finding raised the possibility of discovering novel chemical scaffold against FP-2 with
similar steric shape and binding site requirements from chemically diverse datasets

82

. Further,

optimization and library synthesis of the most potent inhibitor 49 (FP-2 IC50= 2.7 μM) obtained
from the virtual screening resulted in compound 55 having an IC50 value of 1.46 μM 84. Due to
the ease of chemical modifications of compound 54, it was also considered for the library design
and synthesis. The most active from this series, 56, had an IC50 of 10.0 μM against FP-2
(Table 1.3.4, raw 5).

24

85

Table 1.3.4. Non-peptidic inhibitors identified against FP-2 by virtual screening approach

Database

Fine
chemical
library
(55,313)
78, 79

Available
chemical
library
(195419)
47

Chembridg
e
database,20
01 (241000)

Software/
Scoring
function

a
Hit
ratio
(%)

DOCK 3.0/
shape and
force field
based
scoring
method

12.9

Dock 4.0/
Energyscoring and
shapescoring
scheme

15.9

GOLD/
Gold score

28.5

GOLD/
GOLD
Score

22

Structure of the representative compounds

80

Available
chemical
library
(~355000)
86

25

SPECS
(~287000)
82, 84, 85

GLIDE
SP/XP/
GAsDock,
Energy
score,
Cscore

34.5

a

hit ratio is calculated by dividing the number of active hits retrieved against FP-2 by the number
of compounds evaluated in the biological assay. The number in bracket in database column
shows number of compounds available in the database at the time of virtual screening.

1.3.5. Natural Product-Based Drug Discovery
E-64,(N-(L-3-Trans-carboxyoxiran-2-carobnyl)-L-leucyl)-amido(4-guanido)butane),
isolated from the culture of Asperigillus japonicas, was an irreversible broad-spectrum inhibitor
of papain-like cysteine proteases (clan CA, family C1) (compound 3,)

63

. Recently, the X-ray

crystal structure of FP-2 was published in a complex with E-64 (shown in Figure 1.2) that
showed a covalent, irreversible hemithioketal formation between thiolate of Cys 42 in the FP-2
active site and the epoxy carbon of E-64 50.
Several chalcone derivatives were developed after the discovery of the antimalarial
activity of lipochalcone A, a natural product obtained from Chinese liquorice root
chalcone derivates exhibited potent antimalarial activity

79, 88, 89

87

. These

. Molecular modeling studies as

well as experimental evaluation of the chalcones indicated that they exert antimalarial activity
via multiple mechanisms, one of which involved the inhibition of FP-2. Representative
compound (57) from the chalcone series is shown in figure 1.3.5 (compound 57, FP2 IC50 = 1.8
μM) 90.
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Isatin represents a natural product from the plants of the Isatis genus, which was a
biologically validated starting point for the design and synthesis of chemical libraries against
cysteine and serine proteases

91, 92

. Several efforts were pursued to synthesize and evaluate the

Isatin derivatives against FP-2 as well as cultured parasites. Resultant compounds vary in range
from higher to lower micromolar activity

93, 94

. Representative members of this class are shown

in Figure 1.3.5 (compound 58, FP2 IC50 = 4.4 μM, compound 59, FP2 IC50 = 0.375μM). Both
compounds also inhibited cysteine proteases of trypanosomes, rhodesin and cruzain.

Figure 1.3.4. Natural product-based inhibitors of FP-2.
In brief, P. falciparum cysteine protease „falcipains‟, can be a promising target for the
development of novel malarial chemotherapy. Several peptidic inhibitors/peptidomimetics
mainly from vinyl sulphone class as well as structurally diverse non-peptidic inhibitors displayed
an excellent activity against falcipains and cultured parasites. Recently, published crystal
structures of FP-2-E-64 (epoxysuccinate inhibitor) and FP-3-leupeptin (peptidic aldehyde
inhibitor) provide more insights for structure guided drug designing. As noted before, the P2-Leu
and P1-HPhe boost the inhibitory potencies towards FP-2. In addition, the polar residues (Asp
234 and Ser 149 in FP-2, and Glu 243 and Ser 158 in FP-3) buried in the hydrophobic S2 pocket
should be considered while designing selective inhibitors against these enzymes. Also, difference
in the size of S2 pockets of FP-2 and FP-3, can be addressed for designing selective inhibitors of
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these enzymes, although, combined drug discovery efforts targeting different subtypes of
falcipains might be beneficial in reducing level of cultured parasites. Selection of suitable
scoring functions plays major role in structure-based virtual screening approach. Published
virtual screening studies against falcipains pinpointed suitability of GOLD and DOCK scoring
functions for apolar binding sites of FP-2 over GScore. These findings are particularly important
in future structure-based virtual screening studies against FP-2. Moreover, the sequence
similarity of falcipains with several homologous parasitic cysteine proteases can be used to
develop broad spectrum inhibitors against these targets as previously reported by our group 80, 81.
The cysteine proteases discussed here are of the utmost importance for drug design
considerations. For instance, several efforts are currently underway to develop effective
antimalarials for encountering the parasite resistance to all front line drugs, including the most
potent artemisinin derivatives 95. In such scenarios, falcipains manifests an emerging drug target
due to its unique function in hemoglobin degradation and survival of the protozoa. Moreover,
effective peptidic and non-peptidic inhibitors of falcipains (summarized above) with good
inhibitory potency project this enzyme as a promising target for the development of antimalarial
chemotherapy.
In the next sections, various drug design approaches adopted against highly pathogenic
SARS virus are discussed.
1.4. SARS cysteine protease “3CLpro or Mpro”: genesis, function and structural
requirements
SARS is a life threatening upper respiratory tract illness which reached an epidemic
status in 2003. Within the short span of a year, this disease proliferated from the Guangdong
28

province of China, where it originated, to 32 countries of Asia, North America and Europe. The
SARS epidemic infected nearly 8000 people and resulted in approximately 800 causalities from
November 2002 to August 2004

96-99

. A novel form of the coronavirus (CoV), SARS-CoV, was

identified as an etiological agent for the disease 7, 100-102.
The SARS-CoV genome has been reported to contain fourteen functional ORFs, which
provide accessories for encoding the proteins for virus replication and transcription. Two large
ORFs connected by a ribosomal frame shift constitute the replicase gene which transcribes two
overlapping polyprotein (pp), ppla (~450 kDa) and pplb (~750 kDa), necessary for
propagation

103

viral

. These polyproteins are cleaved by virus proteases to generate the functional

proteins required for replication of the virus. The SARS-CoV proteases responsible for this
function involve papain-like proteases (PLpro) and a chymotrypsin-like protease (3C-like protease
or 3CLpro) due to their distant relationship with 3C protease of picornaviruses. The 3CLpro is also
called

the main protease (Mpro) because of its dominant role in the processing of viral

polyproteins and control of replicase complex activity

103-106

. Due to the pivotal role of Mpro in

viral replication and infection process, the enzyme demonstrates itself as an attractive target for
the design of antivirals 8.
During the outbreak of SARS, several homology models of SARS Mpro were developed
by different groups shortly after its genome sequencing, based on its sequence similarity with
other known CoV-like proteases such as human CoV (HCoV) or porcine transmissible
gastroenteritis (TGEV)

8, 103, 107

. Within a short time of the outbreak, multiple crystal structures

of SARS Mpro were published 104, 108-117. The published structures revealed remarkable degree of
conservation in the substrate-binding sites during SARS mutation and provide an opportunity for
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the design and screening of inhibitors for anti-SARS activity.
The structure of the monomeric unit of SARS Mpro is shown in Figure 1.4a. SARS Mpro
is a functional homodimer in which each subunit is composed of three structural domains: I
(residues 8-101), II (residues 102-184), and III (residues 201-301). Domains I and II show a β–
barrel fold resembling trypsin-like serine protease whereas domain III is α-helical. The substratebinding site is located in a cleft between domains I and II. The enzyme is atypical cysteine
protease containing a catalytic dyad (His-41-Cys145) instead of a triad, which is required for
proteolytic activity

8, 116, 118

. The N-terminal is comprised of seven residues (N1-N7) known as

“N-finger”. A 16-residue loop (residues 195-200) forms a bridge between domains II and III (see
fig.1 (a)). While domains I and II are important for catalytic activity, domain III plays an
essential role in the dimerization of Mpro and the maintenance of quaternary structure

116, 119, 120

.

N-finger is more important for enzyme activity than dimerization as confirmed by site-directed
mutagenesis or deletion studies 118, 121-123. Figure 1.4b shows the magnified view of the active site
of SARS-CoV Mpro with co-crystallized peptidic ligand (2AMD, PDB code) 115.

T 190

R 188 M 49

P5

Q 189

Domain I

His 41
Cys 145

Q 192

P4

S2

T 25

P2

S4

Domain II
C

L 167
N-finger

H 41
S1’
P1’

P3

P 168
Domain III

Y 54

A 191

C 145

P1

E 166
H 172

L 27

M 165

S1

H 163

N 142

F140

Fig.1.4 a) The overall topology of SARS 3CLpro. Individual domains, N-finger and catalytic
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residues, Cys 145 and His 41 are shown; b) magnified view of the substrate-binding site in
surface representation. P1-P5 and P1‟ groups (red) of peptidic inhibitor (gray), subsites S1‟, S1,
S2 and S4 (black), and residues forming the substrate-binding pockets (white) are labeled.
The substrate binding pockets S4, S2 and S1 are highly conserved among the CoV

124

.

Successful cloning and expression of recombinant SARS-CoV Mpro has unveiled important
insights on the substrate-specificity data for this enzyme. Along with the absolute specificity of
Glu at P1, recent data elucidated an equal preference for the P1-His containing substrate

125, 126

.

The S2 subsite of SARS-CoV can accommodate the side chains of Leu, Phe, Val, Met and Thr
residues as opposed to traditional preference of only Leu/Ile at P2 for other CoV 125, 126. The side
chain of P3 residue is mainly solvent-exposed in all CoV Mpro and is capable of accommodating
side chains of a broad range of functionalities

115

. Small residues such as Ser, Thr, Val, Pro and

Ser, Ala, Gly can be tolerated at P4 and P1‟, residues respectively

124

. The knowledge of

substrate specificities has not only increased the understanding of polyprotein processing
mechanism by the enzyme but also provided important clues for drug design 125.

1.5.

DRUG DESIGN APPROACHES AGAINST SARS-COV MPRO
During the epidemic of SARS, combinations of drugs were given to individuals suffering

from this life threatening disease and these multi-drug treatments resulted in several post-therapy
side effects

127, 128

. As more information became available for the key components of the virus

life-cycle, target-oriented drug design efforts were pursued to prepare against the possibility of
the next epidemic of this disease. Early phases of drug discovery against SARS Mpro were
centered on the structural modification of the known drugs with established safety profiles in
humans in order to avoid painstaking efforts of finding and characterizing new drug entities in
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the scenario of a global outbreak of SARS. The drug design efforts pursued against SARS 3CLpro
are summarized below.
1.5.1. Structure-guided drug designing
Anand et al. published a homology model of SARS Mpro using the X-ray crystal
structures of HCoV 229E Mpro and TGEV Mpro (40 and 44% sequence identity respectively ) as a
template to stimulate drug discovery efforts against this promising target 8. Also, they unveiled
remarkable degrees of conservation among the substrate-binding sites of CoV as supported by
the cleavage of the TGEV Mpro substrate by the recombinant SARS-CoV Mpro. During the
outbreak of SARS, rupintrivir (formerly designated as AG7088), a potent inhibitor of human
rhinovirus (HRV) 3C protease, was in the early stages of drug development by Pfizer Inc. for the
treatment of the common cold

129-131

. Anand et al. addressed that Rupintrivir could partially fit

into the putative binding pocket of SARS-CoV 3CLpro based on the identical orientation of the
hexapeptidyl chrloromethyl ketone (CMK) inhibitor 60 in TGEV Mpro and Rupintrivir 61 in
HRV2 3Cpro and suggested a possibility to use rupintrivir as a model to develop inhibitors
against SARS-CoV 3CLpro 8 (Figure 1.5.1).
Ghosh et al. carried out the modification of the P2 side chain of rupintrivir with P2benzyl 62 and prenyl 63 considering the P2-Phe substrate-specificity of SARS Mpro

132

. Also,

they developed another series by replacing the ketoethylene of compound (67) with
hydroxyethylene 64. Compound 63, having a P2-prenyl group, was more potent than the
corresponding analogue 62 with a P2-phenylmethyl group, which further indicated the possibility
of accommodating other small side chain residue at the P2 position. The inhibitor with
hydroxyethylene isostere 64 showed little inhibition of the SARS Mpro enzyme. To gain
molecular level insights, an X-ray structure of SARS Mpro co-crystallized with 63 was resolved.
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The crystal structure revealed the covalent binding mode for the inhibitor as expected. Also, the
crystal structure offered insights about poor inhibitory activity of 64 was due to the loss of
hydrogen bond interaction between the backbone amine nitrogen of Glu166 and the carbonyl
group of the inhibitor 132 (Figure 1.5.1).
Shie et al. designed novel analogs of rupintrivir and pursued combinatorial synthesis of a
series of ketomethylene isosteres (representative compounds 65, 66 as well as tripeptidomimetic
α, β unsaturated esters (representative compounds 67, 68 having lactam-glutamate or Phe at P1
133

. Interestingly, compounds with L-phenylalanine at P1 were found to have enhanced activity

compared to corresponding lactamglutamate (Compound 66, Mpro IC50 = 13 µM, Compound 68,
Mpro IC50 = 11 µM). Although, rupintrivir 61 was found to be inactive at the concentration >100
μM against SARS Mpro 133 as well as in a cell-based assay 134, the higher activity of its analogue
66 motivated the authors to predict the binding mode of these compounds by molecular docking
studies using previously reported crystal structures 104. Docking studies depicted that P1 and P2Phe of 66 fit well into the S2 and S3 pockets respectively, placing the conjugated ester moiety in
the S1 pocket to interact with His163 and Gly 143. Also, 66 was stabilized by multiple H-bond
interactions with the active site residues. However, the conjugated ester was still too far (> 4.5
Å) from Cys145 for a covalent bond formation. In contrast, the docking of rupintrivir 61 showed
an improper placement of the terminal ester group in the S1‟ pocket as a result of poor fitting of
the P1-lactam moiety in the S1 pocket. In addition, P2-flurophenyl and P4- isoxazoyl moiety of
61 exhibited steric clashes with the residues of S2 and S4

133

. This might be responsible for the

inactivity of 61 as well as the lower activity of corresponding lactamglutamate analogs (Figure
1.5.1).
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Based on the higher activity of Phe-Phe dipeptide inhibitors 66 and 68, several Phe-Phe
dipeptide inhibitors were designed with two Michael acceptors at N and C-terminals mimicking
pseudo C-2 symmetry. Dedicated synthesis of compounds from this series identified 69
(JMF1521) with an IC50 value of 1 μM and a Ki value of 0.52 μM

133

. Further, synthesis of a

series of peptide anilide with L-phenylalanine as P1 residue attached with a 2-chloro-4nitroaniline moiety (considering the activity of niclosamide against replication of SARS-CoV
135

) was pursued

136

. Among the synthesized compounds, anilide 70 functioned as a potent

inhibitor of enzymes having Ki and IC50 values of 0.06 and 0.03μM, respectively. SAR of
various analogs of 70 confirmed that chloro, nitro and dimethylamino groups in 2-chrlo-4nitroaniline of 70 were indispensible for the activity. The key interactions of 70 as revealed by
the docking studies involved interactions of a nitro group with the NH of Ala 46, 3 Å distance of
chlorine from γ-S of Cys145 and ϵ-N2 of His41, as well as hydrophobic interaction of a
(dimethylamino) phenyl moiety in the S2 pocket. Also, authors indicated the possibility of
modifying P1 phenyl residue of 70 in the S1 pocket to enhance interactions with Phe140,
His163, and Glu166 to further enhance activity 136 (Figure 1.5.1).
In search of the effective drug candidates, Chou et al. performed docking studies using
previously developed homology model of SARS Mpro 8 by modifying the bulkier p-flurobenzyl
side chain of 61 with p-flurophenyl (KZ7088, 71) and the octapeptide AVLQSGFR to
understand the binding interactions of SARS-CoV Mpro with its ligand

137

. The octapeptide was

chosen by considering its size to occupy protease-specificity sites, specificity of SARS-CoV for
Gln↓(Ser, Ala, Gly) and for the rational designing of new peptidic analogs based on the
“distorted key approach.” The distorted key approach involved modifications of the substrate34

cleavage site by keeping other residues of the peptide (substrate) intact for tight binding. Such a
substrate could behave as a distorted key which binds effectively in the enzyme active site but
blocks the function of the enzyme. Also, this approach could help to identify the competitive
inhibitors against this enzyme 138. Docking studies of 71 and AVLQSGFR revealed the presence
of multiple hydrogen bonds between the SARS proteinase and respective ligands

137

. However,

the experimental binding affinity of 71 was not reported. Gen et al. confirmed the efficacy of
octapeptide for the inhibition of the replication of SARS-CoV (EC50 = 0.031 μM) with no
detectable toxicity on vero cells under experimental conditions. Sirios et. al. encoded the
receptor interactions of 71 in pharmacophoric features and conducted a pharmacophoric search
over 3.6 millions of compounds to identify only 0.03% of potential compounds for further
experimental analysis 127 (Figure 1.5.1).
Du et al. studied catalytic interactions between the experimentally cleavable octapeptide
AVLQSGFR and SARS Mpro using molecular mechanics (MM) and quantum mechanics (QM)
calculation with the help of a previously developed homology model of SARS-CoV Mpro

8, 139

.

The residues of catalytic dyad His 41 and Cys 145 were found to attract electron density of
peptide bond between Gln and Ser, which accelerated the positive charge on C(CO) of Gln and
the negative charge on N (NH) of Ser. The replacement of the carbonyl of Gln to CH2 or CF2
distorted the π–bond system of the peptide bond, making it uncleavable by the enzyme, situation
analogues to the “distorted key” approach discussed above 139. The modified octapeptide showed
tight binding with the enzyme and represents a good starting point for the design of peptide
based anti-SARS drugs (Figure 1.5.1).

35

36

Figure 1.5.1. Inhibitors of SARS-Mpro identified by structure-guided drug design.
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1.5.2. Knowledge-Based Drug Design
Anand et al. pinpointed the use of the rhinovirus protease inhibitor, rupintrivir, as a
starting point for the design of inhibitors against SARS 3CLpro. Further development of inhibitors
based on the structural modifications of rupintrivir has already been discussed in previous
sections.
Jain et al. performed the synthesis and biological evaluation of a series of keto-glutamine
analogs with a phthalhydrazido group at the α-position against SARS Mpro 140. Their knowledgebased approach was based on a previously identified lower micromolar reversible inhibitor 72 of
the hepatitis A virus (HAV) 3C proteinase bearing a phthalhydrazido moiety

141

and preference

of P1-glutamine by SARS Mpro. Initial efforts for the synthesis of N, N-dimethylglutamine
analogs with leucine, threonine, and valine at the P2, P3, and P4 positions respectively, resulted
in compounds having higher micromolar activity (representative compound 73, Mpro IC50 = 28
µM). Further, optimization and structure-activity relationships (SAR) identified cyclic glutamine
analogs, among which compound 74 exhibited an IC50 of 0.6 μM against SARS Mpro

142

.

Docking studies of 74 indicated that the active site of the enzyme had enough room to
accommodate the bulkier phthalhydrazide group with minimal rearrangement of protein (Figure
1.5.2).
Bacha et al. identified a cluster of serine residues (Ser139, Ser144 and Ser147) close to
catalytic residues of the active site

143

. Sequence alignment of this region among the proteases

from other CoV revealed the presence of a conserved serine cluster among CoV. This
observation motivated the authors toward designing inhibitors targeting serine cluster of the
active site. Based on the knowledge of the reactivity of boronic acid compounds to the hydroxyl
group of serine, inhibitory potencies of several boronic acid compounds were evaluated against
38

SARs-CoV Mpro. Compound 75 found to have an inhibition constant (Ki) of 40 nM. Further
studies revealed a reversible binding mode of 75 in an energetically favorable fashion, defining it
as an attractive scaffold for further optimization 143 (Figure 1.5.2).
Meanwhile, Zhang et al. extended their knowledge from the studies of active caspase
(another cysteine protease) inhibitor 76 toward the discovery of potential SARS-CoV Mpro
inhibitors

144

. A series of dipeptides analogs were synthesized with N, N-dimethyl glutaminyl

FMK at the P1 site and different amino acids (leucine/valine/phenylalanine) at the P2 site from
the knowledge of a peptide-substrate recognition sequence by the enzyme. N, N-dimethylglutamine analogs were specifically chosen to prevent possible cyclization of the free glutamine
side chain with FMK

145, 146

. Compound 77 was found to have an EC50 value of 2.5 μM in the

CPE inhibition assay against 6109 strains of SARS-CoV with a selectivity index (SI) of >40,
presumably through the inhibition of SARS CoV Mpro 144 (Figure 1.5.2).
The nucleophilic attack of cysteine thiol to trifluoromethyl ketone (TFMK) leads to a
tetrahedral adduct formation which mimics the substrate-enzyme intermediate

147, 148

and

compounds bearing TFMK have a potential to be a serine/cysteine protease inhibitor. Syndes et
al. designed and synthesized derivatives of Gln and Glu possessing a TFMK moiety considering
the utility of TFMK as a warhead and P1-Glu preference of the enzyme

149

. Compounds 78 and

79 displayed Ki values of 134.5 μM and 116.1 μM, respectively. Further, structure-based
optimization of 79 led to synthesis of mono-, di- and tripeptide analogs with modification in the
halogen content of warhead as well as in the P1 side chain

108

. Five inhibitors were identified

with activity in the nanomolar range. One of the inhibitor 80 showed unexpected reversible
inhibition of SARS 3CLpro by forming a thioether complex with Cys145 of the active site,
supported by the co-crystallized structure of 80 with SARS Mpro 108. Regnier et al. noticed the
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moderate activity of compounds might be due to possible cyclization of the free acid/amine side
chains of 78 and 79 at P1 with TFMK as reported previously with FMK derivatives
resulted in the poor binding of the cyclized compounds in the active site

150

.

144

, which
Several

modifications were carried out in P1, P2, P3 side chains as well as warhead groups. Compound
81 containing P1 pyrollidone and thiazolyl units as a warhead showed an IC50 of 2.2 µM against
SARS Mpro 150. Recently, Shao et al. synthesized a series of TFMK by variation in the amino acid
at P1-P4 chains as well as incorporation of alkyl chains at P2-P4

151

. Compound 82 with an

identical arrangement of P1-P4 amino acids to the substrate inhibited SARS-CoV 3CLpro in a
time dependent manner with an IC50 of 0.8 µM and a Ki of 0.29 µM after a four hour incubation.
The computational model of 82 pointed that the formation of a covalent bond between the
cysteine thiol and inhibitor 82, as well as other key interactions of inhibitor with the active site
residues, were favored only with the [S, S, S, S] isomer of 82 with R configuration of carbonyl
carbon adjacent to the trifluoromethyl group 151 (Figure 1.5.2).
Several Aza-peptide epoxides (APEs) were reported as inhibitors of clan CD proteases,
for example, leguminases

152

and caspases

153

. The architecture of APE involves an epoxide

moiety attached to the carbonyl group of the P1 residue, nitrogen at the Cα position of P1 and
target-specific side chain of P1 residue. Synthesis of APE possessing an azaglutamine (AGln) as
the P1 residue was performed to evaluate their efficacy against SARS-CoV Mpro 154. Micromolar
quantities of the [S, S] diastereomer 83 showed strong inhibition for the cleavage of a peptidic
substrate whereas the corresponding R, R diastereomer was inactive against Mpro. Later, the
crystal structures of the [S, S] diastereomer with Mpro revealed the formation of a covalent bond
between the Sγ atom of catalytic Cys145 and the epoxide C3 atom of the aza-peptide component
of the inhibitor, suggesting the irreversible mode of action of this class of cysteine protease
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inhibitors. Models of different diastereomers of APEs revealed the importance of S
configurations of the epoxide C3 atom of APE to avoid clashes with the active site residues and
other components of azapeptide. Also, the S configuration of epoxide provided better geometry
for a nucleophilic attack by active-site cysteine thiol 154 (Figure 1.5.2).
Peptidyl aldehydes are effective against multiple proteases including serine protease
156

, aspartic protease

157, 158

, and cysteine protease

159, 160

155,

. Moreover, they possess reversible

electrophilic isostere and are capable of mimicking the endogenous substrate by retaining an Hbonding framework of backbone and addressing different subsites of enzyme with their side
chains. Considering these advantages of the designing inhibitor with peptidic aldehyde scaffold,
Al-gharabli et al. employed an efficient method for the synthesis of their designed peptidic
library against SARS 3CLpro 161. They considered two approaches for the design of their peptidic
aldehyde library. In the first approach, they carried out a sequence homology search using the
extracted binding pockets of SARS 3CLpro. The information gained from the bound ligand
fragments in homologous proteins were used for the modeling of the putative side chains for the
corresponding sub-pockets of enzyme. In their second approach, natural and non-natural amino
acids from the ACD and Sigma-Aldrich library were docked in the S1, S2 and S4 pocket of
SARS 3CLpro using the FlexX docking program. Amino acids which scored well for the
respective pockets were selected for the designing. The peptide backbone was retained as in the
complex structure of SARS-CoV 3CLpro with a CMK inhibitor (1UK4, PDB code). Evaluation of
the designed library identified 84 and 85 with IC50 of 7.5 µM as a reversible inhibitor of SARS
Mpro

161

. The presence of the hydrophilic residue at the P2 position prompted the authors to

predict non-canonical binding modes of compounds 84 and 85 as observed in the active
41

monomer A of SARS 3CLpro (1UK4, PDB code) (Figure 1.5.2).

Figure 1.5.2. Inhibitors of SARS-CoV Mpro obtain by knowledge-based drug design approach.
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1.5.3. Structure-Based Virtual Screening
This section will review the discovery of the non-peptidic inhibitors developed against
SARS-CoV Mpro by a structure-based virtual screening approach. Table 1.5.3 summarizes the
commercial databases, methods, softwares and scoring functions used for virtual screening, hit
ratio along with the chemical structures of hits obtained.
In 2005, Liu et al. screened chemical databases (listed in Table 1.5.3, raw 1) against the
“flexible homology model” developed by combined molecular dynamics (MD) simulation and
multicanonical sampling protocol 162. The top 10% of docked compounds were retained based on
their dock energy-score and contact-score. Subsequent filtration steps involved removal of
compounds with pKi > 4.0 (to remove score bias caused by a single empirical function) followed
by selection of the top 2000 compounds by score and Xcscore scoring functions

162

. Final pools

of compounds were subjected to a pharmacophore filter (developed using the POCKET module
from LigBuilder) and evaluated using drug-like criteria for similarity to the original drug
framework as well as to known antiviral compounds. After visual inspections, 48 compounds
were subjected to an enzyme assay, out of which three compounds 86-88 including
calmidazolium 86, a well known antagonist of calmodulin, were found to inhibit the enzyme
with ki ranging from 61 to 178 μM 162 (Table 1.5.3, raw 1).
Chen et al. carried out the docking studies of compounds from the CMC database
(comprised of drugs which have been used or are currently used against human) against
previously developed homology model of SARS Mpro to expedite the screening process against
the SARS epidemic

107, 163

. The potential candidates were ranked using a consensus scoring

function along with the scoring function implemented in AutoDock3.0. Cinanserin 89, a well
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characterized serotonin antagonist found to inhibit the catalytic activity of SARS-CoV Mpro with
IC50 of 5μM,) also interfered with SARS-CoV replication in cell culture (IC50 = 31 μM) (Table
1.5.3, raw 2).
Chen et al. screenedthe SPECS database using dock 4.0. After the first phase of docking,
the top 2000 compounds were selected based on the highest dock score and subjected to
consensus scoring

164

and drug-like property calculations

83

. Finally, a set of 256 compounds

were evaluated in an integrated assay platform comprised of a Surface Plasmogen Resonance
(SPR) assay (for measuring binding affinity of the candidate compound with the SARS-CoV
Mpro) and fluorescence resonance energy transfer (FRET) technologies-based assays (to measure
the inhibition of proteolytic activity of SARS-CoV Mpro). Eight novel inhibitors of SARS-CoV
Mpro were discovered (representative compounds 90-96), resulting in IC50 values of 6.86 to 80.46
μM 18 (Table 1.5.3, raw 3).
Lu et al. performed a virtual screening of the Maybridge database using a published Xray structure of SARS Mpro with a covalently bound CMK inhibitor (1UK4, PDB code)

116, 165

.

The molecules were first ranked by the fitness score component of GOLD score after docking to
select the best pose followed by reranking of the compounds with the external H-bond energy
term implemented in GOLD score for ranking the binding affinity of compounds. This was the
first report, to the best of our knowledge, to use only H-bond energy term to rank and select
compounds. The top 50 compounds were subjected to a SARS-CoV Mpro inhibition assay. Two
active compounds 93 and 94 were identified from an enzyme inhibition assay. The core
structures of these two hits, defined by the docking study, were used for further analogue
searches. Twenty-one analogs derived from these two hits exhibited IC50 values below 50 μM,
with the most potent one, 95, showing an IC50 of 0.3 μM 165 (Table 1.5.3, raw 4).
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Dooley et al. presented a genome-to-drug-lead approach which uses terascale computing
to model flexible regions of protein and thus encodes genetic information to identify drug leads
166

. A homology model of SARS-CoV Mpro complexed with a substrate fragment

(ATVRLQp1Ap1‟) was developed by predicting the conformation of the flexible loop with a total
of 200 simulations, and average structure (deposited in PDB, 2AJ5, PDB code) was used as a
drug target in virtual screening for small-molecule inhibitors using the EUDOC docking
program. A total of 3958 compounds were selected based on the total and Van der waals
interaction energies. Twelve inhibitors were tested in a cell-based inhibition assay after removing
compounds with poor solubility, poor cell permeability, multiple chiral centers and commercial
unavailability. Compound 96 inhibited the SARS-CoV Toronto-2 strain with an EC50 of 23 µM.
Further, screening of a similar set of compounds against two published crystal structures of
protease failed to identify compound 96 166. This observation suggested that terascale computing
could complement the crystallography, increase the hit rate in virtual screening and accelerate
the process of drug discovery against emerging infectious diseases (Table 1.5.3, raw 5).
Tsai et al. carried out a structure-based virtual screening against Maybridge database

167

.

After the initial filtration of the database using drug-like filters, remaining compounds were
docked into the co-crystallized structure of SARS-CoV Mpro with an octapeptide CMK inhibitor
using DOCK4.0.2. 93 compounds were subjected for the inhibition assay, twenty one of these
showed inhibition against SARS-CoV Mpro (IC50 ≤ 30 μM), with three of them found having a
common substructures. In order to search analogs of these compounds, 2D substructure searches
were carried out in the Maybridge, ChemBridge, and SPECS databases, which further identified
25 compounds against SARS-CoV Mpro with an IC50 of 3-1000 μM (most active compound 97,
IC50 =3 µM) 167 (Table 1.5.3, raw 6).
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Bacha et al. generated a pharmacophore model using low energy conformation of the
most active compounds from a previously developed peptide library (mostly peptidic halomethyl
ketones) with the pharmacophore application module of MOE

108, 149

. A threshold of 1000 µM

was selected (active = <1000 µM, inactive = >1000 µM) based on the distribution of Ki data in
their developed library of compounds for the generation of the qualitative pharmacophore.
Exclusion spheres were added for improving the ability of pharmacophore model to discriminate
between actives and inactives. A pharmacophore-based database search conducted in a
commercial database implemented in MOE resulted in 40 potential compounds, 38 of which had
Ki <1000 µM. The most active hits 98-100 from this screening are shown in a Table 1.5.3, raw 7
with Ki = 4.5-27 µM 108.
Mukherjee et al. conducted structure-based virtual screening of Asinex platinum
collection against the crystal structures of SARS-CoV Mpro (PDB code: 1UK4, 2AMD) using the
GOLD docking program

19

. The initial database was prefiltered using various drug-like and

ADME (absorption, distribution, metabolism and excretion) filters. The filtered database was
subjected to multi-stage cascade docking involving computationally less intensive and faster
docking protocol (GOLD 7-8 times speed up mode) at the early stages of the screening with
computationally complex protocol (GOLD 2-times speed up mode and GOLD standard mode)
towards the end. After the cascade docking, top-ranked poses (based on GOLD score) were
rescored using a cumulative score obtained by summing six scores (Fscore, Gscore, Pmfscore,
Dscore, and Chemscore calculated using Cscore module of Sybyl 6.9), including the GOLD
score. The diversity analysis of the top 500 hits obtained after rescoring retained 100 molecules
that were visually inspected for their ability to obtain key substrate specificity sites, geometric
quality of the binding pose, hydrophobic/ lipophilic mismatches and complementarity of the key
46

interactions. Meanwhile, publication of the co-crystallized ligand structure of SARS Mpro
(2AMD, PDB code) as well as reports of several inhibitors prompted the authors to perform a
scoring function-based enrichment study using the previously mentioned six scoring functions.
Gscore followed by Dscore gave better enrichment of the true actives and were combined in the
range-scaled format to generate a composite GDR score. In the extended phase of screening,
pharmacophore filters based on the crystal pose of the peptidic inhibitor (2AMD, PDB code),
docking pose-based descriptors as well as GDR scoring function were used to select the
compounds for biological assay. Two hits were identified (101, 102) with IC50 of 17 and 18 µM,
respectively (Table 1.5.3, raw 8) 19
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Table 1.5.3. Non-peptidic inhibitors of SARS-CoV Mpro obtained by an experimental HTS

Database

Crystal
structure/
Homology
model

Method/
Software/ Scoring
function used

Hit
ratio
(%)

National
chemical
institute
diversity set
(~230 000),
ACD 3D
2002.2 (~280
000), MDDR3D 2002.2
(~120 000)

flexible
homology
model,
1UK4,
1UK3

Docking /
DOCK4.0/ Dockenergy-score,
Contact-score,
XCscore
Pharmacophore
and Drug like filter

7.5

Comprehensive
Medicinal
Chemistry
Database of
Molecular
Design Limited
(MDL-CMC)
(~8000 )

Homology
model,
1UK4

Docking/Dock4.01,
Dock score, Cscore

0.013

1UK4

Docking/ DOCK
4.01/ Dock score,
Cscore & scoring
function of
Autodock 3.0

3.12

Maybridge
(58 855)

1UK4

Docking,
Similarity search/
GOLD2.1, fitness
score and H-bond
energy component
of Gold score

4

361413 small
molecules

Homology
model
(2AJ5)

Docking/EUDOC

-

SPECS
(81287)

a
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Structure of the most active compounds

Maybridge,
ChemBridge,
SPECS

1UK4

Docking,
Similarity search/
DOCK 4.0.2/
Internal ligandreceptor binding
energy term,
electrostatic energy
term

MOE
2006.0804

-

Pharmacophore/
MOE

Asinex
platinum.2004

1UK4,
2AMD

GOLD 2.2
/composite GDR
score

7.63b

12.5

1.8

a

hit ratio is calculated by dividing the number of active hits retrieved against FP-2 by the
number of compounds evaluated in the biological assay. bCompounds having IC50 values
below 30 µM were considered for the calculation of hit ratio.
1.5.4. Hightroughput Screening (HTS)
HTS against SARS 3CLpro implemented rapid and sensitive fluorescence resonance
energy transfer (FRET) assay in most of the screening discussed below

168

. The anti-SARS

activities of the potential inhibitor identified through HTS were evaluated in a plaque reduction
assay (PRA) or cytopathic effect (CPE) inhibition assay. HTS against SARS-CoV 3CLpro can be
classified into three approaches: experimental HTS where the in-vitro binding affinities of the
screened hits were measured; virtual HTS where the binding affinities of the screen hits were
only predicted; and finally, a novel dynamic ligand screening (DLS) methodology which
perform the screening in a highthroughput manner, and has several advantages over conventional
HTS. These approaches are summarized in the following sections.
1.5.4.1. Experimental HTS

49

Kao et al. screened the Chembridge database of structurally diverse 50,240 compounds
using a continuous FRET assay against recombinant SARS-CoV Mpro. Compound 103 inhibited
SARS-CoV by an IC50 value of 2.5 µM and exhibited an EC50 value of 7 µM in cell-based
antiviral assays

169

. Blanchard and colleagues screened the small molecule library of 50,000

drug-like compounds using a quenched FRET assay. Through a series of experimental and
virtual filters, five novel inhibitors of SARS Mpro were discovered (IC50 = 0.5-7µM), the most
potent compound 104 in their screening had an IC50 of 0.5 µM 170 (Figure 1.5.4.1).
Wu et al. carried out the screening of >10,000 compounds from the diverse source based
on ELISA, immunofluorescence, flow cytometry and Western blot analysis. As a result of their
efforts, compound 105 was found to have a Ki value of 0.6 μM against SARS-CoV Mpro 134. The
docking simulation of compound 105 revealed that the inhibitor is folded into a ring-like
structure in the active site and was stabilized by multiple H-bonds and hydrophobic interactions
with the active site residues. Compound 105 was previously reported as a transition state
inhibitor of HIV protease and found to be a promising candidate for further development against
SARS due to its established in vivo efficacy in cats for anti-AIDS effects 134 (Figure 1.5.4.1).
Goetz et al. conducted HTS of a library of compounds developed using known cysteine
protease inhibitor scaffolds with the substrate-specificity data obtained by in-house screening of
natural tetrapeptides against recombinant SARS-CoV 3CLpro 126. WRR495 (106) with dipeptidyl
epoxyketone scaffold inhibited enzyme and viral replication (>50%) at a concentration of 10
µM. Further optimization of 106 with the help of computational modeling as well as knowledge
of substrate-specificity (valine at P3) identified WRR495 (107), which was 175 fold more potent
than parent compound 107 with a k3/ki of 0.5 M-1S-1 against SARS 3CLpro and an EC50 of 12 µM
against SARS-CoV 126. The crystal structures of these compounds with SARS-CoV 3CLpro were
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developed which showed interesting binding mechanism. The cysteine mediated nucleophilic
attack on epoxide C2 resulted in the formation of an alcohol group in the P1 position exhibiting
direct as well as water-mediated H-bonds in the S1 pocket, but also shifted the alanine from P1
to the P2 position. This observation raised the possibility of developing non-covalent inhibitors
using this scaffold. Also, the P2-Ala side chain was exposed to a solvent supporting the less
stringent P2 specificity for SARS Mpro. The P3-Phe side chain seemed to form sulfur-arene
interactions with Met 49 and Met 165 of the canonical S2 pocket. Higher activity of 107 might
be due to the use of the preferred amino acid Val for the S3 pocket 126 (Figure 1.5.4.1).
Recently, Kuo et al. evaluated a compound library of 6800 compounds to find out
individual and common inhibitors of coronavirus and picornavirus Mpro. Five novel inhibitors of
SARS Mpro were identified (IC50 = 3.3 to 10.6μM). Compound 108 inhibited all the proteases
(SARS Mpro, 229E Mpro, CVB3 3CLpro, EV71 3CLpro, RV14 3CLpro) with an IC50 of < 10 µM 171.
The synthesis of analogs of 108 identified 109 as a broad spectrum inhibitor against CoV
proteases. Compound 109 exhibited an IC50 of 2.5 M against SARS Mpro as well as inhibited
other CoV proteases with an IC50 of < 3 µM 171.
Other known compounds identified by HTS against SARS Mpro include metal ions
containing compounds (phenyl nitrate, thimerosal)
polyphenols from black tea

174

172

, hexachlorophene and its analogs

, diuretic ethacrynic acid

phenolic compound hesperetin 176.
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175

172, 173

,

, isatin derivatives and plant-derived

Figure 1.5.4.1. Non-peptidic inhibitors of SARS-CoV Mpro obtained by an experimental HTS
1.5.4.2. Virtual HTS
Jenwitheesuk et al., carried out preliminary docking studies of 29 approved and
experimental drugs against the homology model of the SARS-CoV proteinase as well as the
experimental structure of the transmissible gastroenteritis virus (TGEV) proteinase to obtain an
enzyme-inhibitor complex which was then refined by MD simulation protocol followed by final
docking calculations to predict the binding affinity based on the lowest energy-solution

177

.

Docking calculations were performed using Auto Dock version 3.0.5, which employs the
Larmarckian Genetic Algorithm (LGA) whereas MD simulations were carried out with the
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NAMD (version 2.5b1) package in the TIP3 water shell using the X-PLOR force field. The
inhibitory constant (Ki) was calculated according to Hess‟s law to define the binding affinity of
the inhibitors. HIV-1 protease inhibitor, L-700417 110 showed the highest binding affinity with
an identical binding mode to the substrate and has proposed as a good starting point for the
designing of SARS-CoV 3CLpro inhibitors 177 (Figure 1.5.4.2).
Plewczynski et al. conducted structure-based in silico virtual HTS by extracting potential
compounds from the protein-ligand complexes selected from the protein data bank (PDB) based
on sequence similarity with SARS-CoV Mpro 178. Identified complexes mainly included the viral
cysteine protease bearing the trypsin fold. Later, flexible docking was performed on the small
molecules and peptides extracted from the protein-ligand complex in the crystal structure of
SARS-CoV Mpro using eHITS (a flexible docking method for finding an accurate docking pose
based on exhaustive positional and conformational searches in a timely manner). The best
scoring compounds were then subjected to 2D similarity searches in Ligand.info Meta-Database
(comprised of publically available database). A set of closely related structures bearing 2methyl-2, 4-pentanediol 111 scaffolds were identified as lead candidate compounds against
SARS-CoV Mpro 178 (Figure 1.5.4.2).
Zhang et al. performed the docking studies of existing HIV, psychotic and parasitic drugs
(lopinavir, ritonavir, PNU, UC2, niclosamide and promazine) against the crystal structure of Mpro
using the Hex docking program in a strategy of discovering new leads from old drugs. The
estimated binding affinities of these compounds, especially lopinavir 112 and ritonavir 113
against SARS-CoV Mpro, indicated the potential of these drugs for designing new inhibitors of
SARS-CoV Mpro

179

. Meanwhile, Savarino et al. supported strong binding of ritonavir 113 with
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SARS-CoV Mpro (Ki ~10-5 M) stabilized by multiple H-bond network in their independent MD
simulation 180. Zhang et al. developed a pharmacophore model based on the previously predicted
pose of six drugs 179 and the crystal pose of the CMK inhibitor (1UK4, PDB code) in SARS-CoV
Mpro using the POCKET module in the LIGBUILDER program

181

. The developed four-point

pharmacophore model was used to search NCI database. A total of 30 drugs were selected after
consideration of pharmacophoric criteria and preference for compounds with antiviral activity.
Interestingly, six of the identified drugs already have known anti-SARS-CoV activity

181

.

Meanwhile, Wu et al. also evaluated HIV protease inhibitors, currently in clinic as inhibitors of
SARS-CoV Mpro, and discarded the possibility of ritonavir as a potential inhibitor of SARS-CoV
Mpro. However, lopinavir 112 showed moderate activity against SARS Mpro with an IC50 value of
50 μM (Ki =14 μM) 134 (Figure 1.5.4.2).

Figure 1.5.4.2. Proposed inhibitors of SARS-CoV Mpro by virtual HTS and DLS approach
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1.5.4.3. Dynamic Ligand Screening (DLS)
Recently, Schmidth et al. reported the DLS approach for the discovery of non-peptidic
inhibitors against SARS-CoV 3CLpro

182

. This approach involves site-directed identification of

low-affinity inhibitory fragments against a particular target by in situ formation of inhibitory
species followed by its detection with a fluorogenic reporter substrate of that target (readers are
referred to original reference

182

for more detail). This method presents several benefits over

conventional HTS or fragment-based approach using NMR or X-ray crystallography, for
example, possible detection of low affinity fragments with inhibition constant in milimolar
range, requirement of minimal amount of protein for assay, exploration of a wide range of the
chemical space, minimum requirements equipments and transformation of a moderately active
peptide to an entirely non-peptidic inhibitor with a micromolar range. A “reverted” DLS
methodology adopted for screening against SARS 3CLpro successfully identified a lower
micromolar non-peptidic inhibitor 114 of the enzyme (Figure 1.5.4.2) with an IC50 of 2 µM.
In short, although, SARS has been contained, the virus is not eradicated yet. In these
circumstances, high potency of the developed inhibitors of SARS-CoV Mpro illustrates this
enzyme suitable for the development of anti-SARS therapy. Also, the availability of multiple
crystal structures of SARS-CoV Mpro in complex with peptidic/non-peptidic inhibitors from
diverse classes presents unique opportunities to discover promising inhibitors of this enzyme by
structure based drug designing. As mentioned before, P1-Glu/His triggers the potency of SARS
inhibitors and should be focused while designing of peptidomimetics. Moreover, S1, S2 and S4
subsites which are highly conserved among Co-V can be targeted to develop broad spectrum
inhibitors against Co-V related diseases. Also, structure analogs of Rupintrivir with established
activity against 3Cpro of rhino and other Co-V protease can serve as a template for discovery of
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common inhibitors of Co-V. In addition, with number of inhibitors in hand, efforts can be made
to correlate the physical, chemical, biological properties of reported inhibitors with SARS-CoV
Mpro activity in the form of 2D Quantitative Structure Activity Relationships (QSAR) model and
can be used for virtual screening of chemical libraries to identify novel hits. Also, 3D QSAR
modeling can be performed with the help of published crystal structures enabling structural
alignment of known inhibitors.
1.6.

Conclusions
This chapter highlights a variety of the rational approaches for drug discovery against

two cysteine proteases, protozoal protease “falcipain” and viral protease “SARS 3CLpro”. To the
best of my knowledge, this chapter covers the peptidic and non-peptidic inhibitors from major
classes of inhibitors reported against falcipain and SARS-CoV Mpro to date. The cysteine
proteases discussed here are of the utmost importance for drug design considerations. For
instance, several efforts are currently underway to develop effective antimalarials for
encountering the parasite resistance to all front-line drugs, including the most potent artemisinin
derivatives

95

. In such scenarios, falcipains manifests an emerging drug target due to its unique

function in hemoglobin degradation and survival of the protozoa. Moreover, effective peptidic
and non-peptidic inhibitors of falcipains (summarized above) with good inhibitory potency
project this enzyme as a promising target for the development of antimalarial chemotherapy.
Likewise, although SARS has been contained, possible reemergence of the disease with mutated
forms of the virus still remains a potential threat to human health. From this view, structurally
and biochemically well-characterized SARS-CoV Mpro, playing pivotal role in the virus
replication, provide an opportunity for drug development in case of the next pandemic of SARS.
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As discussed above, knowledge-based drug design approaches have been effective for the
rapid discovery of inhibitors against these targets, for example, evaluation of inhibitors of other
cysteine proteases such as papain, cathepsins, calpain or cruzain against FP-2, identified vinyl
sulphone class of inhibitors, the most potent inhibitors reported till date against this enzyme.
Structure-guided drug design helped to optimize the potential or known compounds against the
target protease with the help of three-dimensional structure and knowledge of the substrate
specificity. For instance, structure modifications of rupintrivir (known rhinovirus protease
inhibitor with no efficacy against SARS) identified potent inhibitors of SARS 3CLpro with a
nanomolar to lower micromolar activity range. In addition, structure-based virtual screening and
HTS helped to discover non-peptidic inhibitors with diverse scaffolds against both enzymes.
Taken together, although the cysteine protease discussed here are quite different from each other,
the approaches presented here provide general guidelines for drug design against the cysteine
protease of existing and possible emerging pathogens as well as those present in humans. In
addition, the rational approaches described for developing inhibitors against SARS set successful
examples to initiate drug design efforts against other viral pandemics such as the swine flu
(H1N1) virus.
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Chapter 2

Identification of Falcipain-2 Inhibitors Using
Structure-Based Virtual Screening of Focused
Cysteine Protease Inhibitor Library

Content of this chapter is published in: Shah F., Mukherjee, P., Jiri G., Rosenthal, P., Tekwani
B., Avery M. A. Identification of Novel Malarial Cysteine Protease Inhibitors Using StructureBased Virtual Screening of a Focused Cysteine Protease Inhibitor Library, Journal of Chemical
Information and Modeling, 2011, 51 (4), 852.
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2.1. Introduction
In the Chapter 1, extensive efforts conducted for the discovery of inhibitors against FPs using
rational drug design approaches were described. In general, drug design efforts against FPs can
be broadly classified in two main categories: peptide/peptidomimetic covalent inhibitors and
non-peptidic small molecule inhibitors. The covalent irreversible inhibitors contain reactive
warheads or electrophiles such as vinyl sulfones67,

75

, epoxy-succinate43,

50

, and fluoromethyl

ketones (FMKs)43, 61 whereas compounds with electrophiles such as α-keto amide69, aldehydes69
and nitriles183 function as a reversible covalent inhibitors of the FPs (Figure 2.1a and 2.1b). In
particular, the covalent modifiers with reactive warheads blocked the hydrolysis of hemoglobin
by erythrocytic parasites, formed hemoglobin-filled food vacuoles in trophozoites and, hampered
parasites development43,

60-62, 64, 184

. Despite their excellent invitro potency against cultured

parasites, these compounds exhibited poor selectivity towards the parasitic cysteine protease over
mammalian cysteine proteases62,

77, 185

. In addition, potential toxicity associated with these

compounds due to the formation of protein adducts restricted their further development as
potential drug candidates. Moreover, peptidic nature of these inhibitors makes them susceptible
to hydrolysis by host cell proteases. The other categories of FP-2 inhibitors include non-peptidic
small molecule inhibitors of the enzymes (Figure 2.1c). Several structure based virtual screening
attempts were made to identify non-peptidic reversible inhibitors against 3D models of FPs from
the commercial databases80, 86, 186. However, to date, only a few non-peptidic inhibitors of FP-2
are available with a lower micromolar (<10 μM) affinity as well as with the ability to inhibit
cultured parasites. Thus, design of non-peptidic, non-covalent inhibitors of FPs is an important
goal, with the likelihood of being able to develop compounds with desirable druggable
59

properties, good in vivo potency, and biochemical selectivity.

Figure 2.1. Representative FP-2 inhibitors (a) covalent irreversible inhibitors50, 75, 77; (b) covalent
reversible inhibitors 69, 75 and, (c) non-peptidic small molecule inhibitors80, 86, 186.
Over the past decade, structure-based virtual screening (SBVS) has gained attention and
successfully identified novel scaffolds against different targets

187

. In brief, SBVS involves the

computational docking of a commercial database into the active site of the 3D structure of the
target, followed by the selection of putative binders using scoring functions188-191. With this
approach, only a small set of compounds is selected and evaluated in a biological assay, as
opposed to the high throughput screening of an entire compound library192, 193. As a part of our
efforts to discover non-peptidic reversible inhibitors of FP-2, we conducted SBVS against the
crystal structure of FP-2 (PDB code: 2GHU) 49 using the Glide docking program. We first built a
focused cysteine protease inhibitor (FCPI) library by substructure searching for compounds
bearing soft electrophiles of interest from the pool of several commercial databases. The
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developed FCPI library was then screened against the crystal structure of FP-2 (PDB code:
2GHU, apo form of the enzyme) to discover novel non-covalent inhibitors of the enzyme.
Evaluation of the selected set of compounds identified 21 diverse non-peptidic inhibitors of FP-2
with lower micromolar potency and a potential for further structural optimizations in to the lead
candidates. Four compounds also inhibited FP-3. Two compounds showed corresponding
inhibition of the cultured parasites. In addition, selected compounds were evaluated against
mammalian cysteine proteases (cathepsin B, K and L) of the papain-family. One compound was
found to be a selective inhibitor of FP-2. Finally, an assessment of electrophilicity of
electrophiles in selected target compounds was carried out by calculation of LUMO density of
each atom. The results suggested the soft-nature of electrophiles in identified hits.
2.2. Methods
2.2.1. Computational Tools. All calculations were performed on a Linux workstation equipped
with four parallel Intel Xeon X5460 processors (3.16 GHZ) with 8 GB total RAM. LigPrep157
was used to produce low energy 3D structures of compounds. Glide docking program194 was
used for pose validation, enrichment study and SBVS. QikProp195 was used to calculate chemical
properties of the FCPI library. Phase196 was used to build docking pose based pharmacophore
query. Diversity analyses of the final hits were performed using the Dissimilarity module
available in Sybyl197. Geometry optimization and measurement of electrophilicity of identified
compounds were performed using Atomic Fukui indices implemented in Jaguar198. All images
were created using Pymol199.
2.2.2. Building the Focused Cysteine Protease Inhibitor (FCPI) Library. The selected softelectrophiles of interest used for building of FCPI library include α-heteroatom substituted
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ketones, α-heteroatom substituted amides, azetidinones, α-keto amide, α-keto acid and α-keto
ester (Figure 2.2.2). Substructure searches were conducted with single line notations (SLN) of
the soft electrophiles (Figure 2.2.2) as a query in Asinex platinum (http://www.asinex.com),
Chembridge

(http://www.hit2lead.com),

Specs

(http://www.specs.net),

Enamine

(http://www.enamine.net), IBScreen (http://www.ibscreen.com) and Aurora Fine Chemicals Ltd
(http://www.aurorafinechemicals.com), using the dbsearch command from the Unity search
module of Sybyl 8.1 (Tripos Inc., St. Louis, MO). The identical compounds obtained from a pool
of different databases were removed. Thereafter, the database was filtered using chemical
properties calculated by QikProp, such as molecular weight (MW) = 250-550, H-bond acceptor
1-10, H-bond donar = 0-5 and no. of rotatable bonds = 0-10. In addition, compounds containing
problematic groups, such as metals, N-oxides, chloramines, aldehydes, and peroxides, were
removed from the FCPI library. The dbslnfilter utility of the Unity module of Sybyl 8.1 was used
to carry out database filtration. Around 65,000 compounds with desired soft-electrophiles were
thus stored in the FCPI library.

Figure 2.2.2. Soft-electrophiles used in the substructure search to build FCPI library.
2.2.3. Protein Preparation. In the present SBVS study, we utilized a recently published crystal
structure of FP-2 available in the apo form (PDB code: 2GHU)49. The residues within 14 Å of
the Cys42 were included in the binding site definition. The PPREP utility of Maestro
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(Schrodinger, LLC, Portland, OR) was used for protein preparation. The protein preparation was
carried out at pH 5 to mimic the acidic environment of the P.falciparum food vacuole (pH = 4-6)
where the enzyme is located. Acidic residues Asp and Glu and basic residues Arg and Lys were
treated as charged unless they were surrounded by hydrophobic residues. Figure 3a shows the
magnified view of the FP-2 active site with subsites S1, S1‟, S2 and S3 labeled. Protein with all
hydrogens added was then submitted to restrained molecular mechanics refinement using the
OPLS2001 force field incorporated in the IMPREF (Schrodinger, LLC, Portland, OR) protein
structure refinement utility, and minimization was continued until the root mean square deviation
(RMSD) reached 0.3 Å. The final refined structure was used for the docking calculations.
2.2.4. Pose Validation, Enrichment Study and Docking Pose-Based Pharmacophore Query.
In the absence of the co-crystallized structure of FP-2, a preliminary docking study was carried
out in the homologous cysteine protease cruzain, the major cysteine protease of T. cruzi, cocrystallized with a vinyl sulfone (VS) inhibitor (PDB ID: 1F2A)200. The criteria for selecting
cruzain as a surrogate platform to establish a docking protocol are as follows: (a) both cruzain
and falcipains are papain family cysteine proteases; (b) the superimposition of FP-2 (2GHU) and
cruzain (1F2A), using DaliLite server201, matches 209 α-carbons with an RMSD of 1.6 Å, a Z
score of 30.4 and, with an overall sequence identity of 38% (Figure 2.2.4.1). Both proteins were
found to have 62% of sequence identity and, RMSD of 2.6 Å in the ligand binding domain as
defined by 10 Å radius from catalytic cysteine (Cys42 in FP-2 and Cys25 in cruzain, see Figure
S0); (c) vinyl sulfone inhibitors, for example, shown in Figure 2.1(a) is a common inhibitor of
both enzymes 67, 200.
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Figure 2.2.4.1. Superimposition of FP-2 (shown in cyan) and Cruzain (shown in orange) using
DaliLite server.
Structural alignment of cruzain complexes, for example, with the irreversible covalent vinylsulfone inhibitor (PDB code: 1F2A, 2OZ2) as well as the reversible covalent inhibitors such as
hydroxyl methyl ketones (PDB code: 1ME3) and a purine nitrile (PDB code: 3I06) using
superimposition module of maestro showed an average RMSD of 0.45 Å. This suggests that
receptor structure does not change substantially upon the binding of inhibitors from different
chemotypes. Therefore, rigid receptor docking protocol implemented in glide was used
throughout the study. Once initial docking protocol is established in cruzain, subsequent
enrichment and docking studies were performed in the crystal structure of FP-2.
A pose validation study was performed using the Glide XP mode without any docking
constraints. The top ranking pose obtained for the VS inhibitor in cruzain using the Gscore
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scoring function was closest to its experimental binding mode (Figure 2.2.4.2b). The RMSD
between predicted and experimental poses of VS inhibitor was found to be 0.97 Å, which was
quite satisfactory considering the number of rotatable bonds of VS (structure shown in Figures
2.2.4.2b and 2.2.4.2d). Subsequent docking of VS inhibitor in FP-2 active site reproduced the
arrangements of P1-P3 groups as observed in X-ray structure of cruzain. Moreover, hydrogen
bonds of VS inhibitor with Trp177, Gln19, Gly66, and Asp158 of cruzain binding site were
reproduced in the FP-2 active site.
The actives from the previous SBVS study 80, 86 (having FP-2 IC50 ≤ 30 µM, see Figure 2.2.4.3
and Table 2.2.4.1) were selected for the enrichment study. Active compounds were seeded with a
total of 1000 decoys downloaded from the Directory of Useful Decoys (DUD) database202.
Decoys were selected by considering the chemical properties such as MW (250-550), no. of
HBD (2-4), no. of HBA (2-8) of known actives. Selection of the diverse sets of decoys
resembling properties of known actives made the enrichment study quite challenging.
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Figure 2.2.4.2 (a) Magnified view of the substrate-binding
b. pocket of FP-2 (PDB code: 2GHU).
Subsites S1, S1‟, S2 and S3 of the enzyme are shown; (b) Pose validation study: superimposition
of co-crystallized pose (green) and the top-ranked pose (cyan) obtained through docking; (c)
Enrichment study: a bar graph showing percentage of actives recovered at 5% (blue), 10% (red)
and 30% (green) of the ranked database with Gscore and Emodel scoring functions; (d) Docking
pose-based pharmacophore query: HBD= hydrogen bond donor; HBA=hydrogen bond acceptor;
HY=hydrophobic. P1, P1‟, P2 and P3 side chains of VS and interacting residues Gln36, Cys42,
Gly83, Tyr78, Leu84, Leu172 and Ala175 of FP-2 binding site are shown.
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Figure 2.2.4.3. Chemical structures of previously reported FP-2 hits (IC50 <=30μ M) used in
enrichment study80, 86
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Table 2.2.4.1 Reported IC50 of previously identified FP-2 hits.

Compound

Code

FP-2a
IC50
(μM)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

1.0
1.4
1.6
2.1
2.2
2.9
3.9
4.6
5.4
5.7
6.2
6.2
6.5
7.0
7.5

16
17
18
19
20
21
22
23
24
25
26
27
28
29

Compound

Code

FP-2b
IC50
(μM)
7.5
10.4
10.8
12.4
13.2
13.8
14.3
15.3
19.0
20.8
22.5
26.6
27.3
31.1
-

In addition, a receptor-based pharmacophore pre-filter was generated based on the docking
pose of the peptidic vinyl sulfone in the crystal structure of FP-2 (2GHU, PDB code) encoding
key receptor-ligand interactions. Phase 3.0 was used to build the pharmacophore query. The
pharmacophore shown in Figure 2.2.4.3d consists of two hydrophobic features (green) mapped
onto the P2 and P3 side chains of VS interacting with hydrophobic residues of S2 and S3
pockets, a hydrogen bond donor feature (cyan) mapped onto the –NH of the P3 side chain
forming H-bond with Gly83 and, a hydrogen bond acceptor (pink) forming the H-bond with the
residues of oxyanion hole (Cys42 and Gln36). As in the S2/S3 pockets, there is no strict
requirement for the ring aromatic feature, the built-in definition for the directional ring aromatic
feature was excluded for performing the search against the FCPI library, and the SMART
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patterns for aromatic rings were included in the hydrophobic feature definition.
2.2.5. Structure-based virtual screening protocol. The FCPI library consisting of ~65,000
compounds was prepared for virtual screening using the ligprep module of Schrodinger (see
Figure 2.2.5). Compounds were subjected to hydrogen additions, removal of salt, ionization, and
generation of low energy ring conformations. The chiralities of the original compounds were
preserved. Finally, the low energy 3D structures of all compounds were produced. To curtail the
database prior to docking, a prepared database was prefiltered using a four-point structure-based
pharmacophore query based on the docking pose of vinyl sulfone. Compounds matching a
minimum 3 out of 4 features of the pharmacophore query were retained. At this stage, filtered
compounds were expected to possess soft electrophiles of interest and relevant pharmacophoric
features of FP-2 inhibitors, which increase the probability for docking of more relevant
compounds in the active site of FP-2. Approximately 30,000 compounds thus retained were
subjected to docking in the crystal structure of FP-2 using the previously validated Glide XP
protocol. The top 3,000 molecules (top 10%) ranked on the basis of Emodel score were selected
for eMBrAce minimization calculation (Macromodel). The eMBrAcE energy minimization in
the energy difference mode was carried out for the protein-ligand complexes to study the
association of ligands with the receptor. The energy difference was calculated as follows:

where ΔE= energy changes upon association; E complex = energy of the receptor-ligand complex;
E

ligand =

energy of ligand alone, and E

protein

= energy of protein alone. Based on EMBrACE

score, the top 500 molecules were selected.
Next, compounds were visually inspected for the following criteria: a) presence of the soft
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electrophile in the vicinity of catalytic Cys42; b) key hydrophobic (Leu172, Leu84) or Hbonding interactions (Gln36, Gly83) between ligand atoms and protein residues; c) the internal
geometry of the ligand in the binding site; d) occupancy of the S2 sub-pocket by the hydrophobic
group of the ligand (hemoglobin cleavage studies demonstrated strong preference for cleavage
sites with Leu at P2 position as a major determinant of the specificity against this enzyme203,
therefore, hydrophobic interactions of ligand in S2 sub-site were considered essential); and, e)
commercial availability of putative hits. Based on these criteria, 200 molecules were selected and
subjected to diversity analysis using the Dissimilarity module of Sybyl 8.1 (Tripos Inc., St.
Louis, MO). A total of 50 diverse compounds were purchased from respective vendors. The
Tanimoto similarity matrix was generated to calculate an average pair-wise Tanimoto similarity
index of identified hits using Similarity/Distance matrix utility implemented in Canvas, version
1.2 (Schrödinger, LLC, New York, NY, 2009), using atom-pair fingerprints. The comparisons of
the obtained hits in the present study with those from previous SBVS studies were carried out
using the dbcmpr utility of Sybyl 8.1 (http://www.tripos.com). The comparison was done by
constructing a UNITY database of each set using Sybyl 8.1.

70

Virtual Screening Workflow
~65,000

FCP library
preparation

Database
prefilter
~30,000

Hydrogen treatment, ionization, desalt,
minimization (Ligprep)

Pharmacophore filter (Phase)

Docking
Glide XP mode (Glide), Emodel

Top 3,000

eMBrAcE
minimization
eMBrAcE calculation in energy
difference mode (Macromodel)

Top 500
Selection

Visual inspection

200
Selection

Diversity analysis
(dissimilarity module)

50
FP-2
Biological
Evaluation
W2

21 hits

6 hits

Figure 2.2.5. A flow chart depicting the virtual screening protocol utilized in the study. W2
stands for chloroquine resistance strain of P.falciparum.
2.2.6. Biological Evaluation. The selected 50 compounds were evaluated for inhibition of FP-2,
FP-3 and against chloroquine resistant (W2 strain) P.falciparum parasites. To determine IC50
values, recombinant FP-2 and FP-3 were incubated for 30 minutes at room temperature in 100
mM sodium acetate, pH 5.5, and 10 mM dithiothreitol with different concentrations of inhibitors
prepared from stocks in DMSO (maximum concentration of DMSO in the assay was 1%). After
30 minutes, the substrate Z-Leu-Arg-AMC (benzoxycarbonyl-Leu- Arg-7-amino-4-methyl71

coumarin) in the same buffer was added to a final concentration of 25 µM. Fluorescence was
monitored for 15 minutes at room temperature in a Lab systems Fluoroskan Ascent
spectrofluorometer. IC50 values were determined from plots of percent activity over compound
concentration using GraphPad Prism software204.
The assays for selected human cysteine proteases, cathepsin B, K and L were conducted in a
similar way as described above for FP-2. The assay concentration used for cathepsin B, K and L
were 7.94 nM, 3.40 nM and, 5.38 nM, respectively. The appropriate substrates (Z-Phe-Arg-AMC
for cathepsin K and L, and Z-Arg-Arg-MCA for cathepsin B) were added to a final concentration
of 25 µM.
Activity against malaria parasites was tested against the chloroquine-resistant (W2) strain of P.
falciparum, which was cultured at 2% hematocrit of human erythrocytes in RPMI 1640 medium
supplemented with 0.5% Albumax (Gibco), 2% heat inactivated human serum and 100 µM
hypoxanthine in 96-well culture plates. Parasites were synchronized with 5% sorbitol205. All
tested compounds were prepared as 10 mM stock solutions in DMSO and diluted in medium at
least 1:1000, resulting in ≤0.1% final concentrations of DMSO. Parasites at 1% parasitemia were
incubated with compounds at 37 °C under 3% O2, 5% CO2, 92% N2. After 48 hours, the medium
was removed, and cells were fixed with 2% formaldehyde in PBS for 24 hours. After fixation, 5
µl aliquots were incubated for 15 min in the dark in 150 µl of 100 mM NH4Cl, 0.1% Triton X100 in PBS, and 10 nM YOYO-1 (Molecular Probes). Parasitemia was determined based on
counts from a FACSort flow cytometer (Beckton Dickinson) using CellQuest software (Beckton
Dickinson). IC50 values for growth inhibition were determined from plots of percent control
parasitemia over inhibitor concentration using Prism® software (GraphPad). Compounds were
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also evaluated for cytotoxicity on VERO (monkey kidney fibroblast) cells by the neutral red
assay206. IC50 values for each compound were computed from the growth inhibition curve.
2.2.7. Calculation of electrophilicity of soft-electrophiles in identified hits
Atomic Fukui indices, derived from Mulliken population of the Highest Occupied Molecular
Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO), were used to quantify
electrophilicity of a molecule at a particular atomic site. Two different set of Fukui indices
calculated include the HOMO and the LUMO. Each index has two subscripts: N stands for the
electron density and, S stands for the spin density. Thus, a total of four indices were calculated
for both, the HOMO and the LUMO: F_NN, F_NS, F_SN, and F_SS. The first index shows
which property responds to a change in the property indicated by the second index, hence, F_NN
indicates the change in the electron density when only the electron density that is changing, and
the spin density is constant. Similarly, F_NS represents the change in the electron density when
only the spin density is changing etc. F_NN_LUMO was considered for measuring
electrophilicity of electrophilic center in the target compounds. Structures were subjected to the
geometry optimization using the hybrid density functional B3LYP207, 208 and a basis set 6-31G*
in a gas phase using Jaguar. The default convergence criterion implemented in Jaguar were used
for SCF calculations (accuracy level= Quick, convergence criteria: maximum iteration=48 and,
energy change= 5 × 10-5 hartree), and, optimization (Maximum steps=100, convergence
criteria=default, initial hessian=Schlegel guess209). The fully optimized geometry of compounds
were subjected to the calculation of Atomic Fukui indices implemented in the property section of
the Jaguar optimization panel, according to formalism presented elsewhere210, 211. Fukui function
for the electron density integrates to one, so the predicted reactivity here are scaled from zero to
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one, one being the most reactive. It is worthwhile mentioning that in all cases, the SH group of
the active site cysteine has been assumed as a nucleophile or HOMO component of a
nucleophilic-electrophilic addition reaction.
2.3.

Result and Discussions

Out of 50 compounds submitted for biological testing, a total of 21 diverse non-peptidic hits
were identified. The IC50 values of hits for FP-2 inhibition ranged from 1.4 µM to 49 µM (shown
in Table 2.3.1). Four compounds 2, 5, 8 and 11 were found to be dual inhibitors of FP-2 and -3.
The structures of identified inhibitors are depicted in Figure 2.3.1.
Table 2.3.1. Biological evaluation of compounds selected hits from SBVS against FP-2 and
cultured parasites.
FP-3a1
IC50
(μM)

W2b
IC50
(μM)

Compound

Codec

FP-2a
IC50
(μM)

Codec

FP-2a
IC50
(μM)

1
2
3
4
5
6
7
8
9
10
11
E-64
Artemisinin
Chloroquine

1.39
2.18
3.26
4.59
7.51
7.85
10.32
11.58
11.86
15.11
20.87
0.08
-

>50
4.95
>50
>50
30.27
>50
>50
45.64
>50
>50
36.05
0.15

NA
NA
NA
NA
1.90
4.34
NA
NA
NA
1.57
NA
0.01
0.05

12
13
14
15
16
17
18
19
20
21
22
E-64
Artemisinin
Chloroquine

23.81
25.25
25.96
25.99
28.66
32.85
37.34
44.94
46.97
49.18
>50
0.08
-

Compound

FP-3a1
IC50
(μM)
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
0.15

W2b
IC50
(μM)
NA
NA
NA
NA
NA
NA
1.92
NA
NA
5.83
7.21
0.01
0.05

NA= not active up to 50 μM; afalcipain-2, a1falcipain-3, bAntimalarial activity against
chloroquine resistant (W2) strain of P. falciparum. call compounds were non-cytotoxic at least up
to 50 μM in VERO (monkey kidney fibroblast) cells. E-64, artemisinin and chloroquine were
used as positive controls.
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A major bottleneck in SBVS is finding a suitable scoring function for the target of interest to
enable the identification of potential active compounds prior to the screening of large chemical
databases. Novel approaches to address this problem include the use of a target-biased scoring
function which takes into consideration the nature of the target (polar vs apolar binding site) as
well as the nature (pharmacophoric patterns and similarity considerations) and key interaction of
known ligands with the target212. In the present study, two scoring functions implemented in the
Glide module of Schrodinger, Gscore and Emodel were evaluated for their abilities to retrieve
known FP-2 inhibitors from decoys downloaded from the DUD database. The recovery rates
(Figure 2.2.4.2c) showed that among the scoring functions evaluated, Emodel performed better
than Gscore in 5%, 10% and 30% database screens. At the 5% database screened mark, the
percentage of actives recovered was 50% for Emodel while at the 10% and 30% database
screened marks, the percentage of actives recovered was 66% and 84% by the Emodel scoring
function as compared to 28% and 50%, respectively, for the Gscore. These results were quite
encouraging considering the diversity of the actives used in this study and enhanced our
confidence in using Emodel as a scoring function for the SBVS study. The higher enrichment
rate associated with Emodel might be because of significant weighting of force field components
such as the Coulomb and van der Waals energy in Emodel as compared to Gscore213. These
interactions may be a major driving factor for the ligand binding for the apolar FP-2 binding site,
and, as a result, Emodel performed better with the FP-2 active site than Gscore. A similar
observation was made by Li et al. in their virtual screening study, suggesting the importance of
Dock energy score (GAsDock) over a Chemscore-based (GScore) scoring function more suitable
for the apolar FP-2 binding site186. The success ratio for the present study in finding novel
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chemotypes was 42%, which suggest the score-based active/inactive separation ability of current
docking protocol against this target. The higher hit ratio also implied the importance of scoring
function based enrichment studies prior to SBVS.

Figure 2.3.1. Structures of the FP-2 inhibitors identified through SBVS of FCPI library.
Substructure containing electrophiles of interest are highlighted in blue.
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Prior to virtual screening of FCPI library, the database was curtailed with a docking pose based
pharmacophore query. Key interactions of vinyl sulfone inhibitor with residues of FP-2 active
site such as Gly83, Cys42, Gln36, along with the hydrophobic residues of S2 and S3 pocket
(shown in Figure 3d) were used to build the pharmacophore query, consisting of four descriptors:
HBD, HBA, HY1, and, HY2. The selection of pharmacophoric descriptors were based on a
thoughtful consideration of crucial interactions of cysteine protease inhibitors with the conserved
residues of the papain-family cysteine proteases. For example, Gly83 is highly conserved in the
S3 subsite of clan CA cysteine proteases34,

214

(Figure 2.3.2), and, the lack of potency was

reported for the cysteine protease inhibitors particularly binding to the non-prime (S1-S4) site
lacking hydrogen bond with the carbonyl oxygen of glycine11,

215

. Similarly, inhibitors of the

papain-family of enzymes, are commonly shown to form hydrogen bonding interactions with
residues forming oxyanion hole such as Gln36 and backbone amine of catalytic cysteine Cys42
in FP-2

11, 216, 217

. Moreover, as with the most other papain-family of proteases, analysis of the

specificity of FP-2 indicated that the amino acid at the P2 position plays a key role in mediating
substrate specificity, at least with peptide substrates34. In addition, substrate mapping and
inhibitor profiling study against FP-2 revealed strong preference for hydrophobic residue at P2
(Leu>Phe>Val) in the S2 Pocket34, 185. Finally, the recently published X-ray structure of FP-2
bound to a covalent irreversible epoxysuccinate inhibitor (E-64)50 gives an additional validity to
our selection of docking-pose based pharmacophoric descriptors (Figure 1.2, Chapter 1). The
carboxyl group of E-64 occupies the oxyanion hole formed by Gln36 and Cys42, resembling
HBA feature of our pharmacophore query. Similarly, peptidyl backbone amine of E-64 forms
hydrogen bond with a backbone carbonyl of Gly83, similar to assigned HBD descriptor of
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pharmacophore query. The P2-leucine of E-64 exhibits hydrophobic interactions in the S2 pocket
with Ile85, L172 and Ala175, whereas P3 side chain of E-64 exhibited hydrophobic interaction
with Gly83, Leu84, and, cation-pi interactions with the Tyr78 in S3 pocket, relating to the HY1
and HY2 descriptors of docking pose-based pharmacophore query.
*
FP-2
FP-3
CAT_K
CAT_L1
CAT_B

--------QMNYEEVIKKYR-GEENFDHAAYDWRLHS----GVTPVKDQK
TLSPPVSYEANYEDVIKKYKPADAKLDRIAYDWRLHG----GVTPVKDQA
-------------------------RAPDSVDYRKKG----YVTPVKNQG
----------------------------FSVDWREKG----YVTPVKNQG
YLKRLCGTFLGGPKPPQRVMFTEDLKLPASFDAREQWPQCPTIKEIRDQG
*
FP-2
NCGSCWAFSSIGSVESQYAIRK--NKLITLSEQELVDCSFK--NYGCNGG
FP-3
LCGSCWAFSSVGSVESQYAIRK--KALFLFSEQELVDCSVK--NNGCYGG
CAT_K
QCGSCWAFSSVGALEGQLKKKT--GKLLNLSPQNLVDCVSE--NDGCGGG
CAT_L1 QCGSCWAFSATGALEGQMFRKT--GRLISLSEQNLVDCSGPQGNEGCNGG
CAT_B
SCGSCWAFGAVEAISDRICIHTNAHVSVEVSAEDLLTCCGSMCGDGCNGG

37
46
21
18
50
83
92
67
66
100

FP-2
FP-3
CAT_K
CAT_L1
CAT_B

LINNAFEDMIELGGICP---DGDYPYVSDAPNLCNIDRCTEKYGIKNYLS
YITNAFDDMIDLGGLCS---QDDYPYVSNLPETCNLKRCNERYTIKSYVS
YMTNAFQYVQKNRGIDS---EDAYPYVGQE-ESCMYNPTGKAAKCRGYRE
LMDYAFQYVQDNGGLDS---EESYPYEATE-ESCKYNPKYSVANDTGFVD
YPAEAWNFWTRKGLVSGGLYESHVGCRPYSIPPCEHHVNGSRPPCTGEGD

130
139
113
112
150

FP-2
FP-3
CAT_K
CAT_L1
CAT_B

VPD------------------------------NKLKEALRFLGPISISV
IPD------------------------------DKFKEALRYLGPISISI
IPEG---------------------------NEKALKRAVARVGPVSVAI
IPK----------------------------QEKALMKAVATVGPISVAI
TPKCSKICEPGYSPTYKQDKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAF

150
159
136
134
200

FP-2
FP-3
CAT_K
CAT_L1
CAT_B

AVS-DDFAFYKEG-IFDGECG-DELNHAVMLVGFGMKEIVNPLTKKGEKH
AAS-DDFAFYRGG-FYDGECG-AAPNHAVILVGYGMKDIYNEDTGRMEKF
DASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQ----------KGN
DAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTE------SDNN
SVY-SDFLLYKSG-VYQHVTGEMMGGHAIRILGWGVEN----------GT

197
206
176
178
238

FP-2
FP-3
CAT_K
CAT_L1
CAT_B

*
YYYIIKNSWGQQWGERGFINIETDESGLMRKCGLGTDAFIPLIE-----YYYIIKNSWGSDWGEGGYINLETDENGYKKTCSIGTEAYVPLLE-----KHWIIKNSWGENWGNKGYILMARNKN---NACGIANLASFPKM------KYWLVKNSWGEEWGMGGYVKMAKDRR---NHCGIASAASYPTV------PYWLVANSWNTDWGDNGFFKILRGQD----HCGIESEVVAGIPRTDQYWE

241
250
216
218
284

Figure 2.3.2. Multiple sequence alignment of FP-2 with homologous cysteine proteases
performed using Clustal 2.0.12 1. Sequence information is from SWISS-PROT (accession
numbers: Q9NAW2, Q9NB39, P43235, P07711 and P07858). The conserved residues among all
papain-family cysteine proteases are shown in green. The amino acid residues of the S2 pocket
differing between FPs and mammalian cysteine proteases are highlighted in red. Catalytic
residues are highlighted in *.
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As mentioned before, the main drawback of covalent modifiers (for example, compounds
bearing electrophiles such as α, β-unsaturated ketones, α-halo ketones, cynamide) is lack of
target specificity. In addition, non-specific binding of covalent modifiers to protein, DNA or
glutathione (GSH) may lead to unfavorable toxicological events such as immunogenic response
or life-threatening idiosyncratic adverse drug reactions (ADRs)218,

219

. Soft-electrophiles

attenuate the reactive nature of hard electrophiles and might reduce the risk of toxicity associated
with covalent modifiers. Thus, use of the soft-electrophiles based FCPI library for SBVS
provides a strategic approach to discover novel, selective inhibitors, preferably modulating the
enzyme through non-covalent interactions. The soft-electrophiles selected here had previously
shown to form tetrahedral intermediates with cysteine proteases, for example, α-heteroatom
substituted ketones217, 220-222, α-keto amide56, 223, α-keto acid56, α-keto ester56 and azetidinones215.
To assess the soft-nature of electrophiles present in target compounds, we performed calculations
of the Atomic Fukui indices on a few selected compounds (1, 3-5, 7, 11, 12, 14, and 15)
containing diverse soft-electrophiles. Fukui indices are partial second derivatives of the electron
or spin density with respect to a change in the electron count or the unpaired spin count. They are
regional descriptor of site reactivity predicting which atoms in a molecule are most reactive
towards electrophilic or nucleophilic attack based on the analysis of Frontier Molecular Orbitals
(FMOs) in a molecule210. The greater the magnitude of an index, the greater change in electron
or spin density near the atoms of interest, and thus, higher reactivity of a molecule at that atomic
site for an electrophilic or a nucleophilic reaction224. Generally, a nucleophilic reaction takes
place preferably in the substrate sites with the largest values for the LUMO density. Likewise, an
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electrophilic reaction is most likely to occur at the largest HOMO electron density in the
molecular site211, 225. Since our goal was to probe the most electrophilic center in identified FP-2
hits and predict its electrophilicity, we considered calculation of Fukui indices, F_NN_LUMO at
a constant spin density in selected compounds. The electrophilicity of electrophilic centers
present in identified FP-2 hits were compared with the known cysteine protease inhibitors with
an irreversible covalent (α-halo ketone, R1; vinyl sulfone, R2) and a reversible covalent (αketoamide, R3) warhead groups. The values of Fukui index F_NN_LUMO, of the most
electrophilic atoms of the FP-2 inhibitors, and, reference compounds (R1-R3) are shown in
Figure 2.3.3.
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Figure 2.3.3. An evaluation of regional Fukui functions to predict the electrophilicity of atomic
site of reference compounds (R1-R3) and selected FP-2 inhibitors is shown here. The most
electrophilic center in the compounds is shown by the arrows. The corresponding value of the
Fukui index, F_NN_LUMO, for the reactive atoms (scaled from zero to one) is shown in blue.
The result from the calculation (Figure 2.3.3) demonstrates that the site specific reactivity of
the identified FP-2 inhibitors is less than the irreversible covalent inhibitors: R1 with an α-halo
ketone (LUMO = 0.518) and R2 with a vinyl sulfone warhead group (LUMO = 0.428) and, are
comparable to the known reversible covalent inhibitor, R3 with an α-keto amide (LUMO =
0.395) moiety. These calculations suggest the soft-nature of the electrophilic atoms in the
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identified FP-2 hits. However, one exception here is compound 14 with a higher than expected
electrophilicity value, presumably because of the ring strain of an azetidin-3-ones moiety, which
is reflected in the calculated LUMO value (0.417). On the basis of the predicted site reactivity of
soft-electrophiles, compounds with an α-hetero ester (5, LUMO = 0.322) were found to be more
electrophilic than those with an α-hetero ketone (7, 11, LUMO = 0.251; 15, LUMO = 0.253),
which in turn had a higher electrophilicity than hits with an α-hetero amide functionality (1,
LUMO = 0.115; 4, LUMO = 0.020). One point worth mentioning here is that the calculated
electrophilicity is influenced by the complex interplay of factors such as a neighboring group
effects, the internal geometry of the compound, intermolecular hydrogen-bonding and the
solvation effects. For example, the predicted electrophilicity of the α-keto amide 12 (LUMO =
0.223) was found to be lower than the R3 LUMO (0.395). This difference may be due to the
presence of an adjacent heteroaromatic system leading to extensive conjugation as well as
intramolecular hydrogen bonding between the nitro group and the enolic OH forming a six
membered chelate. Similarly, in case of hits with α-heteroatom substituted ketones, a slightly
higher predicted electrophilicity of 15 than 7 or 11 might be due to the presence of the electron
withdrawing p-chloro group, increasing the electrophilicity of the carbonyl carbon. However, a
comparison of predicted site-specific reactivity of identified hits with FP-2 inhibition data
suggests a lack of correlation of electrophilicity with the enzymatic inhibition. For instance,
compound 14 with an azetidine-3-one, had the highest predicted LUMO based electrophilicity
among the identified hits, however, it was only moderately active in the FP-2 inhibition assay
(IC50 =25.9 μM). By comparison, compounds with an α-hetero amide (compounds 1, 4) were
predicted to have a negligible electrophilicity but showed relatively higher experimental
82

inhibition of FP-2 (IC50 = 1-5 μM). This observation emphasizes the obvious involvement of
other factors in enzyme inhibition, such as the overall geometry and interaction patterns of the
compounds in the FP-2 binding site.
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Figure 2.3.4. Predicted binding mode of virtual screening hits (a) 1 (b) 2 (c) 6 in the FP-2
binding site.
Figure 2.3.4 shows predicted interaction profiles of representative compounds 1, 2 and 6 in FP2 active site. The 4-oxo-phthalazine core in molecule 1 appears to protrude into the S1‟ pocket
with the carboxylic acid group interacting with the residues of an active site-forming oxyanion
hole such as the backbone –NH of Cys 42 and the amide side chain of Gln 36 (see Figure 2.3.4a).
Also, Trp206 and Val152 of the S1‟ pocket are involved in the van der Waals interactions with
the pthalazine moiety wherein the indole –NH of Trp206 participates in hydrogen bonding with
the carboxylate moiety of 1. The α-ketoamide soft-electrophile exhibits hydrogen bonding
interaction with the backbone –NH of Gly82 and the backbone carbonyl of Asn173. The phenyl
ring at the terminus of the amide linker can undergo hydrophobic interaction with the side chains
of Ala175. The terminal 2, 4 dimethyl phenyl moiety is involved in hydrophobic interactions
with the side chains of Leu84, Ile85 at the entrance of the S3 pocket as well as with the Phe236
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buried deeper in the S2 pocket.
In case of compound 2, the 5-methyl-isooxazole moiety was well placed in the S1‟ pocket of
FP-2, exhibiting hydrophobic interactions with the side chains of Tyr206 and Val152 (Figure
2.3.4b). Also, the isoxazoyl moiety of 2 was involved in multiple hydrogen bonding interactions
with the side chain amide proton of Gln36 as well as the indole -NH of Trp206. The carbonyl
group of the α-keto amide electrophile located over the catalytic Cys42 formed a critical
hydrogen bonding interaction with the backbone amine of Cys42, whereas the –NH of the α-keto
amide electrophile acts as a hydrogen bond donor for the backbone carbonyl of Asn 173. In
addition, the α-keto amide linker was involved in hydrophobic interactions with Gly82. The
nitrogen of the tetrazole moiety acted as a hydrogen bond acceptor with the backbone amine of
Gly83. The phenyl ring attached to the tetrazole moiety of 2 vectors into the critical S2 pocket,
forming hydrophobic interactions with Leu172 at the entrance of the S2 pocket as well as with
the Leu84 side chain lining the S3 pocket. The anilinic -NH of 2 donated a hydrogen bond to the
side chain carboxylic group of Asp234 buried in the hydrophobic environment of the S2 pocket.
The terminal phenyl ring was found to exhibit van der Waals interactions with the side chain of
Leu172, exposing the para fluoro group to the solvent.
A similar observation was made for compound 6 near the S1‟ pocket, especially for the 5methyl-isooxazole moiety (Figure 2.3.4c). The thioacetamide electrophile is placed over the
catalytic cysteine sulfur, and its carboxamide group participates in the hydrogen bonding
interactions with Cys42 and Asn173 in a similar manner as observed for 2. The quinazoline core
of 6 is placed aptly in the S2 pocket, forming van der Waals interactions with Ala175 and
Leu172. In addition, nitrogen on the quinazoline ring of 6 accepts a hydrogen bond from the
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backbone of Gly83. Moreover, the admantyl moiety of 6 protrudes into the S3 pocket and
participates in the van der Waals interactions with the Tyr78 of the S3 pocket.

Figure 2.3.5. Comparison of similarity of hits identified in the current study with previously
identified hits (structure shown in Figure 2.2.4.3) using dbcmpr utility of Sybyl 8.1. The median
Tanimoto coefficient is about 0.33 (where the graph crosses the 50% threshold), and all of
compounds in the current dataset have a Tanimoto of 0.5 or less with their nearest neighbour in
the reference database suggesting identified hits are structurally novel.

The average pair-wise Tanimoto similarity index of the 21 FP-2 inhibitors was 0.24, which
point towards the diverse nature of the identified hits (see similarity matrix, Table 2.3.2). The
diversity of hits obtained in the present study with previously identified FP-2 inhibitors was
analyzed using the dbcmpr module of Sybyl. dbcmpr utility calculates the Tanimoto similarities
using UNITY 2D fingerprints between all compounds identified in current study (test set) with
their nearest neighbors in the previous study (reference set). The result of this comparison
showed that 95% of compounds from the test set has the Tanimoto similarity of less than or
equal to 0.5 to its nearest neighbor in the reference set (see database comparison, Figure S3 in
the supporting information). The results clearly suggest novelty of the hits identified in the
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present study.
Table 2.3.2. The pair-wise Tanimoto similarity matrix table generated using Canvas, version 1.2
(Schrödinger, LLC, New York, NY, 2009) for 21 identified hits. The maximum similarity was
0.5 between compound pairs 4 and 21 which share same core.
Comp

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

20

21

19

1

1.00

0.32

0.25

0.29

0.22

0.19

0.33

0.20

0.33

0.36

0.17

0.26

0.27

0.19

0.22

0.23

0.38

0.29

0.20

0.28

0.17

2

0.32

1.00

0.24

0.27

0.21

0.26

0.32

0.20

0.25

0.31

0.13

0.24

0.20

0.19

0.17

0.23

0.30

0.24

0.20

0.26

0.15

3

0.25

0.24

1.00

0.30

0.36

0.24

0.31

0.20

0.29

0.26

0.19

0.32

0.25

0.29

0.23

0.27

0.31

0.23

0.29

0.28

0.19

4

0.29

0.27

0.30

1.00

0.21

0.26

0.32

0.31

0.33

0.23

0.16

0.23

0.25

0.26

0.21

0.41

0.42

0.46

0.26

0.50

0.29

5

0.22

0.21

0.36

0.21

1.00

0.21

0.26

0.14

0.24

0.37

0.17

0.24

0.23

0.32

0.21

0.25

0.23

0.17

0.26

0.19

0.18

6

0.19

0.26

0.24

0.26

0.21

1.00

0.25

0.20

0.24

0.19

0.15

0.24

0.21

0.23

0.18

0.27

0.25

0.26

0.28

0.24

0.19

7

0.33

0.32

0.31

0.32

0.26

0.25

1.00

0.32

0.27

0.38

0.15

0.32

0.36

0.27

0.36

0.40

0.38

0.33

0.32

0.32

0.21

8

0.20

0.20

0.20

0.31

0.14

0.20

0.32

1.00

0.21

0.18

0.21

0.19

0.33

0.18

0.24

0.31

0.27

0.28

0.42

0.28

0.17

9

0.33

0.25

0.29

0.33

0.24

0.24

0.27

0.21

1.00

0.27

0.17

0.24

0.33

0.20

0.27

0.26

0.31

0.28

0.23

0.33

0.22

10

0.36

0.31

0.26

0.23

0.37

0.19

0.38

0.18

0.27

1.00

0.14

0.28

0.27

0.34

0.30

0.29

0.35

0.28

0.25

0.21

0.18

11

0.17

0.13

0.19

0.16

0.17

0.15

0.15

0.21

0.17

0.14

1.00

0.14

0.24

0.21

0.15

0.16

0.13

0.17

0.18

0.18

0.15

12

0.26

0.24

0.32

0.23

0.24

0.24

0.32

0.19

0.24

0.28

0.14

1.00

0.26

0.27

0.22

0.30

0.28

0.23

0.20

0.20

0.16

13

0.27

0.20

0.25

0.25

0.23

0.21

0.36

0.33

0.33

0.27

0.24

0.26

1.00

0.25

0.29

0.34

0.29

0.27

0.31

0.24

0.19

14

0.19

0.19

0.29

0.26

0.32

0.23

0.27

0.18

0.20

0.34

0.21

0.27

0.25

1.00

0.25

0.34

0.24

0.22

0.22

0.17

0.27

15

0.22

0.17

0.23

0.21

0.21

0.18

0.36

0.24

0.27

0.30

0.15

0.22

0.29

0.25

1.00

0.26

0.25

0.23

0.25

0.21

0.20

16

0.23

0.23

0.27

0.41

0.25

0.27

0.40

0.31

0.26

0.29

0.16

0.30

0.34

0.34

0.26

1.00

0.38

0.35

0.25

0.31

0.22

17

0.38

0.30

0.31

0.42

0.23

0.25

0.38

0.27

0.31

0.35

0.13

0.28

0.29

0.24

0.25

0.38

1.00

0.49

0.26

0.34

0.21

18

0.29

0.24

0.23

0.46

0.17

0.26

0.33

0.28

0.28

0.28

0.17

0.23

0.27

0.22

0.23

0.35

0.49

1.00

0.22

0.31

0.24

20

0.20

0.20

0.29

0.26

0.26

0.28

0.32

0.42

0.23

0.25

0.18

0.20

0.31

0.22

0.25

0.25

0.26

0.22

1.00

0.28

0.17

21

0.28

0.26

0.28

0.50

0.19

0.24

0.32

0.28

0.33

0.21

0.18

0.20

0.24

0.17

0.21

0.31

0.34

0.31

0.28

1.00

0.27

19

0.17

0.15

0.19

0.29

0.18

0.19

0.21

0.17

0.22

0.18

0.15

0.16

0.19

0.27

0.20

0.22

0.21

0.24

0.17

0.27

1.00

In addition to inhibition of FP-2, compounds 5, 6, 10, 18, 21 and 22 exhibited in vitro antimalarial activity. Compounds 5 and 6 showed the same log order IC50 values in whole-cell
assays as in the enzyme assay. Other compounds (10, 18, 21 and 22) displayed greater activity
against cultured parasites than FP-2. These observations might be explained in a number of
ways: First, the compounds might be acting both against FP-2 and non-protease targets, as
suggested by results with phenothiazines226. For example, compound 10 contains napthoquinone
scaffold conferring its redox potential227 and may exert its activity via protein crosslink in the
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cultured parasites in addition to inhibition of FP-2. Second, the compounds may be acting against
targets other than FP-2. This possibility is suggested by the fact that compounds 18, 21 and 22
did not form a swollen, hemoglobin-filled food vacuole, as seen with highly potent covalent
falcipain inhibitors64, 183. Third, the compounds might concentrate in the food vacuole, allowing
activity at culture concentrations below those that inhibit the protease. In any event, our screens
identified a number of compounds with low micromolar antimalarial activity. Of note, all the
compounds shown in Figure 2.3.1 were non-toxic in cytotoxicity assay, suggesting potential for
development of related compounds as drugs.
Next, we screened identified FP-2 hits (compound 1-7, FP-2 IC50 ≤ 10 μM) against selected
human papain-family cysteine proteases (cathepsin B, cathepsin K and cathepsin L), for possible
off-target activity (Table 2.3.3). As expected, the evaluated hits (1-7) were found to inhibit
selected cathepsins that are closely related to the parasitic cysteine proteases. Although,
homology exists between the parasitic cysteine protease and its human orthologues, there are
significant differences in the binding site residues, especially near the S2 pocket of these
enzymes. For instance, sequence comparison (Figure 2.3.2) suggested Ser149 in the S2 pocket of
FPs is replaced by Ala in human orthologues. Ser149A mutation in FP-2 was reported to
decrease the proteolytic activity by 91%
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and, can be targeted for design of selective protozoal

cysteine protease inhibitors. In addition, Ile85 of the S2 pocket of FP-2 and FP-3 is replaced by
methionine in cathepsin K and L and, proline in cathepsin B. Moreover, the polar residues such
as Asp234 and Glu243 in the S2 pocket of the FP-2 and FP-3 binding sites, respectively are
replaced by hydrophobic residues such as Leu and Ala in cathepsin K and L228. These differences
between the proteases can be utilized for the design of selective inhibitors of FPs. To our
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surprise, compound 4 did not show any inhibition up to 50 μM against the evaluated mammalian
cysteine proteases. Further docking studies of 4 in the selected mammalian cysteine protease
panel might provide valuable insights for the binding mode and selectivity of this compound in
FP-2.
Table 2.3.3. The IC50 values of FP-2 hits against selected human cathepsin peptidases
Comp No.
1
2
3
4
5
6
7
E-64

2.4.

Cathepsin K Cathepsin L Cathepsin B
IC50 (μM)
IC50 (μM)
IC50 (μM)
20.00
9.30
10.72
3.83

24.39

37.14

25.60

41.57

14.74

>50

>50

>50

26.70

5.86

49.08

29.66

16.52

21.44

6.12

31.63

17.66

0.004

0.016

0.007

Conclusions

The focused cysteine protease inhibitor library consisting of ~65,000 compounds was screened
against the X-ray crystal structure of FP-2. The attractive components of the virtual screening
approach were the FCPI library based on soft-electrophiles of interest, the enrichment study to
select the best scoring function, the docking pose-based pharmacophore query as a filter in the
SBVS protocol, and, consideration of binding energy of the receptor-ligand complex for the
selection of putative hits. The study reported a high success ratio with novel antimalarial
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scaffolds. Twenty one compounds were active against FP-2 and four were also active against FP3. Two FP-2 hits, compound 5 and 6, showed corresponding inhibition of the cultured parasites,
showing promise for further structural optimization. Moreover, the predicted site-specific
electrophilicity, as measured by calculating the LUMO electron density of each atom in the form
of the atomic Fukui Indices, suggested a soft-nature of the electrophiles present in identified hits.
Thus, any potential risk of toxicity associated with the irreversible inhibition of the cysteine
protease is attenuated. Assessment of the selectivity of identified hits against related mammalian
cysteine proteases (cathepsin B, K and L) revealed compound 4 as a selective inhibitor of FP-2
(IC50 > 50 μM against tested mammalian proteases). The hits obtained through the present
screening efforts can be optimized via substructure/similarity search approaches to identify
structural analogs of the active hits taking into consideration the key residues of the S2 pocket
for the biochemical selectivity as discussed above. In addition, combinatorial library synthesis
for selected hits (for example, compounds 2, 4, 6, 7) using commercially available building
blocks can be pursued taking insights from the recently published co-crystallized structure of FP250, for enhanced binding site occupancy and interaction profiles, to establish an SAR, and, will
be addressed in follow up work.
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Chapter 3

Design, Synthesis and Biological Evaluation
of Benzothiazole Analogs as Falcipain-2
Inhibitors

The content of this chapter is published in: Shah, F., Wu, Y., Jiri G., Pedurri, Y., Rosenthal,
P., Avery M. A. Design, synthesis and biological evaluation of novel benzthiazole and triazole
analogs as inhibitors of falcipain, cysteine protease of malaria parasite Plasmodium falciparum,
MedChemComm, 2011 DOI: 10.1039/C1MD00129A
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3.1. Introduction
As discussed in previous chapters, most of the potent FP-2 inhibitors described in the
literature were peptide analogs, displaying a covalent irreversible binding mode with the active
site cysteine, and were relatively non-selective. It is highly desirable to develop non-peptidic,
non-covalent inhibitors of FPs to minimize toxicity risk while retaining in vivo activity and
selectivity. In our previous study, we carried out the structure-based virtual screening (SBVS) of
the FCPI library built based on soft-electrophiles against the X-ray structure of FP-2229. The
study identified 21 diverse micromolar inhibitors of FP-2. In the present work, we initiated
efforts to optimize the potency of lower micromolar FP-2 hit 1 with a benzothiazole core (Figure
1). Compound 1 was selected for further optimization based on a) ease to synthesize
combinatorial library around commercially available benzthiazole core and to establish an SAR
and b) to test selectivity hypothesis of these series of compounds to FPs over other homologous
mammalian cysteine proteases of the papain-family. The optimization of benzothiazole series
was carried out with mutation of the benzothiazole core with other complementary groups
followed by combinatorial library design and synthesis around the benzothiazole core. A total of
23 analogs were made in this series and evaluated against the enzyme FP-2, FP-3 and for the
activity against cultured P. falciparum parasites. Twelve compounds from the benzothiazole
series showed moderate activity against FP-2. Two compounds from the benzothiazole series
showed dual inhibition of FP-2 and FP-3. One particular compound from benzothiazole series
showed corresponding inhibition of the cultured parasites. Docking of these inhibitors in the FP2 active site provided insights about SAR and interactions of the inhibitors with the active site of
FP-2.
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Figure 3.1. Structures and biological
activity of 1 against the cysteine
proteases: FP-2 and FP-3, the
chloroquine-resistant (W2) strain of P.
falciparum, and the mammalian
cysteine proteases cathepsins (Cat) K,
L, and B are shown.

3.2. Optimization strategies: Core hopping, Structure-based design
Core or scaffold hopping is a technique frequently used by medicinal chemists to discover
novel compounds by mutating the molecule core or scaffold starting from known active
molecules230. Core hopping gives medicinal chemists an opportunity to pursue drug design in a
different chemical space to improve potency, to improve ADMET liabilities of a given scaffold,
to circumvent intellectual property rights associated with a parent scaffold or to speed up the lead
optimization process230.
Our primary goal was to improve the potency of virtual screening hits 1. For the initial
optimization of 1 with core-hoping strategy, we selected analogs which were commercially
available, affordable and had an α-thioketone to act as a soft-electrophile prior to initiating
extensive synthetic efforts. From the docking studies of 1, we envisioned that the replacement of
the benzothiazole core with benzimidazole and thioacetamide moieties may improve the overall
affinity of 1 by forming strong H-bond networks with the backbone Gly83 and Asn173.
Therefore, our selection was limited to commercially available compounds (3-10) containing
these cores with the goal of improving potency. While selecting compounds in these series,
compounds with electron withdrawing groups para to the phenyl ring (for example, 3, 4, 7) were
preferred to enhance the reactivity of the carbonyl carbon with the catalytic Cys42 of the FP-2
active site. It is worthwhile to mention that compounds 9 and 10 can be reasonably enolic and
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may predominantly behave as α, β-unsaturated ketones in the FP-2 active site. This enolic
behavior is in equilibrium, thus availability of the carbonyl tautomer should not be
problematical. Selected compounds were docked in the crystal structure of FP-2 using Glide
extra precision (XP) mode and a previously validated docking protocol229. Although
thioacetamide and benzimidazole compounds showed improved interaction profiles in the
binding site (Figure 3.2.1), they were inactive against FP-2 at concentration up to 50 µM. These
findings, although surprising, suggested the importance of the benzothiazole core for FP-2
inhibition and prompted us to design a library around this core.
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Figure 3.2.1. Docking pose of representative compounds from benzimidazole (3, Left) and
thioacetamide (7, Right) series.

From the docking pose of compound 1 shown in Figure 3.2.2, it was evident that 1 could be
modified to better occupy the S1‟ and, S2 pockets of FP-2. For example, hydrophobic
substituents can be placed on the 6-aminobenzothiazole scaffold to interact with hydrophobic
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residues such as Ala235, Ile85 and Leu172 lining the border of the S2 pocket. Also, the flat S1‟
pocket of FP-2 is composed of hydrophobic residues such as Trp206 and Val152. Therefore, two
regions of the benzothiazole core spanning the S1‟ and S2 sites were selected to perform
chemical transformations and, thereby to develop SAR information. In addition, α-thioketones of
1 were modified to α-thioesters and α-thioacetamide electrophiles to investigate the chemical
reactivity of these electrophiles with the active site cysteine sulfur and determine its effects on
FP-2 inhibition. Thus, two series were designed (Table 3.5.1).
Q 36

C 39

C 80

W 206
V 152

S 41 S1

Y 78 G 82

S1′
H 174

C 42

N 173
N 171

A 175

G 83

S3 I 85

S2
L 172

L 84

S 149
D 234

F 236

A 235

Figure 3.2.2. (top) docking pose of compounds 1 in the FP-2 binding site; (bottom) core hopping
of compound 1 and 2 with tetrazole and benzothiazole cores (highlighted in blue), respectively
are shown. The tetrazole core of 1 was modified to triazole core to take an advantage of click
chemistry. The benzothiazole core of 2 was modified to commercially available benzimidazole
and thioacetamide core containing compounds (3-10) with anticipated gain in potency.
The deep hydrophobic S2 pocket in FPs harbors polar residues such as Asp234 and, Ser149
in FP-2 and Glu243 and, Ser158 in FP-3. Electrostatic interactions of compounds with the polar
residues of the S2 pocket might lead to an overall boost in potency. In addition, sequence
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alignments of FPs with homologous mammalian protease of papain family (Figure 2.3.2)
suggested that polar residues of the S2 pocket are replaced by hydrophobic residues in cathepsin
K, and L and can be targeted to design selective inhibitors of FPs. Therefore, in the α-thioketones
and α-thioacetamide series, compounds with protonated amino groups were designed
(compounds 39-42) to exhibit ionic interactions with Asp234 of the S2 subsite. The preliminary
docking studies suggested a preference for R over S isomers of designed compounds, and, hence,
Boc-(D) phenyl glycine or Boc-(D) valine were used in the synthesis of 39-42.
3.3. Synthetic Schemes. The synthetic strategies adopted to obtain various benzothiazole
derivatives are highlighted in Schemes 1 and 2. Scheme 1 depicts condensation of appropriate αhaloketones (12, 13), α-haloacetate (14), and α-haloamides (15) with the commercially available
6-aminobenzothiazole-2-thione (11) in the presence of triethylamine to give respective Salkylated α-thioketones (16, 17), α-thioesters (18) or α-thioacetamide (19). In the next step of Nacylation, intermediate 16-19 provided corresponding N-acylated derivatives 20-34 by treatment
with various acid chlorides. Synthesis of designed analogs targeting polar residues of the S2
pocket was accomplished as depicted in Scheme 2. Accordingly, compounds 17 and 19 were
coupled with (D)-N-Boc phenyl glycine and (D)-N-Boc valine using standard 1-ethyl-3-(3dimethylaminopropyl)carbodiimide/ hydroxybenzotriazole (EDCI/HOBT) peptide coupling
conditions and triethylamine as a base to yield Boc-protected compounds 35-38. Deprotection of
Boc with 4 M HCl in 1, 4-dioxane provided the target compounds 39- 42 as HCl salts.
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Scheme 3.1

Scheme 3.2

3.4. Biological Evaluation. The synthesized compounds were evaluated for inhibition of
recombinant FP-2 and, FP-3 and, the in vitro growth of the chloroquine resistant W2 strain of P.
falciparum according to previously described procedures229. The epoxysuccinate E-64 was used
as a positive control for the enzyme assays whereas artemisinin and chloroquine were used as
positive controls for testing against W2 strain of P. falciparum.
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3.5. Results and Discussion
The structure and biological evaluations of benzthiazole analogs are shown in Table 3.5.1.
The SAR of compounds in this series is discussed below.
In the benzothiazole series, compounds lacking R2 substituents (for example, compounds 1619) were devoid of activity against FP-2 (Table 3.5.1). A few analogs showed similar log order
activity as that of parent compound 2, whereas others were inactive. Interestingly, no direct
correlation was observed between the chemical reactivity of electrophiles such as α-thioketones
(20-25, and 41, 42), α-thioesters (26-29) and α-thioacetamide (30-34, and 39, 40) towards Cys42 and inhibition of FP-2. Overall, the compounds with α-thioacetamide and α-thioketones
electrophiles showed moderate activity against FP-2 compared to those possessing α-thioesters
electrophiles. Moreover, compounds 41 and 42 with protonated amino groups were the only
compounds from the benzothiazole series displaying dual inhibition of FP-2 and FP-3.
Table 3.5. 1. Biological activity of benzothiazole analogs.

R2

FP-2
Sr.
IC50
No.
(µM)

16

H

>50

27

>50

17

H

>50

28

>50

Sr.
No.

R1
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R1

R2

FP-2
IC50
(µM)

18

H

>50

29

31.34

19

H

>50

30

24.33

20

11.14

31

13.89

21

35.70

32

13.96

22

>50

33

16.48

23

13.18

34

16.87

24

>50

39

>50

25

43.25

40

>50

26

>50

E64

-

-

≠

41

≠

0.05

42

≠

12.22

12.75

IC50 of compound 41 and 42 against FP-3 were 13.77 µM and 14.94 µM, respectively;
compound 24 & 41 also inhibited the growth of W2 strain of P. falciparum with IC50 = 2.08 µM
and 4.65 µM, respectively. IC50 of positive controls, artemisinin and chloroquine, against W2
strain were 0.012 µM and 0.062 µM, respectively.
Among the evaluated compounds, compound 24 and 41 showed activity against the W2
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strain of P. falciparum. However, compound 24 was inactive against FP-2, suggesting action
against targets other than FP-2. The majority of identified compounds specifically inhibited FP-2
but not FP-3, which may account for their inability to block parasite development, as deletion of
only FP-2 by gene knockout was not lethal to parasites231. Activity of compound 41 can be
attributed to its dual inhibition against FP-2 and FP-3. However, compound 42 was not active up
to 10 µM concentration in culture parasites, despite of having same log order of activity against
FPs as 41. This suggests the obvious involvement of other physicochemical properties for
inactivity of 42 in cultured parasites development such as the solubility, lipophilicity, polarsurface area etc.
To gain insight into the binding mode of test compounds, docking of compounds into the FP2 binding site using the Glide docking program was performed. Previously, we compared
abilities of two scoring functions implemented in Glide: Gscore and Emodel, to enrich known
FP-2 actives from decoys downloaded from the DUD database229. In our study, Emodel
outperformed Gscore in retrieving actives from decoys and proved more appropriate for the
apolar FP-2 binding site229. Thus, we applied our validated Glide XP protocol with an Emodel
scoring function to rank order the analogs from both series. Here, the distance of the electrophilic
carbonyl carbon present in the putative hits to the cysteine sulfur (typically <3.5 Å) was used as a
measure of covalent adduct formation. Docking studies revealed some important trends which
are discussed below.
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Figure 3.5.1. Docking pose of 42 (a), 31
(c) in FP-2 and 42 in FP-3 (b).
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Among the benzothiazole series, compounds with α-thioacetamide and α-thioketones
electrophiles were ranked higher (Emodel scores from -61 to -84), whereas compounds with αthioesters showed Emodel scores of greater than -56, except compound 29 (Emodel score -61).
This trend was consistent with the experimental affinity of compounds from the benzothiazole
series. For example, most of the compounds from the α-thioesters were inactive up to 50 µM
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concentration, and, thus, ranked lower, except 29, which showed moderate activity (IC50 = 31.34
µM) against FP-2. In addition, in α-thioesters containing compounds, the distance of reactive
carbonyl carbon from the catalytic Cys 42 of the FP-2 active site was always >4.0Å. On the other
hand, the majority of compounds in the α-thioacetamide series showed a similar log order of
activity against FP-2, and they were always more active than corresponding α-thioesters. These
observations suggest the predictive nature of the scoring scheme used here to separate actives
from inactives in congeneric series of compounds. However, correlation of docking scores with
activity was poor, perhaps due to similar log orders of activity for identified hits and the parent
compound 2. In the benzothiazole series, bulkier R1 and R2 substituents affected the placement
of the reactive carbonyl carbon in the vicinity of the catalytic Cys42 of the FP-2 active site. For
example, compounds 24 and 25 with naphthalene in the S1‟ pocket and quinoline or substituted
phenyl in the S2 pocket, showed modest or no activity against FP-2.
The compounds with the α-thioacetamide electrophile (30-39) formed an additional H-bond
with the Asn173 of FP-2, placing the reactive carbonyl carbon in an appropriate position for
nucleophilic attack by Cys42. The docking pose of representative compound 31 from
thioacetamide series is shown in Figure 3. The p-toluene moiety of 31 showed hydrophobic
interactions with Tyr 206 of the S1‟ pocket. The thioacetamide linker exhibited interactions with
key catalytic residues such as Cys 42 and Gln36 in addition to H-bond formation with Asn173.
The anilinic –NH of 31 formed an H-bond with Asp234 of the S2 site.
FP-2 and FP-3 share 65% sequence identity50. Both of these enzymes have a preference for
substrate with a hydrophobic residue at the P2 position203. The major difference between these
two enzymes is in their S2 pockets. The Asp234, Leu84 and Leu172 of the S2 pocket in FP-2 is
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replaced by the bulkier Glu243, Tyr93 and Pro181 in FP-3, making the S2 pocket more narrow
in FP-350. These differences are likely major contributing factors for distinct biochemical
specificity and ligand recognition among these two homologous hemoglobinases. In the present
study, compounds 41 and 42 showed inhibition of FP-2 and FP-3. The binding modes of 41 in
FP-2 and FP-3 explain their inhibition, as follows (Figure 3.5.1). First, as expected, the
protonated amino functionality of 41 forms charge-charge interactions with Asp234 and Glu243
in the S2 pockets of FP-2 and FP-3, respectively. Second, the isopropyl side chain of 41 forms
van der Waals interactions with Leu172 in FP-2 and Pro181 in FP-3. Third, the thiazole nitrogen
of 41 interacts with the main chains of glycine residue (Gly83 in FP-2 and Gly92 in FP-3) that is
highly conserved in papain-like family of cysteine proteases and considered important for
inhibition of these enzymes. Fourth, the carbonyl carbon of α-thioketone linker interacts with the
residues of an oxyanion hole formed by the backbone of Cys42 and side chain of Gln36. Finally,
the naphthalene moiety exhibits van der Waals interactions with Tyr206 and Val152 in S1‟
pocket of FP-2 and Tyr215 and Ala161 in S1‟ pocket of FP-3. Collectively, the above interaction
profiles of 41 contribute to its activity against both parasitic cysteine proteases.
Next, we screened compound 41 and 42 with protonated amino group against selected human
papain-family of cysteine proteases, cathepsins K, L1 and B (Table 3.5.2). Although, cathepsins
K and L1 lack corresponding polar residues in the S2 pocket (Leu in Cat K and Ala in Cat L1,
see Figure 2.3.2 in Chapter 2) as present in FPs (Asp in FP-2, Glu in FP-3), compound 41 and 42
also inhibited these enzymes, whereas both compounds were inactive against cathepsin B having
polar glutamate residue at the same position. These suggest the polar residues of S2 pocket,
although important for improving potency, may not be crucial for design of selective inhibitors
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against falcipains.

Table 3.5.2. The IC50 values of FP-2 hits against selected human cathepsin (Cat) peptidases, K,
L1 and B.
Compound
Cat K
Cat L1
Cat B
No.
IC50 (µM) IC50 (µM) IC50 (µM)
14.52
5.87
>50
41
5.62
4.39
>50
42
0.004
0.016
0.005
E-64
The compounds reported in this study are ketone-based inhibitors and are likely to bind in a
covalent but reversible fashion with the active site cysteine. However, extensive efforts would be
required to actually prove that these compounds undergo covalent adduct formation with the
catalytic cysteine moiety. The proposed mechanism of action of these compounds (shown in
Figure 4) which involves formation of a tetrahedral intermediate (hemithioacetal) after
nucleophilic attack by the catalytic cysteine (stabilized by the Gln 36, Cys42 residues of the
oxyanion hole) is supported by SAR and recent studies by Ellman and co-workers232, 233.

Figure 3.5.2. The proposed mechanisms of action for the α-thioketone soft-electrophiles
containing compounds.

103

3.6. Conclusions
The present study reports novel, non-peptidic active analogs of the benzothiazole and triazole
series. Fifteen compounds showed moderate activity against FP-2 and, three were also active
against FP-3. In the benzothiazole series, compounds 41 and 42, with protonated amines
inhibited both hemoglobinases. However, these compounds also displayed activity against
homologous mammalian cysteine proteases lacking corresponding polar residues (Asp 234 in
FP-2 and Glu243 in FP-3), suggesting less significance of these residues in the design of
selective inhibitors against FPs. The relative inactivity of synthesized analogs against FP-3 and
cultured P. falciparum needs to be addressed in the subsequent lead optimization process.
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Chapter 4

Analogs of FP-2 Hits: Virtual Screening,
Structure-Activity Relationships, Solvent
Thermodynamics and Reactivity Analysis

Content of this chapter is submitted for publication: Shah F., Jiri G., Legac, J., Shivakumar,
D., Sherman W., Rosenthal, P., Avery M. A. Computer-Aided Drug Design of Falcipain
Inhibitors: Virtual Screening, Structure-Activity Relationships, Solvent Thermodynamics and
Reactivity Analysis.
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4.1. Introduction
Previously, we reported 21 diverse low-micromolar non-peptidic hits against FP-2, originating
from novel scaffolds229. Compound 2 with a tetrazole scaffold was identified as a selective
inhibitor of FP-2. In the first part of our current study, we describe efforts to explore the chemical
space around the core group of virtual screening hits 1-3 with low-micromolar affinity to FP-2
(Figure 4.1). A combined ligand- and structure-based virtual screening approach was adopted
that involved mining of compounds bearing substructures of 1-3 from the Asinex and
Chembridge databases, followed by docking of putative hits into the active site of FP-2. A
number of active analogs were identified, some of which also showed activity against FP-3 and
against development of cultured P. falciparum. Most of the active analogs showed the same order
of potency as the parent compounds. However, the resulting SAR in these congeneric series of
compounds was complex and could not be deciphered by only considering the steric,
electrostatic, or van der Waals interactions of inhibitors in the protein active site. Therefore, the
second part of this work considers additional factors involved in the binding process, such as the
displacement of explicit water molecules and changes in the reactivity of electrophiles based on
different chemical substitutions.
The solvent thermodynamics of FP-2 and FP-3 ligand binding domain were computed using the
recently published method referred to as WaterMap234, 235. WaterMap predicts the location and
thermodynamic properties of the active site solvent using a combination of explicit solvent
molecular dynamics, spatial clustering, and inhomogeneous solvation theory. The result of this
procedure is a map containing water locations, occupancy, and determinations of whether the
water clusters (referred to as “hydration sites”) are favorable or unfavorable in the binding site
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relative to bulk solvent. WaterMap has been successfully applied to number of targets in a variety
of contexts, such as assessing binding affinity of potent inhibitors236, 237, understanding the SAR
in congeneric series of compounds,238, 239 and investigating selectivity of compounds within gene
family targets such as kinases240. Recently, the method was used to rationalize accurate
isothermal titration calorimetry data showing that the addition of lipophilic groups to a ligand
resulted in increased potency that was gained via enthalpy from released water molecules, rather
than the more traditional view that entropy gain from released water is the only driver of the
hydrophobic effect.241
The water displacement patterns of FP-2 and FP-3 inhibitors aided in our understanding of key
experimental observations of known FP-2 inhibitors, perplexing trends in the SAR of identified
hits. However, the relatively modest affinity of some inhibitors (also displacing unstable
hydration sites from FP-2 LBD in a few cases) was not evident from the WaterMap analysis
alone. We hypothesized that poor reactivity of soft-electrophiles were responsible for the low
affinity of some inhibitors towards FP-2. To further support our hypothesis, virtual screening of a
small compound library enriched in diverse aryl and aliphatic nitriles with a moderate reactivity
profile (based on the reactivity index of nitrile-containing compounds proposed by Obella et
al.242) was carried out against FP-2. The biological results showed good agreement between
chemical reactivity and the inhibitory potency of these compounds against FP-2.
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Figure 4.1. FP-2 inhibitors identified by structure-based virtual screening of the Focused
Cysteine Protease Inhibitor library (IC50<10 µM). W2 stands for the chloroquine resistant strain
of P. falciparum parasites. Cathepsin (Cat) K, L and B are human cysteine proteases of the
papain-family. α-heteroacetamide soft-electrophile is highlighted in blue.
4.2. METHODS
4.2.1. Virtual Screening. The protocol used for virtual screening is shown in Figure 4.2. The
substructure search on the highlighted query atoms for compounds 1-3 was conducted in the
Chembridge (http://www.hit2lead.com) and Asinex (http://www. asinex.com) 2009 collections
using the built-in substructure search utilities of these databases. The substructure hits were
prepared for docking using the LigPrep program (Schrodinger LLC, NY). Approximately 1500
compounds matching sub-graphs of 1-3 were subjected to docking using our previously validated
Glide XP protocol229. The top 20% (~300) compounds were selected based on the top Emodel
score. Docking poses were visually inspected for the following criteria prior to submitting them
for biological evaluation: (a) placement of a soft-electrophile within 3.5 Å of the sulfur atom of
the catalytic cysteine; (b) formation of key hydrogen bonds and hydrophobic interactions by
ligand atoms with the key residues of the FP-2 active site such as Gly82, Gly83, Cys42, and
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Gln36; (c) energetically reasonable ligand geometry without obvious strain; and (d) commercial
availability and diversity of putative hits. Based on these criteria, 65 analogs with diverse R1-R3
groups were purchased for analysis.

Virtual Screening Workflow
Substructure Queries
Chembridge, Asinex
2009 collection
~1500

Docking:3BPF
Glide XP, Emodel,
Top 20%
~300
Visual
Inspection
69
Biological
Evaluation
28 FP-2 hits
Figure 4.2. Virtual screening workflow to find hits related to compounds 1-3. Substructure
queries for 1-3 are shown in blue.

An additional substructure search was performed for compounds with aliphatic or aromatic
nitriles, followed by a similar virtual screening protocol to that shown in Figure 2. Compounds
with a match to the query “CC#N” (i.e. carbon connected to carbon connected to nitrogen via a
109

triple bond) were retrieved from the Chembridge database (2009 collection). The matching set of
~5000 compounds was then docked into the FP-2 binding site. The top 10% (~500) of
compounds was visually inspected for the criteria described in the preceding paragraph. Finally,
a total of 14 compounds with aliphatic or aromatic nitriles were prioritized for biological
evaluation based on two criteria a) compound should have similar interactions in the binding site
as predicted for pyrimidine nitrile compounds, a potent class of FP inhibitors183 and b) they
should displace the key unstable hydration sites from the FP-2 LBD
4.2.2. Biological Evaluation. The prioritized hits were evaluated against FP-2, FP-3, and
cultured W2 strain (chloroquine-resistant) P. falciparum. A selected set of compounds was also
evaluated against mammalian cysteine proteases cathepsin K (Cat K), cathepsin B (Cat B), and
cathepsin L1 (Cat L1). These biological assays were conducted using the same protocols as
described previously229.
4.3.3. Thermodynamic Characterization of Waters in the Binding Site. WaterMap predicts
the location of water molecules around a protein and provides a quantitative estimation of
enthalpy (∆H), entropy (-T∆S), and free energy (∆G) associated with the waters234,

235

. The

approach combines explicit solvent molecular dynamics, solvent clustering, and statistical
thermodynamics. In short, a grand canonical Monte Carlo simulation is run to obtain the initial
placement of the waters, followed by a series of equilibration stages and a 2.0 ns production run
of explicit solvent molecular dynamics. The protein is constrained in the simulations, allowing
for convergence in the sampling of water configurations around the protein conformation of
interest. The waters from approximately 2000 equally spaced frames are clustered to determine
regions of high solvent density, termed “hydration sites”234. The entropy for each hydration site is
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computed using inhomogeneous solvation theory.243,

244

The enthalpy of each hydration site is

calculated using the non-bonded molecular mechanics interaction energy with the OPLS_2005
force field.245 These energy terms are calculated relative to a hydration site in bulk water.
WaterMap profiles were generated for FP-2 in complex with an epoxy succinate (E-64)
inhibitor (3BPF, PDB code)50 and for FP-3 in complex with a vinyl sulfone (VS) inhibitor
(3BWK, PDB code)216. Proteins were prepared using the Protein Preparation Wizard in Maestro
(Schrodinger, LLC, Portland, OR). The protonation states of the catalytic His174 in FP-2 and
His183 in FP-3 were adjusted to HIE (histidine with hydrogen on the epsilon nitrogen). Finally,
the proteins were minimized with a harmonic potential restraint as implemented in the Impref
module from Impact to prepare the final systems for the WaterMap calculations. All waters
within 5 Å of the co-crystallized inhibitor were considered for the WaterMap calculations.
4.3. Result and Discussion

The work presented here was initiated to establish structure-activity relationships (SAR)
around the active core of compounds 1-3 (Figure 4.1). The combined sub-structure search and
rigid-receptor docking identified 28 active analogs of 1-3. The activity of these compounds
against FP-2, FP-3, and cultured parasites is shown in Table 1. The SAR in each series is
discussed below.
4.3.1. SAR in 1, 2, 3, 4-tetrazole series. In the tetrazole series, linear compounds showed greater
inhibitory activity against FP-2 as compared to the branched compounds. For example,
compounds with R3 substitutions showed either a decrease (8, 9, and 11) in activity or no activity
(12), whereas compounds with R2 substitutions (4-6) showed moderate inhibition of FP-2 (Figure
3 and Table 1). In addition, compounds lacking R2 substitutions (13) or containing smaller R2
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groups (14) were inactive. This trend was consistent with the SAR of compounds in this series
recently reported by us using the combinatorial library synthesis approach246. Compounds 1, 4
and 9, with heteroaromatic moieties at R1, seem to be well tolerated in the S1-S1‟ pocket,
possibly because of additional interactions with residues of an oxyanion hole, such as Gln36 and
Cys 42 in FP-2 (Figure 4.3.8). Although linear compounds such as 1 and 4 showed decent
potency against both falcipains, they also appeared to inhibit the mammalian cysteine proteases
cathepsin B, K, and L1, and were non-selective (Table 4.3.4). In addition, none of the compounds
in this series showed activity against cultured parasites at concentrations up to 10 µM (Table
4.3.1).

Figure 4.3.1. Chemical structures of compounds with 1, 2, 3, 4-tetrazole core. Original subgraph
is highlighted in blue.

Table 4.3.1. Biological evaluation of analogs of virtual screening hit 1 with 1, 2, 3, 4-tetrazole
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core
FP-2 FP-3 W2
Compound
Compound
IC50 IC50 IC50
Code
Code
(μM)
(μM)
(μM)

FP-2 FP-3 W2
IC50
IC50
IC50
(μM)
(μM)
(μM)

6.67 19.4 >10
38.13 >50 >10
4
11
11.35 43.9 >10
38.13 >50 >10
5
12
19.15 >50 >10
38.13 >50 >10
6
13
31.46 >50 >10
38.13 >50 >10
7
14
33.04 >50 >10
0.03 0.16 NT
8
E-64
35.92
>50
>10
0.092
9
Artemisinin
37.81 >50 >10
10
NT= not tested, W2= chloroquine-resistant strain of P. falciparum
4.3.2. SAR in 1, 2, 4-triazole series. Substituents at R1 and R2 had greater impact on the activity
in the 1, 2, 4-triazole series. For example, compounds lacking R2 substituents (27-34) or with
shorter R2 substituents (35-38) were inactive (Figure 4.3.3). The majority of the active analogs
had phenyl at the R2 position. Compounds 43-48, with substitutions on the R2-phenyl moiety,
were not tolerated either (Figure 4.3.3). At the R1 position, the amino-substituted compounds
(forming thioacetamide) were well tolerated (Figure 4.3.2 & Table 4.3.2). Analogs with the fused
nitrogen heterocycles (40-45) or lacking polar -NH (49, 50) at that position were inactive. This
could be due to lack of ability of these compounds to form an H-bond with Asn173 (Figure
4.3.9c).
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Figure 4.3.2. Chemical structures of compounds with 1, 2, 4-triazole core. Original subgraph is
highlighted in blue.
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Figure 4.3.3. Inactive compounds in 1, 2, 4-triazole series
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Table 4.3.2. Biological evaluation of analogs of virtual screening hit 2 with 1, 2, 4-triazole core

Compound
Code

FP-2
IC50
(μM)

FP-3
IC50
(μM)

W2
IC50
(μM)

Compound
Code

FP-2
IC50
(μM)

15.32
>50
1.61
>50
15
34
18.61
>50
5.91
>50
16
35
20.66
>50
NT
>50
17
36
23.21
>50
6.42
>50
18
37
26.45
>50
1.91
>50
19
38
27.43
>50
4.65
>50
20
39
28.61 31.33
NT
>50
21
40
29.40
>50
8.91
>50
22
41
36.95
>50
NT
>50
23
42
>50
>50
NT
>50
24
43
>50
>50
NT
>50
25
44
>50
>50
NT
>50
26
45
>50
>50
NT
>50
27
46
>50
>50
NT
>50
28
47
>50
>50
NT
>50
29
48
>50
>50
NT
>50
30
49
>50
>50
NT
>50
31
50
>50
>50
NT
0.03
32
E-64
>50
>50
NT
NT
33
Artemisinin
NT= not tested, W2= chloroquine-resistant strain of P. falciparum

FP-3
W2
IC50
(μM) IC50
(μM)
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
0.16
NT

NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
NT
0.092

Substitution at R3 seemed to be crucial for modulating selectivity against FP-2 for this
series of compounds. From the multiple sequence alignment of falcipains and other homologous
mammalian cysteine proteases of the papain family (cathepsin B, K, and L) it was evident that
the composition of the S2 and S3 pocket differs critically in these cysteine proteases229, 246. More
importantly, the gate-keeper Leu at the entrance of the S3 pocket in FP-2 and in cathepsin L is
substituted by the bulkier Tyr in FP-3, Cat K, and Cat B. To further understand the selectivity of
2 against FP-2, preliminary docking studies were carried out in FP-2 and the cathepsins (Figure
4.3.4). As anticipated, the R3 methyl phenyl group of 2 was aptly placed in the S3 pocket of FP-2
and Cat L, whereas this moiety was directed into the S2 pocket in FP-3, Cat K, and Cat B,
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leading to unfavorable placement of 2 (Figure 4.3.5). This might explain the exclusive selectivity
of 2 for FP-2.

a.

b.

d.

e.

c.

Figure 4.3.4. The proposed binding mode of 2 in a) FP-2; b) FP-3; c) Cat K; d) Cat L1 and e) Cat
B.

To further analyze the effects of R3 substituents on FP-3 selectivity, we evaluated selected
active compounds from this series against FP-3 and cathepsins B, K, and L1 (Figure 4.3.5). As
expected, compounds with smaller R3 substituents (e.g. pyridine in compound 21) tended to be
non-selective, showing activity against all the cysteine proteases (except Cat B). As the length of
R3 substituents increased, activity against FP-3, Cat K, and Cat B decreased, probably due to
steric clash with Tyr at the entrance of the S3 pocket (for example, compounds 17, 19, and 2).
Interestingly, compounds with more flexible R3 substituents (16 and 18) showed activity against
FP-2 as well as cathepsins, probably due to the abilities of flexible R3 substituents to enter into
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the S3 pocket. Most of the active compounds from this series were also active against cultured
parasites, with an IC50 of <10 μM. Moreover, a few compounds from this series, although
inactive against FP-2, were active against the cultured parasites, suggesting involvement of other
targets in addition to FP-2 for the mode of action of these compounds (Table 4.3.4).

Figure 4.3.5. Effect of R3 substituents of 1, 2, 4-triazole series on selectivity to FPs and
homologous mammalian cysteine proteases of the papain family: Cat K, Cat L1, and Cat B.
4.3.3. SAR in quinazoline series
In the quinazoline series, activity was retained when aliphatic (t-butyl, isopropyl) or aryl
(phenyl) substituents at the R3 position were directly attached to the quinazoline core (e.g.
compounds 52-54). Alicyclic substitutions such as alkyl cyclopentane resulted in diminished
activity (for example, compound 59) or no activity (compounds 60, 61, Figure 4.3.6, Table 4.3.3)
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against FP-2. Substitutions on the quinazoline core at the R2 position resulted in decreased
activity (compound 58) or inactive analogs (compound 62), probably due to the steric clash in the
narrow S2 pocket of FP-2. At the R1 position, there was preference for ampiphilic aryl groups
such as 1, 2, 5-oxadiazole (3), thiazole (52, 55), 1, 3, 4-thiadiazole (53), isoxzaole (56, 59), and
furan (57). Also, the heterocyclic moiety with three heteroatoms (3, 53) at R1 was more potent
than a two (52, 55, 56) or single (57) heteroatom containing ring. Substitutions at R1 either with
only hydrophobic groups, such as compounds 63 and 64 or polar groups at R1 (such as compound
65), were found to be inactive. From the docking studies, it was suggested that these heterocycles
exhibit hydrogen bonding interactions with the side chains of Gln 36 and Trp 206 in addition to
hydrophobic interactions with Tyr206 (Figure 4.3.10a). The inactivity of 66 versus 54 might be
explained by unfavorable placement of carboxylic acid in the S1‟ pocket, which is composed
predominantly of hydrophobic residues, whereas the inactivity of 67-69 is not clearly understood
based on visual inspection of the interactions.
Among the active analogs, compound 54 showed an IC50 value of 8.5 μM against FP-2
and was also active against cultured parasites (W2 IC50 = 6 µM). Compound 54 moderately
inhibited Cat K (IC50 = 39.2 µM) and Cat L (IC50 = 14.6 µM) and was inactive against Cat B at
concentration up to 50 µM. In addition, as reported previously by our laboratory19, compound 54
was a low-micromolar inhibitor of SARS severe acute respiratory syndrome 3CLpro (IC50 of 5.8
μM), which is the main protease of SARS, playing an important role in viral replication
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. To

the best of our knowledge, 54 is the first common inhibitor of malarial (protozoal) and SARS
(viral) cysteine proteases reported to date. The discovery of 54 holds merit as these two cysteine
proteases are quite different from each other, in terms of their protease family (FP-2 is a member
of the papain-like family whereas SARS-3CLpro is a chymotrypsin-like cysteine protease), and in
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their active site geometry.

Figure 4.3.6. Chemical structures of compounds from quinazoline core. Original subgraph is
highlighted in blue.
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Table 4.3.3. Biological evaluation of analogs of virtual screening hit 3 with quinazoline core

Compound
Code

FP-2
IC50
(μM)

FP-3
IC50
(μM)

W2
IC50
(μM)

Compound
Code

FP-2
IC50
(μM)

52
53
54
55
56
57
58
59
60
61

4.64
5.93
8.57
9.19
14.00
15.81
18.82
>50
>50
>50

>50
>50
>50
>50
49.50
>50
>50
>50
>50
>50

NT
NT
6.0
NT
NT
NT
NT
NT
NT
NT

62
63
64
65
66
67
68
69
E-64
Artemisinin

>50
>50
>50
>50
>50
>50
>50
>50
0.03
-

FP-3
W2
IC50
(μM) IC50
(μM)
>50
>50
>50
>50
>50
>50
>50
>50
0.16
-

NT
NT
NT
NT
NT
NT
NT
NT
0.092

Table 4.3.4. Evaluation of selected FP-2 hits against the mammalian cysteine proteases,
cathepsins K, L1, and B

Compound
Cat K
Cat L1
Cat B
No.
IC50 (µM) IC50 (µM) IC50 (µM)
4.22
3.12
10.07
4
>50
12.80
>50
17
40.74
49.05
>50
18
>50
40.3
>50
19
34.02
20.59
>50
21
39.21
14.55
>50
54
3.99
16.15
5.01
E-64

Several trends in the SAR could not be understood from the molecular docking studies with
FP-2. For example, the experimental SAR of identified hits was very sensitive for compounds
with R2 substituents pointing towards the S2 pocket of FP-2, although no specific interactions in
this pocket suggested such a significant change in potency. Also, there was a general preference
for ampiphilic substituents in the S1-S1‟ pocket that could not be explained based on molecular
interactions. Moreover, the identified analogs showed the same log order of activity, in spite of
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enhanced interaction profiles, compared to the parent compounds 1-3 in the ligand binding
domain of FPs. The steric and electrostatic interactions alone in addition to other terms of the
Emodel scoring function (e.g. van der Waals, H-bond, lipophilic, ligand strain) were not
sufficient to understand the steep SAR or moderate affinities of these compounds. Therefore, we
anticipated a potentially important role of explicit solvent in the binding site and/or reactivity of
the electrophiles in these compounds, both of which are generally not estimated by typical
scoring functions.
Water molecules in protein binding sites have unfavorable entropy compared with those in bulk
solvent due to their restrained movement in the active site, with the amount of entropy loss
related to the degree of translational and rotational restrition234, 235. They may have favorable or
unfavorable enthalpy relative to bulk water, depending on the exact nature of the binding pocket
and interaction with neighboring waters. Therefore, the thermodynamic properties of waters
cannot be estimated by simple visual inspection. Accurately assessing the thermodynamics of
water molecules is important for drug design, since displacement of high-energy water molecules
from the protein binding site by complementary groups of ligands is considered to be a principle
source of binding affinity236. A number of methods can account for solvation effects in the
protein binding site, although many methods, such as MM-GBSA248 and MM-PBSA249, are
based on continuum electrostatics and do not account for the explicit nature of water. One
method that accounts for waters explicitly, WaterMap, uses a combination of explicit solvent MD
simulation and statistical mechanics calculations to provide a quantitative description of
enthalpy, entropy, and free energies of water molecules at the surface of proteins (see methods).
From the design perspective, water molecules with positive values of ∆G should be displaced by
122

complementary groups of the ligand, with expected gains in binding affinity resulting from an
increase in entropy when water is released into bulk solvent. Conversely, water molecules with
negative enthalpy (∆H) should be considered carefully, as displacement will result in a loss of
enthalpy. Therefore, such waters should be avoided, bridged, or judiciously displaced with polar
groups to replace polar interactions of water molecules236.
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Figure 4.3.7. The WaterMap profile of (a) FP-2, (b) FP-3, (c) FP-2 in complex with E-64, and
(d) vinyl sulfone in complex with FP-3. The thermodynamically interesting hydration sites
important for the SAR are shown in spheres. Stable hydration sites (ΔG < 0 kcal mol -1) are
colored in green, whereas significantly unstable hydration sites (ΔG > 1 kcal mol -1) are shown in
purple. The water sites are labeled based on decreasing values of predicted ΔG. Key hydrogen
bonding interactions of inhibitors (shown in yellow) with the residues of FP binding sites (shown
in grey) are displayed as dotted lines.
The WaterMap profiles of FP-2 and FP-3 with and without co-crystallized inhibitors (E-64 in
FP-2 and a vinyl sulfone inhibitor k11017 in FP-3) are shown in Figure 4.3.7a-d. The
thermodynamic breakdown of predicted hydration sites are shown in Tables 4.3.5. and 4.3.6. The
location and energetics values of waters in these homologous proteases are consistent. The
solvent analysis identifies the triangle of enthalpically unstable waters (W1, W5, W12 in FP-2
and W1, W5, W6 in FP-3), solvating the hydrophobic S2 pocket in both FPs. The hydration sites
in the narrow hydrophobically enclosed region of the S2 pocket are enthalpically unfavorable
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(positive ΔH), as they are unable to form a full complement of hydrogen bonds with protein
residues (ΔG = >2.3 kcal mol-1 for all three in FP-2 and ΔG = >3.4 kcal mol-1 for all three in FP3).
WaterMap predicts two unfavorable waters (W10 = 2.6 kcal mol-1 and W19 = 1.7 kcal mol-1 in
FP-2; W2 = 4.22 kcal mol-1and W6 = 3.45 kcal mol-1 in FP-3) near Gly83 in FP-2 and Gly92 in
FP-3. The interaction of a ligand with the conserved glycine near the entrance of the S3 pocket is
considered essential for inhibitors of papain-family cysteine proteases binding to non-prime sites
(S1-S3)11, 50, 215. Compounds lacking these predicted interactions were void of activity. When cocrystallized inhibitors were mapped onto the generated WaterMap profile, they can be seen to
selectively displace these unfavorable hydration sites. For example, the shape of the P2-Leu of
E-64 in FP-2 and of VS k11017 in FP-3 complements the arrangement of the unstable waters of
the S2 pocket, expelling them to the solvent (Figure 4.3.7c and 4.3.7d). This result is consistent
with the observation that FP-2 and FP-3 prefer substrates with leucine in the P2 position

203, 250

and is consistent with previous findings with other targets that show strong preference for
specific amino acids being driven by water displacement251. The amide carbonyl near the P2 side
chain displaces the unfavorable water (W10 in FP-2, ΔG = 2.6 kcal mol-1; W2 in FP-3, ΔG = 4.2
kcal mol-1) and replaces the H-bond with Gly83 in FP-2 and Gly92 in FP-3, thereby presumably
imparting the observed gain in binding affinity.
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Table 4.3.5. Predicted occupancy and thermodynamic
properties of selected WaterMap waters in FP-2

Water Site Occupancy ΔH -TΔS ΔG
0.68
2.55 2.01 4.56
W1
0.51
2.73 1.78 4.51
W2
0.79
0.63 3.03 3.66
W3
0.59
1.67 1.86 3.53
W4
0.40
2.22 1.27 3.49
W5
0.86
0.42
2.8
3.22
W6
0.81
0.13 2.83 2.96
W7
0.46
1.32 1.55 2.87
W8
0.97
-1.63 4.35 2.72
W9
0.46
1.28 1.33 2.61
W10
0.35
1.3
1.03 2.33
W11
0.43
0.98 1.33 2.31
W12
0.38
1.18 1.06 2.23
W13
0.33
1.32
0.9
2.22
W14
0.63
0.28 1.78 2.06
W15
0.52
0.56 1.46 2.02
W16
0.54
0.47 1.51 1.98
W17
0.61
0.15 1.73 1.88
W18
0.37
0.67 1.03 1.70
W19
0.50
-0.09 1.43 1.34
W20
0.47
-0.3 1.46 1.16
W21
0.95
-2.25 3.36 1.11
W22
0.50
-0.52 1.55 1.03
W23
0.58
-3.88 1.94 -1.94
W24
0.58
-4.10 1.97 -2.13
W25
0.36
-3.95 1.19 -2.76
W26

Table 4.3.6. Predicted occupancy and thermodynamic
properties of selected WaterMap waters in FP-3

Water Site Occupancy ΔH -TΔS ΔG
0.43
3.00 1.25 4.25
W1
0.86
1.45 2.77 4.22
W2
0.71
1.62 2.32 3.94
W3
0.96
-0.09 3.91 3.82
W4
0.91
2.50 1.10 3.60
W5
0.45
2.21 1.24 3.45
W6
0.42
2.30 1.15 3.45
W7
0.37
2.27 1.14 3.41
W8
0.84
-0.79 3.28 2.49
W9
0.57
0.62 1.71 2.33
W10
0.51
0.80 1.45 2.25
W11
0.40
1.09 1.09 2.18
W12
0.88
-0.93 2.98 2.05
W13
0.29
0.98 0.84 1.82
W14
0.39
0.45 1.13 1.58
W15
0.43
0.15 1.29 1.44
W16
0.44
0.19 1.24 1.43
W17
0.40
0.28 1.14 1.42
W18
0.31
0.47 0.83 1.30
W19
0.52
-0.36 1.6
1.24
W20
0.61
-2.55 1.89 -0.66
W21
0.48
-2.28 1.37 -0.91
W22

WaterMap identifies unfavorable waters (W7, ΔG = 3.0 kcal mol-1 and W22, ΔG = 1.1 kcal
mol-1 in FP-2; W4, ΔG = 3.8 kcal mol-1 and W16, ΔG = 1.4 kcal mol-1 in FP-3) in the S1 pocket
near the residues of an oxyanion hole (Cys42/51 and Gln36/45). W7 in FP-2 and both unstable
waters (W4 and W16) in FP-3 are displaced by corresponding atoms of the co-crystallized
inhibitors. In addition, the guanidine moiety of E-64 and morpholine side chain of the vinyl
sulfone inhibitor displaces several unfavorable hydration sites from the S3 pocket of FP-2 and
FP-3, respectively. In addition, WaterMap predicts other unfavorable hydration sites near the S3
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pocket (W2, W3 in FP-2 and W9, W11 in FP-3) and in the S1‟ pocket (W6, W8, W9, W11, W15,
and W21 in FP-2; W3, W12, W15, and W20 in FP-3) that are out of the plane of these peptidic
inhibitors. These sites could potentially be targeted, with anticipated gain in binding affinity, with
a different ligand scaffold that is able to place functional groups to displace these waters. Finally,
WaterMap predicts stable clusters of waters (W24-W26 in FP-2; and W21, W22 in FP-3, ΔG and
ΔH < 0 kcal mol-1) in the vicinity of Asp234 and Ser149 of FP-2 and Glu243 and Ser158 of FP-3
of the S2 pocket that can potentially be bridged for water-mediated hydrogen bonding to gain
binding affinity.
Mapping of the newly identified hits in this work on the WaterMap-generated thermodynamic
hydration site profiles of FPs elucidated salient features of the SAR. For example, compound 4, a
linear analog from the tetrazole series, has a complementary shape to the binding site of FPs and
it displaces six unfavorable water molecules with ΔG > 2.0 kcal mol-1 of unfavorable hydration
sites (Figure 4.3.8a and b). In particular, it displaces the unfavorable water W3 bound to Ile 85 in
FP-2 (ΔG = 3.7 kcal mol-1) and W18 (ΔG = 1.9 kcal mol-1). Interestingly, compound 4 binds in a
similar fashion to FP-3 and FP-2, but it did not displace the unfavorable water W9 (ΔG = 2.5 kcal
mol-1) near Ile 95 of FP-3, potentially explaining the log difference in potency of 4 to FP-3 over
FP-2. This difference in hydration site displacement is possibly due to the narrow S2 pocket of
FP-3 (Glu243 in FP-3 versus Asp234 in FP-2, respectively), directing the methoxy phenyl moiety
of 4 close to Pro181.
Likewise, compounds 9 and 14 are unable to displace W3 and W18 from FP-2, and as a result,
these compounds display either diminished activity or inactivity against FP-2 (Figure 4.3.8c and
d). In FP-3 these compounds also miss key unfavorable hydration sites and hence are devoid of
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activity. This may explain why linear compounds in the tetrazole series were more active than the
branched compounds. The oxazole moiety of 4 and 9 displaces the unfavorable water (W22 in
FP-2, ΔG= 1.1 kcal mol-1, W4 in FP-3, ΔG= 3.8 kcal mol-1) from the S1 pocket and forms an
additional H-bond with Tyr 206, potentially explaining why heteroaromatic substituents were
preferred in the S1‟ pocket. These interactions and water displacements profiles together likely
contribute to the higher affinity of 1 and 4 for both falcipains compared to other analogs in the
series.
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Figure 4.3.8. The predicted binding poses and thermodynamic hydration site profile of 4 in
complex with (a) FP-2 and (b) FP-3; the predicted binding poses and thermodynamic profile of
(c) 9 and (d) 14 in complex with FP-2. Water site labeling and color codes are the same as shown
in Figure 4.3.7.
In the triazole series, compounds lacking R2 substituents (29) or with shorter R2 substituents
(36) were unable to displace the hydrophobically enclosed unstable waters from the S2 pocket,
and hence they are inactive (Figured 4.3.9c and 4.3.9d). Moreover, R2 substituents of this series
projected differently than the P2-Leu of E-64. For example, compounds with a phenyl (16) or
substituted phenyl (17) at R2 could not displace the least favorable hydration sites from the S2
pocket, and hence they showed reduced affinity for FP-2 (Figures 4.3.9a and 4.3.99b).
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Figure 4.3.9. The predicted binding poses and thermodynamic hydration site profile of (a) 16 (b)
17; (c) 29 and (d) 36 in complex with FP-2. Water site labeling and color codes are the same as
shown in Figure 4.3.7.
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Compounds 3 and 57 from the quinazoline series with an oxazole moiety are predicted to
displace the unfavorable waters (W7 and W22) from the S1-S1‟ pocket as well as form an Hbond with the residues of the oxyanion hole such as Gln36, Cys42 and Tyr206 (Figure 4.3.10b).
Compounds such as 32 and 38, lacking corresponding heteroaromatic substitutions or unable to
displace the unfavorable waters of the S1‟ pocket, were inactive (Figure 4.3.10c). Compound 54
additionally displaces the unfavorable waters (W8, ΔG = 2.9 kcal mol-1, W21, ΔG = 1.2 kcal mol1

) from the S1‟ pocket. The quinazoline moiety of 54 displaces the unstable waters from the S2

pocket (except the least favorable W1) as well as from the S3 pocket (W14, ΔG = 2.2 kcal mol-1
and W16, ΔG = 2.0 kcal mol-1), which likely accounts for moderate affinity of this compound for
FP-2.
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Figure 4.3.10. The predicted binding poses and thermodynamic profiles of (a) 54 (b) 57 (c) 67
and (d) 68 in complex with FP-2. Water site labeling and color codes are the same as shown in
Figure 4.3.7.

A few analogs with the ability to displace the high-energy waters of the S2 pocket, such as
compound 68 from the quinazoline series (Figure 4.3.10d) or compound 30 (Figure 4.3.13d)
from the triazole series, did not show additional gains in binding affinity. Also, none of the
analogs of this series were more potent than compounds 1-3, suggesting that there was an
additional factor reducing the binding affinity of these compounds. Based on prior work in our
group, we reasoned that the soft-nature of electrophiles present in these hits could account for
their moderate affinity against FPs. In our previous study229, we utilized the LUMO density
variant of atomic Fukui indices to locate the most electrophilic center and to estimate the
reactivity of electrophiles present in the virtual screening hits. The predicted LUMO density of α136

hetero amide electrophiles were in the range of 0.02-0.32 (on the scale of zero to one, one being
the most electrophilic), lower than the LUMO density of compounds containing hard
electrophiles, such as α-fluoro ketone (0.52) or vinyl sulfone (0.43). In a similar reactivity
analysis, Obella and co-workers assessed the reactivity of diverse nitrile containing compounds
using DFT calculations242. Their method involved approximating the free energy of formation of
thioimidate by calculating the difference between the energy of thioimidate adduct [E(Adduct)],
the nitrile molecule [E(Nitrile compound)], and the precursor methanethiol [E(Methanethiol)].
The generated reactivity index was scaled from 0 to -10 kcal/mol. As anticipated, the
heteroaromatic nitriles, in particular triazine and pyrimidine nitriles, were excellent electrophiles
(predicted reactivity of -10 kcal mol-1), whereas the aliphatic and the aryl nitriles were predicted
as poor electrophiles (0 to -2 kcal mol-1). Furthermore, the authors validated their findings by
measuring the ability of representative aliphatic, aromatic, and heteroaromatic nitriles to form
irreversible thiazoline adducts upon incubation with cysteine. The calculations showed that
poorly electrophilic aryl nitriles (such as naphthalene or pyridine nitrile) have a reduced ability to
form cysteine adducts, whereas more electrophilic pyrimidine nitriles or cyanamide have
enhanced cysteine adduct formation. Their results showed excellent correlation between
predicted reactivity and the ability to form irreversible cysteine adducts242.
Recently, Coteron et al. published data for a 2-pyrimidinecarbonitrile series, showing subnanomolar activity against FPs as well as cultured parasites.183 The representative compounds
from this series are shown in Figure 4.3.11. As discussed above, the strong electrophile
pyrimidine nitrile could be a major contributor in the high affinity of these compounds against
FPs. This motivated us to further assess the importance of reactivity of electrophiles in the
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inhibition of cysteine proteases by evaluating a subset of aliphatic or aryl nitriles (purchased from
Chembridge Corporation) with moderate electrophilicity (as proposed by Obella et al.) against
FP-2 (Figure 4.3.12). If reactivity of electrophiles plays an important role in the affinity of FP
inhibitors, then these compounds were expected to show moderate or less binding affinity as
compared to CN-1 to 3.

Figure 4.3.11. Potent inhibitors of FP-2, FP-3, and W2 from the 2-pyrimidinecarbonitrile series
reported by Obella et al.183
The identified hits 70-73, although having similar binding modes and water displacement
profiles as CN-1 (Figure 4.3.13a-c), displayed moderate affinity towards FP-2 (IC50 = 10-20
μM). In addition, out of fourteen compounds evaluated, only four compounds (70-73) were
active against FP-2 (Figure 4.3.12). Our data clearly demonstrates that it can be difficult to
achieve potent inhibition of FPs with compounds lacking reactive electrophilic centers.
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Figure 4.3.12. Aryl- or aliphatic nitrile-containing compounds discovered by substructure search
in the Chembridge database. Alkyl nitrile electrophiles are highlighted in blue.
Table 4.3.5. Biological evaluation of analogs of virtual screening hit 3 with quinazoline core

Compound
Code
70
71
72
73
74
75
76
77

FP-2 IC50
(μM)

FP-3
IC50
(μM)

18.96
10.33
18.39
11.21
>50
>50
>50
>50

>50
>50
>50
>50
NT
NT
NT
NT

W2
IC50
(μM)
7.89
5.92
>10
6.75
>10
>10
8.53
>10
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Compound
Code

FP-2
IC50
(μM)

FP-3
IC50
(μM)

78
79
80
81
82
83
E-64
Artemisinin

>50
>50
>50
>50
>50
>50
0.03
-

NT
NT
NT
NT
NT
NT
0.16
-

W2
IC50
(μM)
>10
>10
>10
>10
>10
>10
0.092
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Figure 4.3.13. The predicted binding poses and thermodynamic hydration site profiles of (a) CN1 (b) CN-2; (c) CN-3, and (d) 30 in complex with FP-2. Water site labeling and color codes are
identical to those shown in Figure 3.
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4.4. Conclusions
A combined ligand- and structure-based virtual screening was performed against the Asinex
and Chembridge databases to discover non-peptidic inhibitors of FP-2. The core structures of
previously discovered virtual screenings hits were used as a query to mine commercial databases
for structural analogs. A total of 69 putative hits with diverse R-groups, prioritized based on
docking calculations, were evaluated against FP-2. As a result, 28 compounds inhibited FP-2,
with IC50s of 5-48 μM. Some of these compounds were also active against cultured malaria
parasites, with IC50s <10 μM.
The complex SAR of these congeneric series of compounds was difficult to explain using
traditional computational descriptors like hydrogen bonds, van der Waals energy, electrostatic
interactions, and ligand strain. However, we found that accounting for the thermodynamic
characteristics of explicit solvent in the ligand binding domain of FP-2 and FP-3 provided an
explanation for most of the SAR. The hydration site thermodynamics revealed multiple
unfavorable hydration sites, most notably in the S2 pocket of FP-2 and FP-3. Modeling predicted
that the leucine moiety at the P2 position of the co-crystallized inhibitors E-64 and vinyl sulfone
k11017 in the S2 pockets of FP-2 and FP-3 complemented the arrangement of these
hydrophobically enclosed waters and, as a result, displaced them from the S2 pocket of both FPs
for increased binding affinity. This also reflected the preference for a P2-Leu as a recognition
element for FP inhibition. The most potent hits generally displaced the least favorable hydration
sites; however, a majority of the identified hits were unable to displace the least favorable water
of the S2 pocket (in a similar pattern to leucine), which accounts for the moderate affinity
observed for most of these compounds.
In a few cases, displacement of the least favorable hydration sites did not correlate with the
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binding affinity. This could be explained based on the poor reactivity of soft electrophiles toward
the catalytic cysteine in these weak hits. We evaluated moderately electrophilic alkyl and aryl
nitrile inhibitors against FP-2 to further highlight the effect of the reactivity on cysteine protease
inhibition. The aryl and alkyl nitriles only showed moderate affinity (10-20 μM) towards FP-2 as
opposed to compounds with strong electrophiles such as pyrimidine nitriles, which have subnanomolar affinity.
The present study highlights three important factors that appear to maximize inhibition of FP:
a) strong hydrogen bond networks with the key residues of the FP-2 active site such as Gly83,
Cys42, Gln36 and Asn173; b) displacement of unfavorable hydration sites (in particularly the
triangle of unstable waters from the S2 pocket) by complementary groups of the ligands, and c)
chemical reactivity of electrophiles to the catalytic cysteine of the active site. In general,
computing binding energies is a complex process with many factors involved. The work
presented here shows that terms that are often neglected from scoring functions (i.e. explicit
water energies and chemical reactivity) can play an important role in binding. While the chemical
reactivity of a ligand is likely to be most important in cases of covalent bond formation, as was
the case for the FPs studied here, the hydration site thermodynamics are expected to be important
in most ligand binding processes. More work is needed to develop a unified scoring function that
can simultaneously account for all of these terms.
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Chapter 5

Understanding Binding Affinity of α-Keto
Substituted Peptidomimetics for the Inhibition
of Plasmodium falciparum

Part of this chapter will be submitted for publication: Weldon, D., Shah F., Chittiboyina, A.,
Jiri, G., Rosenthal, P., Shivakumar, D., Sherman W., Desai, P., Jung J. C., Avery M. A. Design,
Synthesis, and Biological Results of α-Keto Substituted Peptidomimetics for the Inhibition of
Plasmodium falciparum.
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5.1. Introduction
In our parallel efforts for drug discovery against FP-2, several peptidomimetics were designed
and synthesized taking an advantage of a published crystal structure for cruzain, a related
cysteine protease from Trypanosoma cruzi. Docking of compound 1 into a homology model of
falcipain-2 developed in our laboratory252
revealed that inhibitors of cruzain would be
good templates for the design of inhibitors
against falcipains. Therefore, a congeneric
series of compounds utilizing 1 as a template
were designed. The initial design 2 and its

Figure 5.1.1. Overlap of cruzain inhibitor
1 with design template 2.

overlap with 1 are shown in blue in Figure 5.1.1. Of particular note, one of the phenylalanine
residues in 1 has been replaced with a homophenylalanine in 2. In addition, the other Cbzprotected phenylalanine has been replaced with a Cbz-protected proline. These changes from
natural to unnatural amino acids were incorporated to prevent peptidases from cleaving the
compound, thereby increasing the compound half-life, and also to increase the rigidity of the
falcipain inhibitor in order to improve its cell permeability. Docking studies of these compounds
in a homology model of falcipain-2 suggested that they could closely mimic the binding modes
of non-covalent inhibitor 1 and might form important hydrogen bonds, similar to those seen in
the co-crystal structures of 1-like compounds in complex with cruzain10. Thirty-six
peptidomimetics were designed and synthesized (Figure 5.1.2, compounds 15-50) in our
laboratory considering the prime and non-prime substrate sites of falcipain-2 to elucidate the
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SAR and evaluated for activity against falcipain-2, falcipain-3, and cultured malaria parasites
(Table 5.1).

Figure 5.1.2. Chemical structures of synthesized peptidomimetics 15-50.
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Table 5.1. Activity of compounds 15-50 against Falcipain-2 (FP-2), Falcipain -3 (FP-3) and
cultured malaria parasites. All values shown are IC50s in μM.
Series
s
1

2

3

4

Compoun
d
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

FP-2

FP-3

W2

112.22
48.13
154.23
>250
72.81
235
170
192
168
5.52
7.32
4.42
33.74
61.64
80.71
>250
>250
36.63
>250,000
69.17
33.86
3.25
16.54
29.67
30.08
87.23
33.64
0.08
1.10
65.3
232
>250
>250
>250
>250
>250

357.06
149.01
36.36
>250
5.43
>250
>250
>250
47.46
0.54
1.86
0.91
5.88
20.18
23.90
>250
>250
37.47
>250000
47.23
73.98
8.22
11.53
131.13
11.91
>250
25.44
0.06
0.52
3.56
223
>250
>250
>250
>250
>250

>50
13.77
18.12
>50
21.57
>50
>50
>50
>50
>50
32
47.6
>50
>50
>50
>50
>50
27.5
>50
23.29
>50
28.16
>50
>50
37.21
>50
47.21
7.70
19.64
18.64
10.16
41.51
19.48
>50
>50
19.92
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From the analysis of experimental SAR, it was evident that hydroxyl proline in the S2 pocket,
an α-hydroxy ketone electrophile in the S1-S1‟ pocket, and homophenylalanine (hPhe) in the S1
pocket were suitable substituents for high binding affinity peptidomimetics. Efforts to understand
the SAR of this series by means of steric and electrostatic interactions derived from the docking
calculations in falcipains did not provide useful insights. Van der Waals energy, electrostatics,
hydrogen bonds, or DockingScore from Glide SP

253, 254

docking calculations did not reveal any

correlation with experimental affinity. Furthermore, implicit solvent binding energy estimations
from MM-GBSA (as implemented in the program Prime255,

256

) did not show a significant

correlation with experimental affinity. In light of the above findings, we anticipated the
involvement of explicit water molecules in the binding of these inhibitors and therefore
generated thermodynamic profiles of waters present in the LBD of falcipain-2 and falcipain-3
using WaterMap.
5.2. Methods
5.2.1. WaterMap Calculations: Thermodynamic characterization of water molecules in the
falcipain ligand binding domain were carried out with WaterMap, which computes the location
and energetics of water molecules around protein using explicit solvent MD simulation, solvent
clustering, and statistical thermodynamics.234,

235

In short, the simulation consists of an initial

equilibration followed by 2 ns of production molecular dynamics. Water molecules from a
collection of snapshots taken every 1.2 ps were clustered into “hydration sites”. The enthalpy of
the waters within each hydration site was computed using the non-bonded interaction energy
with the OPLS_2005 force field.245 The entropy was computed using a local expansion of the
spatial and orientational correlation functions as described in inhomogeneous solvation theory243,
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244

. WaterMap has been effectively applied to a broad range of pharmaceutically relevant targets,

including PDZ domains251, kinases240, G-protein coupled receptors (GPRCs)239, protein-protein
interaction interfaces257, and serine proteases238.
WaterMap analysis was carried out for falcipain-2 in complex with the epoxy succinate
inhibitor E-64 (3BPF, PDB code)50 and with falcipain -3 in complex with the vinyl sulfone
inhibitor k11017 (3BWK, PDB code)216. Structures were prepared using Protein Preparation
Wizard of Maestro (Schrodinger, LLC, Portland, OR). Protonation states of catalytic His 174 in
falcipain -2 and His 183 in falcipain -3 were adjusted to HIE (proton on the epsilon nitrogen).
Finally, proteins were minimized with a harmonic positional restraint using the Impref module
from Impact to prepare the final systems for the explicit MD simulation. All waters within 5 Å of
the co-crystallized inhibitor were considered for the WaterMap calculations.
5.2.2. Calculation of LUMO density using Atomic Fukui Indices. Quantum mechanics
calculations were run to determine the effect of electronegative substituents on the reactivity of a
series of compounds, with the aim of correlating the activation of a bond with the potential to
gain binding potency through enhanced interactions. Atomic Fukui indices are regional
descriptors of site-specific reactivity and can be used to predict which atoms in a molecule are
most reactive toward electrophilic or nucleophilic attack by analyzing frontier molecular orbitals
(FMOs).210

We used the program Jaguar198 to compute Atomic Fukui indices for several

compounds in a similar manner as described in Chapter 2. The values were normalized on a scale
from 0-1, with 1 being the most reactive.
5.3. Results and Discussion
WaterMap computes the location and thermodynamic properties (enthalpy, entropy, and free
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energy) of water clusters (“hydration sites”) using explicit solvent simulations.234, 235 WaterMap
analysis was performed on the recently published crystal structures of falcipain-2 (3BPF, PDB
code) and falcipain -3 (3BWK, PDB code) using default settings. The WaterMap calculations
revealed several highly unstable water molecules in the binding domain of falcipains. The
thermodynamic values of selected hydration sites in falcipain -2 and falcipain-3 as calculated by
WaterMap are shown in Tables 5.3.1 and 5.3.2.
Typically, water molecules with unfavorable free energy (ΔG > 1 kcal mol -1) should be
displaced by ligand functional groups complementary to the protein active site to gain in the
overall binding free energy through release of the water molecule into bulk solvent. Conversely,
water molecules with negative free energy values should be considered as structural water
molecules that can either be bridged or judiciously displaced with the polar atoms of ligands.258
Waters with negative ΔG also have negative enthalpy (ΔH), because the entropy contribution (TΔS) is, by definition, always unfavorable for waters in the binding site relative to bulk solution.
Given the above considerations, the emerging SAR trends of peptidomimetics from series 1-4 are
explained here in the context of the most active compound 42.
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Figure 5.3.1.The WaterMap profile of (a) FP-2 and (b) FP-3 LBD in complex with 42 is shown.
The thermodynamically interesting hydration sites important for the SAR are shown in spheres.
Stable hydration sites (ΔG <0 kcal mol-1) are colored in green, whereas significantly unstable
hydration sites (ΔG >1 kcal mol-1) are shown in purple. The water sites are labeled based on
decreasing values of predicted ΔG.

The full thermodynamic profile of falcipain -2 and falcipain-3 LBD in complex with 42 are
shown in Figure 5.3.1. The WaterMap hydration sites in falcipain -2 and falcipain-3 binding sites
along with compound 42 are shown in Figure 5.3.2. The proline hydroxy group of 42
successfully displaces the most unstable hydration site (W1, ΔG = 4.6 kcal mol-1 in falcipain -2;
W1, ΔG = 4.3 kcal mol-1 in falcipain-3) in the S2 pocket of both falcipains and forms an
additional H-bond with the backbone of His174/183 in the active site of the proteases.
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Furthermore, the hydroxy proline moiety displaces two other unfavorable hydration sites (W5
and W12 in falcipain -2; W5 and W6 in falcipain -3) with ΔG ≥ 2.3 kcal mol-1 from the S2
pockets of both enzymes. The boost in the potency of 42, as compared to other analogs in this
series, is mainly attributed to its proline hydroxyl substituent displacing highly unstable water
sites of the S2 pocket. The inactivity of 15 and 23 (Figures 5.3.3a and 5.3.3b) from series 1 and
2, respectively, can be explained by their inability to displace the unfavorable water sites of the
S2 pocket. Compound 42 also displaces W10 in falcipain -2 (ΔG = 2.6 kcal mol-1) and W2 in
falcipain -3 (ΔG = 4.2 kcal mol-1), with the replacement of a critical hydrogen bond with Gly83,
which is considered important for inhibitors of papain family cysteine proteases binding to the
non-prime site229. Moderate activities of compound 24 (Figure 5.3.3c), 36 37, 39, and 41(not
shown) are due to the formation of a strong H-bond network with Gly83 in addition to the
displacement of a few unfavorable water sites (ΔG ≥ 2.3 kcal mol-1) of the S2 pocket of
falcipain-2. The Cbz moiety of 42 also displaces several unfavorable water sites from the S3
pocket of falcipains (W4, W14, W16 and W20 in falcipain -2; W7, W8, W17 and W18 in
falcipain -3) into the solvent, and is a suitable substituent for the S3 subsite.
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Table 5.3.1. Predicted occupancy and thermodynamic
properties of selected WaterMap waters in FP-2

Water Site Occupancy ΔH -TΔS ΔG
0.68
2.55 2.01 4.56
W1
0.51
2.73 1.78 4.51
W2
0.79
0.63 3.03 3.66
W3
0.59
1.67 1.86 3.53
W4
0.40
2.22 1.27 3.49
W5
0.86
0.42
2.8
3.22
W6
0.81
0.13 2.83 2.96
W7
0.46
1.32 1.55 2.87
W8
0.97
-1.63 4.35 2.72
W9
0.46
1.28 1.33 2.61
W10
0.35
1.3
1.03 2.33
W11
0.43
0.98 1.33 2.31
W12
0.38
1.18 1.06 2.23
W13
0.33
1.32
0.9
2.22
W14
0.63
0.28 1.78 2.06
W15
0.52
0.56 1.46 2.02
W16
0.54
0.47 1.51 1.98
W17
0.61
0.15 1.73 1.88
W18
0.37
0.67 1.03 1.70
W19
0.50
-0.09 1.43 1.34
W20
0.47
-0.3 1.46 1.16
W21
0.95
-2.25 3.36 1.11
W22
0.50
-0.52 1.55 1.03
W23
0.58
-3.88 1.94 -1.94
W24
0.58
-4.10 1.97 -2.13
W25
0.36
-3.95 1.19 -2.76
W26

Table
5.3.2..
Predicted
occupancy
and
thermodynamic properties of selected WaterMap
waters in FP-3

Water Site Occupancy ΔH -TΔS ΔG
0.43
3.00 1.25 4.25
W1
0.86
1.45 2.77 4.22
W2
0.71
1.62 2.32 3.94
W3
0.96
-0.09
3.91 3.82
W4
0.91
2.50 1.10 3.60
W5
0.45
2.21 1.24 3.45
W6
0.42
2.30 1.15 3.45
W7
0.37
2.27 1.14 3.41
W8
0.84
-0.79 3.28 2.49
W9
0.57
0.62 1.71 2.33
W10
0.51
0.80 1.45 2.25
W11
0.40
1.09 1.09 2.18
W12
0.88
-0.93 2.98 2.05
W13
0.29
0.98 0.84 1.82
W14
0.39
0.45 1.13 1.58
W15
0.43
0.15 1.29 1.44
W16
0.44
0.19 1.24 1.43
W17
0.40
0.28 1.14 1.42
W18
0.31
0.47 0.83 1.30
W19
0.52
-0.36 1.6
1.24
W20
0.61
-2.55 1.89 -0.66
W21
0.48
-2.28 1.37 -0.91
W22
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Figure 5.3.2. The WaterMap profile of 42 in (a) falcipain -2 and (b) falcipain -3 is shown. The
thermodynamically interesting hydration sites important for SAR are shown in spheres. The
unstable hydration sites (ΔG >1 kcal mol-1) are shown in purple. The water sites are labeled
based on decreasing value of predicted ΔG. Key hydrogen bonding interactions of 42 (shown in
yellow) with the residues of falcipain binding (shown in cyan) sites are displayed as dotted blue
lines.
The carbonyl moiety of the α-hydroxy ketone in 42 displaces the proximal unstable water (W7 in
FP-2, ΔG = 3.0 kcal mol-1, W16 in FP-3, ΔG = 1.4 kcal mol-1) from the S1 pocket and replaces
its H-bond interaction with the side chain of Gln36/45 and backbone of Cys42/51 in FP-2/3,
respectively. The hydroxy group of the α-hydroxy ketone forms an H-bond with His 174/283 in
FP-2/3. Additionally, the hydroxy ketone also stabilizes the unfavorable water molecule of the
S1‟ pocket (W22 in FP-2 with ΔG = 1.1 kcal mol-1, W4 in FP-3, ΔG = 3.6 kcal mol-1) by forming
a water-mediated H-bond with Trp (206/215) in both enzymes. However, WaterMap did not
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provide any additional insights about the preference of α-hydroxy ketone in the S1-S1‟ pocket
over other electrophiles. This might be expected, given that WaterMap only accounts for solvent
displacement and not direct interactions made with the receptor. We anticipate that the reactivity
of the carbonyl carbon in the vicinity of catalytic cysteine (42/51) with different α-substituents
might play an important role in the activity of these compounds (discussed below).
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Figure 5.3.3. The predicted binding poses and interesting hydration sites for (a) 15 (b) 23 (c) 24
and (d) 49 in FP-2 are shown. Hydration sites labeling and color codes are same as shown in
Figure 5.3.2.

The HPhe in the S1 pocket displaces unfavorable water sites (W19 and W23 in FP-2; W14 and
W19 in FP-3) in both enzymes. The replacement of HPhe with a phenyl moiety, a modification
that was expected to reduce the flexibility of these peptidomimetics, resulted in the inactive
analogs 47-50. As shown in Figure 5.3.3d, compound 49 is not able to displace unfavorable
waters (W19 and W23 in FP-2) into the bulk of the solvent, as observed with HPhe in 42. In
addition, the increased rigidity resulted in unfavorable placement of the α-hydroxy ketone
electrophile near the catalytic cysteine in the S1-S1‟ pocket (Figure 5.3.3d). This observation is
further supported by the inactivity of compound 47, with an α-chloro ketone electrophile,
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anticipated to show higher reactivity with the catalytic cysteine.
In addition, WaterMap predicts other unfavorable waters in the LBD of FPs that were not
assessed in this work. For example, WaterMap predicts unstable water (W3 in FP-2 with ∆G =
3.66 kcal mol-1; W9 in FP-3 with ∆G = 2.5 kcal mol-1) interacting with the backbone carbonyl of
ILE 85/87 lining the S2 pocket of the proteases. W9 is also present in the X-ray structure of FP3216. Moreover, WaterMap shows a stable water (W24-W26 in FP-2 with ∆G = <-2 kcal mol-1;
W21, W22 in FP-3 with ∆G = <-0.7 kcal mol-1) at the bottom of the S2 pocket forming an Hbond with Asp234 in FP-2 and Glu243 in FP-3. These water sites can be either targeted
(displacing unstable waters) or interacted with (water-mediated H-bonds) in future work to gain
additional binding affinity.
To understand the reactivity of electrophiles with the catalytic cysteine residue and its effect
on the inhibitory activity of 42-45, we calculated the LUMO variant of Atomic Fukui indices at
constant spin density using the quantum mechanics package Jaguar, as described previously.259
The congeneric series of compounds 42-45 with different electrophilic groups were considered
for these calculations. The LUMO variant of Fukui indices was considered for predicting
electrophilicity of the carbonyl carbon. The predicted LUMO values were scaled from zero to
one, one being the most reactive, and are shown in Table 2.
The predicted reactivity of electrophiles was significantly higher for the compound with an αhydroxy ketone (42, LUMO = 0.52), than the compound with an α-thio ketone (43, LUMO =
0.46; 44, LUMO = 0.26), which in turn had a higher electrophilicity than the α-amino ketone (45,
LUMO = 0.01). The activity of 43 with the α-thio ketone might be due to its elongated alkyl
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phenyl chain displacing unfavorable waters from the S1‟ pocket in FP-2 over 42. The calculated
LUMO density values predict correct ordering of the inhibition of FPs for compounds 42-45.
Table 5.3.3. Predicted LUMO density of the most electrophilic center (shown by asterisk *) in
compound 42-45.
Compound No.

Electrophiles

F_NN_LUMO values

42

0.52

43

0.46

44

0.26

45

0.01

5.4. Conclusions
WaterMap highlighted the putative role played by water molecules in the binding of
peptidomimetics in falcipains and provided important insights about the SAR. In particular,
WaterMap analysis explained the role played by the hydroxyproline moiety in the potency of 42
based on the displacement of the most unstable predicted waters in the falcipain binding site and
the reason a homophenylalanine (HPhe) binds significantly tighter than phenylalanine.
Furthermore, the quantum mechanics calculations of Atomic Fukui indices correctly predicted
the trend in electronegative substitution effects on potency. The information gained from
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WaterMap analysis and Atomic Fukui indices can be used to design the next generation of
inhibitors of falcipains. Specifically, we plan to synthesize compounds that are able to displace
unstable hydration sites that were not displaced by the compounds presented in this work. This
may require developing new chemical scaffolds, as some of the unstable hydration sites are not
accessible with the R-group positions in the chemotypes studied here. Further design efforts
against FPs will consider the reactivity of electrophiles in addition to the displacement of
unfavorable waters, in particular from the S2 pocket of falcipain-2 and falcipain-3.
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Chapter 6

Understanding the Binding Affinity of
Inhibitors of SARS-3CLpro by Explicit
Molecular Dynamic Simulation

Content of this chapter is partly adapted from: Mukherjee, P., Shah, F., Desai, P., Avery M.
A. SARS-3CLpro: Virtual Screening, Biological Evaluation and Molecular Dynamics
Simulation Studies, Journal of Chemical Information and Modeling, 2011, 51 (6), 1376.
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6.1. Introduction
SARS-CoV (Severe acute respiratory syndrome-coronavirus) is a previously unidentified
virus belonging to the coronaviridae family which has been recognized as the etiological agent
for SARS, a highly infective upper respiratory tract disease. The disease was first diagnosed in
the winter of 2002 amongst patients in the remote Guangdong province of southern China. This
highly infectious disease with ~10% mortality rate, quickly reached pandemic status, spreading
to over 37 countries worldwide and causing over ~9000 infections96,

97, 260-262

. Although the

initial outbreak of the virus was stymied about an year from its first discovery, recent findings on
the isolation of the virus from animals including the Chinese horse shoe bats263-265 which act as
natural reservoirs for this virus are suggestive of the possibility of a future animal to human
transmission of the SARS-CoV or other closely related corona viruses in the near future. The
imminent threat from this disease led to the discovery of a number of viral proteins266 which
could be utilized as possible targets for the development of antiviral therapy. Among these
targets, SARS-3CLpro, a cysteine protease indispensible to the viral life cycle, has been identified
as one of the key therapeutic target against SARS. Chapter 1 describes the detailed overview of
SARS-3CLpro functions and various classes of inhibitors developed so far. As a part of our
efforts to discover inhibitors against SARS-3CLpro, we previously reported a cascading virtual
screening study, involving similarity/substructure searching, docking and ranking based on
docking pose based descriptors was carried out against the Asinex Platinum collection in our
laboratory19,

267

. As a result, numbers of lower micromolar inhibitors of SARS-3CLpro were

identified (Table 6.1), the structures of which are shown in Figure 7.1.1 and their docking pose in
the binding site of SARS-3CLpro are shown in Figure 6.1. 2.
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Figure 6.1.1. SARS-3CLpro inhibitors identified by combined structure/ligand-based drug design
approach.
Table 6.1. Results from the SARS-3CLpro enzyme inhibition assay
ID

%Inh (10 μM)

PJ207
PJ224
PJ225
PJ316

25.03
44.93
61.26
55.69

SARS-3CLpro IC50
(μM)
39.4
15
5.8
10.3

The present efforts were initiated to understand the binding affinity of the identified hits
and to highlight trends in the SAR of these compounds. Our aim was to incorporate the
information gained from binding affinity analysis into future structure-based design of SARS3CLpro inhibitors. Therefore, we carried out multi nanosecond explicit MD simulation of SARS3CLpro in complex with PJ207, PJ224, PJ225, PJ316 to study the overall stability of the
interaction profiles predicted from rigid docking studies as well as novel interactions that were
not observed during the docking study. The studies revealed several novel interactions that can
be considered for future structure-based drug design of SARS-3CLpro inhibitors.
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a)

b)

c)

d)
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e)

f)

g)

h)

Figure 6.1.2. Interaction profile and surface representation of the poses of the identified hits
(a)(b) PJ207, (c)(d) PJ224, (e)(f) PJ225 and (g)(h) PJ316.
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6.2. Methods
The docked ligand/SARS-3CLpro complexes of the biological hits (Figure 6.1.2) were
used to perform MD simulations with the parallelized Desmond Molecular Dynamics System
v2.2 (D. E. Shaw Research, New York, NY) within the maestro environment. The model system
for simulation was prepared using the „system builder‟, a graphics tool in maestro. The OPLSAA/2005 force field parameters were assigned for all the simulation systems. Each inhibitorenzyme complex was placed in the center of a cubic box with a dimension of 94.4 Å ensuring 10
Å solvent buffers (~23,400 water molecules) between the solute and the boundary of simulation
box in each direction. The SPC model was used to describe the water molecules. Na+ and Clions were added at physiological concentration of 0.15 M to ensure the overall neutrality of the
systems. Any solvent molecules that overlapped with the solute structures were removed. The
final size of the solvated system was close to ~33,000 atoms. The crystallographic waters were
retained as part of the simulation system.
The model systems were relaxed using a six step default protocol implemented in
Maestro, utilized to prepare systems for production-quality simulation. The relaxation protocol
implemented in Maestro involved a series of minimizations followed by a series of short MD
runs to relax the model systems. The solvated systems were first minimized for 10 steps of
steepest-descent followed by the limited-memory Broyden-Fletcher-Goldfarb-Shanno (LBFGS)
minimization over a maximum of 2000 steps, keeping all the protein and ligand atoms fixed. The
convergence criterion and force constant on the solute was set to 50.0 kcal mol-1 Å-1. In the
second step all positional restraints were removed and the system was minimized to a
convergence criterion of 5 kcal mol-1 Å-1 using the same sequence as the last step. In the third
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step, a 12 ps simulation was performed using the NVT ensemble using a Berendsen
thermostat268, a temperature of 10K, a fast temperature relaxation constant of 0.1 ps, velocity
rescaling at every 1 ps and restraints on all non-hydrogen solute atoms with a force constant of
50.0 kcal mol-1 Å-1. Following these, two short simulations of 12 and 24 ps were performed
using the NPT ensemble using a Berendsen barostat268, maintaining pressure at 1 atm and a slow
pressure relaxation constant of 50 ps with all other parameters preserved from the previous NVT
simulation. The restraint set from the third step was preserved through the fourth and fifth steps.
Temperature was maintained at 10k for the fourth step and then elevated to 300k for the fifth
step. In the final stage of the relaxation protocol, all atoms were set free and the simulation was
performed using the NPT ensemble for a simulation time of 24 ps using a pressure relaxation
constant of 2.0 ps. This final step resembled the conditions of the actual production runs.
The relaxed systems were subjected to a production phase, using the NPT ensemble and
periodic boundary conditions for a period of 5 ns. The Martyna-Tobias-Klein269 pressure control
method was used to maintain the pressure of the cell at 1.013 bar using the isotropic coupling
method. The Nose-Hoover thermostat method was used to control the temperature at 300K.
Heavy atom-hydrogen covalent bonds were constrained using the SHAKE algorithm270 which
allowed a 2-fs integration step to be used. The integration of the equation of motion as
implemented according to the RESPA271 multiple time step scheme was used in the simulations.
Long-range electrostatic forces were computed using the smooth Particle-Mesh Ewald (PME)
method272. The cutoff distance for calculating short-range electrostatics and Lennard-Jones
interaction was set to 9.0 Å. The trajectories and the energies were recorded at every 25 and 6 ps
respectively. The glue option was turned on for proper display of recorded trajectories and
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convenience in structure analysis. The simulation quality analysis tool was used for the analysis
of the energetics of the simulations whereas the simulation event analysis tool provided the
graphical interface for calculating the root mean square deviations (RMSDs), as well as the Hbond distance, angles and Van der Waals interaction monitors.
6.3 Result and Discussions
Molecular Dynamics simulations were carried out to investigate the overall stability of the
predicted docking poses as well as conformational changes of the inhibitors relative to the active
site resulting in altered interaction profiles as well as movements of amino acid side chains lining
the binding site. The overall stability of the individual simulations was evaluated by plotting the
total energy of the system as a function of time (Figure 6.3.1) and was suggestive of
energetically stable complexes with maximum fluctuations at < 1% of the total energy of the
system.

Figure 6.3.1. Potential energy plot for the production phase of dynamic simulation of
ligand/SARS-3CLpro complex.

The superposition of the trajectories onto the system conformations at the start of the
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production phase helped in the analysis of the RMSD progression over the time of the
simulation. The average heavy atom RMSD of the binding site (BS) side chain residues (Thr25,
Leu27, His41, Met49, Phe140, Leu141, Asn142, Cys145, His 163, Met 165, Glu166, His172,
Asp187, Gln189 and Gln 192) of SARS-3CLpro in complex with PJ207, PJ224, PJ225 and
PJ316 were found to be 1.14 Å, 1.41 Å, 1.44 Å and 1.49Å respectively for 5 ns of simulation
time and were suggestive of a stable binding site. The average RMSD of the ligands PJ207,
PJ224, PJ225 and PJ316 were 0.72 Å, 1.05 Å, 1.0 Å, and 1.48 Å respectively (Figure 7b, 8b,
9b, and 10b) and were suggestive of stable binding poses. The average RMSD of the inhibitors
were at the same level (PJ316) or lower (PJ207, PJ224, PJ225) than the corresponding average
heavy atom RMSD of the binding site (BS) side chain residues, suggesting that the movement of
inhibitors in the active site should be relatively smaller as compared to the overall
conformational changes of the SARS-3CLpro binding site. The most noticeable side chain
movements were shown by Gln189. This residue are solvent exposed and are located in the
opening of the catalytic cleft located between domain I and II273 might explain their positional
variability due to inter domain movements.
In addition, the MD trajectories of the representative inhibitors were analyzed for the
presence of H-bonds as well as hydrophobic interactions between the inhibitors and important
residues of the enzyme binding site predicted by the docking studies. Analysis of the MD
trajectories indicated the presence of several H-bonds and hydrophobic interactions with
moderate to high frequency of occurrence. MD studies also helped to identify new interactions
formed over the period of the simulation and suggested the possibility of considering these
interactions for the rational designing of the inhibitors against SARS-3CLpro. A D-A (Donor171

Acceptor) distance cut-off of ≤3.5 Å and angle (D-H-A) of ≥ 120° was used for the identification
of H-bonds. For hydrophobic interactions, a cut-off distance of ≤4.5 Å between corresponding
hydrophobic heavy atoms from the protein and ligand was considered. The interactions of each
inhibitor with the active site residues of SARS-3CLpro are discussed below in detail. The plots of
the MD simulation of all inhibitors are graphically shown in Figure 6.3.2.-6.3.5. The distance
monitors (Figure 6.3.2a, 6.3.3a, 6.3.4a and 6.3.5a) used for H-bonds and hydrophobic
interactions are shown using red and green dotted lines respectively.
a)
T25

L 27

H 163
H 172
M 49

E 166
M 165

b)

c)

172

d)

e)

Figure 6.3.2. (a) Docking pose of PJ207 showing the H-bond (red) and hydrophobic (green)
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of
enzyme‟s binding site (BS), PJ207 and side chain of four residues of BS that showed maximum
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of His163[NH]-[O]PJ207 and Glu166[-NH]-[O]PJ207; (e) Hydrophobic [CH-CH] interactions of PJ207
with Thr25, Leu27, Met49 and M165 and a cation(pi)-pi interaction with His172.
The results from the simulation of the PJ207/SARS-3CLpro complex are shown in Figure.
6.3.2. All the H-bonds (Figure 6.3.2 c, d) formed between PJ207 and residues of the BS were
transient in nature. A very interesting observation was made in respect to the critical H-bonding
interaction in the S1 sub pocket. In the 0-3ns of the simulation the H-bond interaction between
the NE2 of His 163 from the S1 subsite of the enzyme and the amide side chain carbonyl of
PJ207 was retained an average D-A distance of 2.69Å and D-H-A angle of 120.1°. Following
this the H-bond is lost and was compensated by the formation of a new H-bond between the
carbonyl side chain of PJ207 and backbone –NH of Glu 166 located close to the S1 pocket with
an average D-A distance of 2.85 Å and D-H-A angle of 135° for 4-5 ns of the simulation time
(Figure 6.3.2 c, d). The hydrophobic interaction profile (Figure 6.3.2e) showed interactions of
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PJ207 with Thr25, Leu27 of the S1‟ site as well as Met49 from S2 and Met165 where the
corresponding heavy atom distances were retained at ≤ 4.5 Å for 42%, 70.5%, 50%, and 64.5%
of the simulation time respectively. A cation(pi)-pi interaction could also be observed between
the thiazole group and the His172 in the 0-3ns of the simulation. It‟s likely, that the relatively
polar nature of the aromatic group (compared to the other active analogues) at the end of the S 1
substitution could also contribute to the observed higher movement of the amide side chain. It is
also interesting to note that the RMSD fluctuation of Met165 shows a biphasic behavior between
0-3 and 3-5 ns of the simulation showing larger fluctuations in the second phase which
corresponds with the H-bond compensation phenomenon observed between the ligand‟s amide
side chain carbonyl and the His163 and Glu166 residues (discussed above). Overall, the more
transient nature of the interactions in case of PJ207 (compared to the other hits) may be
indicative of its relatively weaker affinity.
a)

T25

N 142

Gly -1
H 163
H 172
M 49

M 165
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Figure 6.3.3. (a) Docking pose of PJ224 showing the H-bond (red) and hydrophobic (green)
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of
enzyme‟s binding site (BS), PJ224 and side chain of four residues of BS that showed maximum
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of
Asn142[O]-PJ224[NH], His163[-NH]-[O]PJ224 and Gly-1[NH]-PJ224[O]; (e) Hydrophobic
[CH-CH] interactions of PJ224 with Thr25, Met49, and Met165 and a cation(pi)-pi interaction
with His172.
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The results from the simulation of the PJ224/SARS-3CLpro complex are shown in Figure.
6.3.3. As predicted from the docking studies, the amide carbonyl side chain of PJ224 appeared
to form a strong H-bond with the NE2 of His163 with an average D-A distance of 2.61 Å and
average D-H-A angle of 124.2° (Figure 6.3.3 c, d). Another H-bond was observed between the
side chain -NH of Asn142 and the side chain carbonyl oxygen of PJ224 with an average D-A
distance of 2.9 Å and average D-H-A angle of 120.9° for 0.55-5.0 ns of the simulation time. This
interaction was not observed in the static docking pose and pointed towards the importance of
the MD simulation in detecting a possible additional interaction. MD simulation also revealed a
new H-bond between the carboxylate moiety of PJ224 and N-terminal Gly-1 (of subunit B) with
an average D-A distance of 2.69 Å for the first 2.2 ns of the simulation time which was not
observed in the docking pose. The additional H-bond interactions in PJ224 vis-a-vis PJ207 may
contribute to its higher affinity. Thr25 from the S1‟ sub site exhibited strong hydrophobic
interactions with the benzpyrimidine scaffold of PJ224 with the corresponding hydrophobic
heavy atom distance at ≤4.5 Å for 88% of the simulation time with an average distance of 4.03
Å. Also, Met165 and Met49 from the S2 sub site were found to interact with the phenyl side
chain of PJ224 with the corresponding hydrophobic heavy atom distance at ≤4.5 Å for 87% and
71% of the simulation time respectively (Figure 6.3.3 e). A transient cation (pi)-pi interaction
was observed between the phenyl group and His172 in the S1 pocket.
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Figure 6.3.4. (a) Docking pose of PJ225 showing the H-bond (red) and hydrophobic (green)
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of
enzyme‟s binding site (BS), PJ225 and side chain of four residues of BS that showed maximum
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of
Asn142[NH]-PJ225[O], Ser144[OH]-PJ225[O] and His163[NH]-[O]PJ225; (e) Hydrophobic
[CH-CH] interactions of PJ225 with Thr25, Met49, Phe140, Leu141 and Met165 and a
cation(pi)-pi interaction with His172.
The results of the MD studies for SARS-3CLpro in complex with PJ225 are shown in Figure
7.3.4. Similar to PJ224, a stable H-bond was observed between the side chain amide carbonyl
oxygen of PJ225 with the NE2 of His 163 with an average D-A distance of 2.69 Å and average
D-H-A angle of 125.6° (Figure 9 c, d). Also, a transient H-bond was observed between the side
chain OH of Ser144 and amide carbonyl oxygen of PJ225 (D-A distance ≤3.5 43.5% of the
simulation time). This residue is located on the loop (residues 140-146) involved in the oxyanion
hole formation and stabilization of the covalent tetrahedral intermediate generated during
substrate hydrolysis by the enzyme. Coincidentally, this interaction was not observed in the
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docking pose of PJ225. However, the Gly-1 H-bond is not possible in case of PJ225 and the
Asn142 interaction had a lower residence time in comparison to PJ224. During the course of the
simulation, several strong hydrophobic interactions were observed. These included interactions
of PJ225 with the side chains of Thr25, Leu141, Phe140, Met165 and Met49 where the
corresponding hydrophobic heavy atoms were retained at ≤ 4.5 Å for 82.5%, 30.5%, 85.5%, 72%
and 59% of the simulation time respectively. As predicted from the docking study, PJ225 in
comparison to PJ224 and PJ207 demonstrated additional hydrophobic interactions (Figure 7.3.4
e) between the ethyl moiety of the ligand with Phe140 and Leu141. A highly stable cation(pi)-pi
interaction was observed between the phenyl ring and His 172 with the distance ≤ 4.5 Å 100% of
the time. These additional and/or stronger interactions in the S1 pocket observed for PJ225 could
account for its higher inhibitory activity (IC50=5.8 μM) against SARS-3CLpro in comparison to
PJ224 (IC50=15μM) and PJ207 (IC50=39.4 μM).
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Figure 6.3.5. (a) Docking pose of PJ316 showing the H-bond (red) and hydrophobic (green)
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of
enzyme‟s binding site (BS), PJ316 and side chain of four residues of BS that showed maximum
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of Phe140
[O]-[NH]PJ316, G143[-NH]-[CO]PJ316, Ser144 [NH]-[O]PJ316 and H163[-NH]-[O]PJ316; (e)
Hydrophobic [CH-CH] interactions of PJ316 with Thr25, Met49, Leu141 and Met165 and a
cation(pi)-pi interaction with His172.
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The simulation plots for the PJ316/SARS-3CLpro complex are shown in Figure 7.3.5.
Multiple H-bonds were predicted for PJ316 based on the docking simulations (Figure 7.3.5 c, d).
The amide carbonyl oxygen of the benzpyridone moiety of PJ316 appeared to form a stable Hbond with NE2 of His 163 (Avg. D-A distance= 2.47Å and Avg. D-H-A angle=125°) of the S1
pocket. The amide nitrogen of the bicyclic ring of PJ316 also formed a H-bond with the
backbone carbonyl oxygen of Phe140 with an average D-A distance of 2.22 Å and D-H-A angle
of 139°. In addition, the amide side chain of PJ316 formed a bifurcated H-bond with the
backbone amide of Gly143 (Avg. D-A distance= 1.83Å and Avg. D-H-A angle=164°) and
Ser144 which forms the oxyanion hole to stabilize the covalent tetrahedral intermediate resulting
from substrate hydrolysis by the enzyme. The hydrophobic interactions profile for PJ316enzyme complex is shown in Figure 7.3.5e. Also, Thr25 exhibited a strong interaction with the
benzyl side chain of PJ316 with a distance ≤ 4.5 Å for 91.5% of the simulation time and an
average distance of 4.48 Å. Met49 exhibited hydrophobic interaction with PJ316 for 57.5% of
the simulation time. In addition, the hydrophobic interactions between the side chain of Met165
with the phenyl side chain of PJ316, and Leu141 with the benzpyridone moiety of the ligand
falling within the cutoff distance of ≤4.5 Å for 40% and 51% of the simulation time respectively.
Amongst the current hits only PJ316 may explore the S4 pocket through the chlorine substitution
on the phenyl ring. Also of interest is the RMSD fluctuation of the Met49 and Met165 residues
which show a biphasic behavior. The residues appear to undergo induced-fit in the 0-2 ns of the
simulation following which they preserve their conformational states for the remainder of the
simulation. The hydrophobic distance progression (Figure 7.3.5e) for Leu141 also showed a
biphasic behavior (0-1.5ns and 1.5-5ns) suggesting the possible stabilization of the interaction
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with the dimethyl moiety of the ligand in the second phase which would also stabilize the two Hbonds in the S1 pocket.
6.4 Guidelines for future structure-based drug design of SARS-3CLpro inhibitors.
Based on the analysis of SAR trends as well as MD simulation, certain guidelines could be
formed for structure-based modification schemes that could be used for the synthesis of
analogues. First, the S2 sub site appears to be highly specific to the hydrophobic groups that may
be utilized to occupy this subsite. While the smaller/bulkier aliphatic groups didn‟t provide
adequate hydrophobic interaction/caused steric clash, longer groups would require a
corresponding S1 group of compatible size for proper fit. A phenyl group at the S2 position is
advantageous because it allows a vector into the S4 packet which could be occupied with a
hydrophobic group potentially leading to an increase in overall affinity. In case of PJ316, we
observed the hydrophobic chlorine group vectored into the S4 cavity adds to the overall stability
of the binding pose and suggest that such structure-based modifications in both active
chemotypes could be beneficial towards potency gain. Furthermore, additional smaller
hydrophobic substituents may be useful in probing the depths of the S2 pocket. The S1 interaction
with His163 was found to be highly stable in all the simulations except PJ207 and is one of the
most critical binding site requirements. The alternate H-bonding demonstrated by PJ207 with the
backbone of Glu166 in lieu of His163 and the Ser144 (from the oxyanion hole ) interaction
observed in case of PJ225 suggests that possible modifications vectoring two hydrogen
acceptors (e.g. sulfonamide for Ser144) could be utilized to harness additional binding affinity.
Also, of interest would be the interaction with Asn142 as observed in the MD simulations of
PJ224 and PJ225. It would also appear that, the interaction with Leu141 (observed in the
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docking pose and MD simulations of the two more potent hits PJ225 and PJ316) through
aliphatic hydrophobic groups may add to the overall stability by forming additional hydrophobic
interactions which in turn helps in the stabilization of the H-bonds formed in the S1 pocket.
Additionally, as shown in case of PJ316 the H-bonding interactions with the backbone of
Gly143 and Ser144 residue forming the oxyanion hole could form a strong anchor point for
ligand stability. The Gly-1 residue from the second monomer was found to participate in a
transient H-bonding interaction during the MD simulation and may be pursued as part of the
structure-based design strategy. The binding site appears to prefer an amphiphilic group
extending into the S1 pocket and is critical towards the stability of the interactions formed in this
region.
6.5. Conclusions
A multi nanosecond explicit solvent simulation were carried out using the docking poses of the
identified hits to study the overall stability of the binding site interactions as well as identify
important changes in the interaction profile that may not be apparent from a docking study.
Additionally, the docking poses from the identified hits were utilized for a series of multi
nanosecond simulations to study the overall stability of the interaction profiles and well as novel
interactions not observed during the docking study. The information from these analyses would
be utilized for further structure guided synthesis of analogues that might help in the identification
of potent antiviral leads targeted against SARS-CoV. Cumulative analysis of the evaluated
compounds and the simulation studies led to the identification of certain SAR traits which would
be useful in further structure based design efforts.
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1

H and 13C spectra of intermediates and final compounds 16-41 (Chapter 3) were recorded on
Bruker ][500MHz, 400MHz, or Bruker 400MHz Ultra Shield and the analyses conducted in
CDCl3, MeOD, or DMSO-d6.
2-((6-aminobenzo[d]thiazol-2-yl)thio)-1-phenylethanone (16)
1
H NMR (500 MHz, DMSO-d6) δ 8.06 (d, J = 6.84 Hz, 2H), 7.64 - 7.78 (m, 1H), 7.58 (d, J =
6.41 Hz, 2H), 7.43 (d, J = 8.55 Hz, 1H), 6.99 (br. s., 1H), 6.69 (d, J = 7.27 Hz, 1H), 5.34 (br. s.,
2H), 5.03 (br. s., 2H); 13C NMR (126 MHz, DMSO-d6) δ 193.2, 157.4, 146.6, 144.1, 136.6,
135.4, 133.7, 128.8, 128.4, 121.5, 114.4, 103.9, 40.9; HRMS (m/z): [M +H] calcd for
C15H13N2OS2 301.0469, found 301.0448
2-((6-aminobenzo[d]thiazol-2-yl)thio)-1-(naphthalen-2-yl)ethanone (17)
1
H NMR (500 MHz, DMSO-d6) d 8.83 (br. s., 1H), 8.11 - 8.42 (m, 2H), 8.04 (br. s., 2H), 7.58 7.78 (m, 2H), 7.44 (br. s., 1H), 7.01 (br. s., 1H), 6.70 (br. s., 1H), 5.27 - 5.47 (m, 2H), 5.17 (br.
s., 2H); 13C NMR (126 MHz, DMSO-d6) d 193.0, 157.3, 146.5, 144.0, 136.5, 135.1, 132.5,
131.9, 130.5, 129.5, 128.8, 128.3, 127.6, 126.9, 123.6, 121.3, 114.2, 103.7
HRMS (m/z): [M + H] calcd for C19H15N2OS2 351.0626, found 351.0626
ethyl 2-((6-aminobenzo[d]thiazol-2-yl)thio)acetate (18)
1
H NMR (400 MHz, DMSO-d6) δ 7.48 (dd, J = 3.14, 8.41 Hz, 1H), 7.00 (br. s., 1H), 6.66 - 6.86
(m, 1H), 5.36 (br. s., 2H), 4.16 - 4.29 (m, 2H), 4.13 (dd, J = 3.01, 7.03 Hz, 2H), 1.09 - 1.30 (m,
3H) ; 13C NMR (101 MHz, DMSO-d6) δ 168.2, 146.7, 144.1, 136.6, 135.9, 121.6, 114.4, 103.9,
61.2, 34.8, 14.0; HRMS (m/z): [M + H] calcd for C11H13N2O2S2 269.0418, found 269.0389
2-((6-aminobenzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (19)
1
H NMR (400 MHz, DMSO-d6) δ 10.27 (br. s., 1H), 7.42 - 7.66 (m, 2H), 7.10 (br. s., 2H), 6.74
(br. s., 1H), 5.34 (br. s., 2H), 4.24 (br. s., 2H), 2.14 - 2.39 (m, 3H); 13C NMR (101 MHz, DMSOd6) δ 165.3, 157.8, 146.7, 144.3, 136.7, 136.3, 132.6, 129.2, 121.6, 119.3, 114.5, 104.0, 37.9,
20.5; HRMS (m/z): [M + H] calcd for C16H16N3OS2 330.0735, found 330.0700
2-nitro-N-(2-((2-oxo-2-phenylethyl)thio)benzo[d]thiazol-6-yl)benzenesulfonamide (20)
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.07 (d, J = 7.28 Hz, 2H), 7.87 (d, J = 7.78 Hz, 1H),
7.76 - 7.80 (m, 1H), 7.67 - 7.72 (m, 2H), 7.62 - 7.67 (m, 2H), 7.55 - 7.59 (m, 1H), 7.50 - 7.55 (m,
2H), 7.35 (s, 1H), 7.17 (dd, J = 2.13, 8.66 Hz, 1H), 4.93 (s, 2H); 13C NMR (126 MHz,
CHLOROFORM-d) δ 193.8, 166.9, 150.6, 148.4, 136.3, 135.8, 135.5, 134.7, 133.6, 133.3,
131.6, 130.8, 129.7, 129.1, 125.2, 122.1, 121.6, 115.2, 41.3; HRMS (m/z): [M - H] calcd for
C21H14N3O5 S3 484.0095, found 484.0066
N-(2-((2-oxo-2-phenylethyl)thio)benzo[d]thiazol-6-yl)-4-(trifluoromethoxy)benzene
sulfonamide (21)
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.06 - 8.12 (m, 2H), 7.77 (d, J = 8.78 Hz, 2H), 7.62 7.67 (m, 2H), 7.58 (d, J = 2.01 Hz, 1H), 7.50 - 7.56 (m, 2H), 7.25 (s, 1H), 6.99 (dd, J = 2.26,
8.53 Hz, 1H), 6.64 (br. s., 1H), 4.94 (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 192.8, 179.1,
165.4, 151.1, 149.7, 138.1, 135.7, 135.3, 133.9, 133.8, 129.3, 128.9, 128.4, 121.5, 121.4, 120.2,
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113.8, 40.9; HRMS (m/z): [M-H] calcd for C22H13 F3N2O4 S3 523.0067, found 523.9977
N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)-4(trifluoromethoxy)benzenesulfonamide (22)
1
H NMR (400 MHz, DMSO-d6) d 8.86 (br. s., 1H), 8.16 (br. s., 2H), 7.99 - 8.12 (m, 2H), 7.86
(br. s., 1H), 7.60 - 7.81 (m, 3H), 7.27 (br. s., 1H), 5.29 (br. s., 2H), 4.56 (d, J = 9.54 Hz, 2H),
4.13 (br. s., 1H), 1.27 (br. s., 3H), 0.86 (br. s., 2H); 13C NMR (126 MHz, CHLOROFORM-d) δ
192.7, 165.2, 149.7, 135.8, 135.3, 133.7, 132.7, 132.1, 130.7, 129.7, 129.0, 128.5, 127.7, 127.1,
123.7, 121.5, 120.2, 113.3, 41.0; HRMS (m/z): calcd for C21H14F3 N2O3S3 495.0041, found
495.0118
N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)acetamide (23)
1
H NMR (500 MHz, CHLOROFORM-d) δ 8.65 (s, 1H), 8.27 (br. s., 1H), 8.10 (dd, J = 1.71,
8.55 Hz, 1H), 7.99 (d, J = 7.69 Hz, 1H), 7.93 (dd, J = 8.33, 17.31 Hz, 2H), 7.72 (d, J = 8.55 Hz,
1H), 7.65 (t, J = 7.05 Hz, 1H), 7.59 (t, J = 7.05 Hz, 1H), 7.34 (br. s., 1H), 7.20 - 7.26 (m, 1H),
5.07 (s, 2H), 2.21 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 192.9, 181.9, 168.4, 163.8, 136.2,
135.4, 135.3, 132.7, 132.1, 130.7, 129.7, 129.0, 128.5, 127.7, 127.1, 123.7, 121.0, 118.4, 111.1,
79.2, 41.0, 24.0; HRMS (m/z): [M + Na] calcd for C21H16 N2 NaO2S2 415.0550, found 415.0566
N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)quinoline-8-sulfonamide
(24)
1
H NMR (400 MHz, CHLOROFORM-d) δ 9.15 - 9.22 (m, 1H), 8.58 (s, 1H), 8.55 (br. s., 1H),
8.32 (br. s., 1H), 8.30 (d, J = 2.35 Hz, 1H), 8.00 - 8.07 (m, 2H), 7.96 (d, J = 8.02 Hz, 1H), 7.86 7.94 (m, 2H), 7.64 (dt, J = 4.18, 8.27 Hz, 2H), 7.53 - 7.60 (m, 2H), 7.50 - 7.53 (m, 1H), 7.48 (d,
J = 8.80 Hz, 1H), 6.92 (dd, J = 1.96, 8.61 Hz, 1H), 4.99 (s, 2H); 13C NMR (126 MHz, DMSO-d6)
δ 192.7, 164.6, 151.5, 149.1, 142.7, 137.0, 135.4, 135.2, 135.0, 134.6, 134.3, 132.6, 132.2, 132.1,
130.7, 129.6, 129.0, 128.4, 128.4, 127.7, 127.1, 125.6, 123.7, 122.6, 121.1, 119.6, 112.5, 41.0;
HRMS (m/z): [M + Na] calcd for C28H19N3O3S3Na, 564.0486; found, 564.0499
4-fluoro-N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)benzene
sulfonamide (25)
1
H NMR (500 MHz, CHLOROFORM-d) δ 8.63 (s, 1H), 8.08 (s, 1H), 7.99 (d, J = 8.12 Hz, 1H),
7.92 (dd, J = 8.33, 16.03 Hz, 2H), 7.75 (dd, J = 4.92, 8.76 Hz, 2H), 7.58 - 7.69 (m, 3H), 7.55 (d,
J = 1.71 Hz, 1H), 7.09 (t, J = 8.55 Hz, 1H), 6.98 - 7.04 (m, 1H), 5.05 (s, 3H); 13C NMR (126
MHz, DMSO-d6) δ 192.7, 165.3, 149.6, 135.7, 135.2, 134.1, 132.6, 132.1, 130.7, 129.7, 129.7,
129.0, 128.5, 128.4, 127.7, 127.1, 127.0, 123.7, 121.4, 120.2, 116.5, 116.3, 113.6, 40.9;
HRMS (m/z): [M + Na] calcd for C25H17FN2O3S3Na, 531.0283; found, 531.0308
ethyl 2-((6-(2,2,2-trifluoroethylsulfonamido)benzo[d]thiazol-2-yl)thio)acetate (26)
1
H NMR (500 MHz, CHLOROFORM-d) δ 7.74 (d, J = 8.55 Hz, 1H), 7.69 (s, 1H), 7.40 (br. s.,
1H), 7.22 (dd, J = 2.14, 8.55 Hz, 1H), 4.28 (d, J = 7.27 Hz, 4H), 4.16 (s, 2H), 3.80 (d, J = 8.98
Hz, 2H), 1.32 (t, J = 7.05 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 168.0, 164.8, 149.7, 135.9,
133.7, 123.4, 121.7, 120.3, 113.4, 61.4, 52.5, 34.7, 14.0; HRMS (m/z): [M + H] calcd for C13H14
F3N2O4S3 415.0068, found 415.0059
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ethyl 2-((6-(4-fluorophenylsulfonamido)benzo[d]thiazol-2-yl)thio)acetate (27)
1
H NMR (400 MHz, CHLOROFORM-d) δ 7.72 - 7.81 (m, 2H), 7.63 (d, J = 8.61 Hz, 1H), 7.56
(s, 1H), 7.17 (br. s., 1H), 7.10 (t, J = 8.51 Hz, 2H), 7.01 (dd, J = 1.96, 8.61 Hz, 1H), 4.26 (q, J =
7.17 Hz, 2H), 1.30 (t, J = 7.14 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 168.0, 165.3, 164.8,
163.3, 149.5, 135.8, 135.6, 134.2, 129.8, 129.7, 121.5, 120.2, 116.5, 116.3, 113.6, 61.3, 34.7,
13.9; HRMS (m/z): [M +H] calcd for C17H16FN2O4S3 427.0256 found 427.02562
ethyl 2-((6-(2-nitrophenylsulfonamido)benzo[d]thiazol-2-yl)thio)acetate (28)
1
H NMR (500 MHz, CHLOROFORM-d) δ 7.85 - 7.93 (m, J = 7.69 Hz, 1H), 7.80 (d, J = 7.69
Hz, 1H), 7.71 (br. s., 2H), 7.54 - 7.61 (m, 1H), 7.38 (br. s., 1H), 7.29 (s, 1H), 7.16 - 7.23 (m, J =
8.12 Hz, 1H), 4.23 - 4.31 (m, 2H), 4.16 (s, 2H), 1.31 (t, J = 6.84 Hz, 3H); 13C NMR (101 MHz,
DMSO-d6) δ 168.0, 165.3, 149.8, 147.9, 135.8, 134.7, 133.3, 132.6, 131.2, 130.1, 124.6, 121.6,
120.6, 114.2, 61.4, 34.7, 14.0; HRMS (m/z): [M + Na] calcd for C17H15N3NaO6S3 476.0021,
found 476.0068
ethyl 2-((6-(quinoline-7-sulfonamido)benzo[d]thiazol-2-yl)thio)acetate (29)
1
H NMR (500 MHz, CHLOROFORM-d) δ 9.20 (d, J = 4.27 Hz, 1H), 8.58 (br. s., 1H), 8.33 (t, J
= 6.62 Hz, 2H), 8.04 (d, J = 8.12 Hz, 1H), 7.65 (dd, J = 4.27, 8.55 Hz, 1H), 7.55 - 7.61 (m, 2H),
7.53 (d, J = 8.55 Hz, 1H), 6.93 (dd, J = 1.92, 8.76 Hz, 1H), 4.21 (q, J = 7.12 Hz, 2H), 4.09 (s,
2H), 1.26 (t, J = 7.05 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 167.9, 164.1, 151.5, 149.0,
142.7, 136.9, 135.4, 135.0, 134.7, 134.3, 132.2, 128.3, 125.6, 122.6, 121.2, 119.6, 112.6, 61.3,
34.6, 13.9; HRMS (m/z): [M+H] calcd for C20H18N3O4S3 460.0459, found 460.0483
N-(p-tolyl)-2-((6-(2,2,2-trifluoroethylsulfonamido)benzo[d]thiazol-2-yl)thio) acetamide (30)
1
H NMR (500 MHz, DMSO-d6) δ 10.29 - 10.34 (m, 1H), 9.77 (br. s., 1H), 7.69 - 7.75 (m, 1H),
7.40 - 7.46 (m, 1H), 7.32 - 7.37 (m, 2H), 7.31 (br. s., 1H), 7.01 (d, J = 8.12 Hz, 2H), 4.09 (br. s.,
2H), 3.72 - 3.89 (m, 2H), 2.21 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 165.2, 164.6, 149.7,
143.7, 135.7, 133.3, 132.4, 128.8, 121.2, 119.8, 119.1, 112.9, 37.5, 20.3; HRMS (m/z): [M - H]
calcd for C18H15 F3N3 O3 S3 474.0306, found 474.0145
2-((6-acetamidobenzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (31)
1
H NMR (500 MHz, DMSO-d6) δ 9.88 (br. s., 1H), 9.67 (br. s., 1H), 8.28 (s, 1H), 7.66 (d, J =
8.98 Hz, 1H), 7.48 - 7.54 (m, 1H), 7.39 - 7.44 (m, 1H), 7.35 (d, J = 8.12 Hz, 2H), 7.00 (d, J =
8.12 Hz, 2H), 4.08 (br. s., 2H), 2.21 (s, 3H), 2.08 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ
168.5, 165.0, 164.1, 148.5, 136.3, 135.4, 132.6, 129.2, 121.0, 119.2, 118.5, 111.2, 37.8, 24.0,
20.4; HRMS (m/z): [M + H] calcd for C18H18 N3 O2 S2 372.0840, found 372.0797
2-((6-(quinoline-7-sulfonamido)benzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (32)
1
H NMR (500 MHz, CHLOROFORM-d) δ 9.59 (br. s., 1H), 9.22 (d, J = 2.99 Hz, 1H), 8.69 (br.
s., 1H), 8.35 (dd, J = 8.12, 9.83 Hz, 2H), 8.06 (d, J = 7.69 Hz, 1H), 7.68 (dd, J = 4.06, 8.33 Hz,
1H), 7.64 (d, J = 8.55 Hz, 1H), 7.60 (d, J = 7.69 Hz, 1H), 7.56 - 7.59 (m, 1H), 7.33 (d, J = 8.12
Hz, 2H), 7.29 (s, 1H), 7.07 (d, J = 8.12 Hz, 2H), 3.99 (s, 2H), 2.26 - 2.36 (m, 3H); 13C NMR
(101 MHz, DMSO-d6) δ 164.8, 151.5, 149.2, 142.7, 137.0, 136.2, 135.4, 135.0, 134.6, 134.3,
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132.5, 132.2, 129.2, 128.4, 125.6, 122.6, 121.1, 119.6, 119.2, 112.6, 52.9, 37.7, 20.4;
HRMS (m/z): [M + Na] calcd for C25H20N4O3S3Na, 543.0595; found 543.0584
2-((6-(4-fluorophenylsulfonamido)benzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (33)
1
H NMR (500 MHz, CHLOROFORM-d) δ 9.55 (br. s., 1H), 7.78 (dd, J = 5.77, 8.33 Hz, 3H),
7.62 (d, J = 1.71 Hz, 1H), 7.36 (d, J = 8.55 Hz, 2H), 7.08 - 7.17 (m, 4H), 6.78 (br. s., 1H), 4.06
(s, 2H), 2.30 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 166.0, 165.4, 163.5, 150.1, 136.7, 136.2,
136.0, 134.6, 133.0, 130.2, 129.6, 121.9, 120.7, 119.7, 117.0, 116.8, 114.1, 63.8, 38.2, 20.8;
HRMS (m/z): [M + H] calcd for C22H19 FN3 O3 S3 488.0573, found 488.0602
N-(p-tolyl)-2-((6-(4-(trifluoromethoxy)phenylsulfonamido)benzo[d]thiazol-2-yl)thio)
acetamide (34)
1
H NMR (400 MHz, CHLOROFORM-d) δ 9.60 (br. s., 1H), 7.80 (dd, J = 2.35, 8.80 Hz, 2H),
7.64 (d, J = 1.96 Hz, 1H), 7.36 (d, J = 8.22 Hz, 2H), 7.28 (br. s., 1H), 7.14 (d, J = 1.76 Hz, 1H),
7.10 (d, J = 8.41 Hz, 2H), 6.81 (br. s., 1H), 4.06 (s, 2H), 2.30 (s, 3H); 13C NMR (101 MHz,
DMSO-d6
119.2, 113.7, 63.2, 37.7, 20.4; HRMS (m/z): [M +H] calcd for C23H19 F3N3 O4 S3 553.0412,
found 553.0545
(R)-tert-butyl (3-methyl-1-oxo-1-((2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo [d]thiazol-6yl)amino)butan-2-yl)Carbamate (35)
1
H NMR (400 MHz, CHLOROFORM-d), δ 9.81 (s, 1H), 9.36 (br. s., 1H), 8.13 (br. s., 1H), 7.56
(d, J = 7.78 Hz, 1H), 7.36 - 7.43 (m, J = 8.28 Hz, 2H), 7.14 (d, J = 8.03 Hz, 1H), 7.04 - 7.11 (m,
J = 8.03 Hz, 2H), 5.54 (d, J = 8.03 Hz, 1H), 4.24 (t, J = 6.65 Hz, 1H), 3.90 - 4.09 (m, 2H), 2.26
(s, 3H), 2.14 (d, J = 19.07 Hz, 1H), 1.50 (s, 9H), 1.08 (d, J = 5.77 Hz, 6H); 13C NMR (101 MHz,
CDCl3) δ 171.11, 166.42, 165.92, 156.85, 148.23, 135.84, 135.51, 135.19, 133.92, 129.49,
120.47, 119.64, 118.59, 111.58, 80.55, 77.38, 77.07, 76.75, 61.14, 37.44, 30.91, 28.44, 20.86,
19.33, 18.64.
(R)-tert-butyl (2-oxo-2-((2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo[d]thiazol-6-yl)amino)1-phenylethyl)carbamate (36)
1
H NMR (400 MHz, DMSO-d6) δ 10.07 (br. s., 0H), 9.88 (br. s., 1H), 8.19 - 8.32 (m, 1H), 7.65
(d, J = 8.78 Hz, 1H), 7.38 - 7.48 (m, 3H), 7.34 (d, J = 8.53 Hz, 3H), 7.23 - 7.29 (m, 2H), 7.21 (d,
J = 6.53 Hz, 1H), 6.99 (d, J = 8.53 Hz, 2H), 6.20 (br. s., 1H), 5.43 (br. s., 1H), 4.06 (s, 3H), 3.42
(br. s., 1H), 2.93 - 2.99 (m, 1H), 2.20 (s, 3H), 1.36 (br. s., 9H); 13C NMR (101 MHz, DMSO-d6)
δ 165.1, 164.5, 148.2, 137.7, 135.3, 135.1, 135.0, 132.8, 128.6, 128.0, 127.3, 126.4, 120.2, 118.9,
118.8, 118.4, 111.3, 37.0, 27.6, 20.1
(R)-tert-butyl
(3-methyl-1-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6yl)amino)-1-oxobutan-2-yl)carbamate (37)
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.90 (br. s., 1H), 8.61 (s, 1H), 8.16 (br. s., 1H), 8.06
(d, J = 8.53 Hz, 1H), 7.96 (d, J = 8.03 Hz, 1H), 7.88 (t, J = 8.66 Hz, 2H), 7.59 - 7.65 (m, 1H),
7.56 (d, J = 7.53 Hz, 2H), 7.15 (d, J = 7.28 Hz, 1H), 5.37 (d, J = 7.78 Hz, 1H), 5.05 (d, J = 2.26
Hz, 2H), 4.16 (br. s., 1H), 2.19 (br. s., 1H), 1.47 (s, 9H), 1.05 (t, J = 5.77 Hz, 6H); 13C NMR
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(101 MHz, CHLOROFORM-d) δ 193.0, 170.7, 156.6, 149.4, 135.8, 134.5, 132.8, 132.4, 130.6,
129.7, 128.9, 128.7, 127.8, 127.0, 123.9, 121.1, 118.4, 111.8, 77.3, 77.2, 77.0, 76.7, 71.5, 41.2,
30.7, 28.4, 19.4
(R)-tert-butyl (2-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)amino)-2oxo-1-phenylethyl)carbamate (38)
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.63 (s, 1H), 8.27 (br. s., 1H), 8.14 (br. s., 1H), 8.09
(d, J = 8.28 Hz, 1H), 7.99 (d, J = 8.03 Hz, 1H), 7.90 (d, J = 8.53 Hz, 1H), 7.93 (d, J = 8.78 Hz,
1H), 7.63 (d, J = 8.03 Hz, 2H), 7.55 - 7.61 (m, 1H), 7.48 (d, J = 7.03 Hz, 2H), 7.37 (d, J = 7.78
Hz, 3H), 7.15 (d, J = 8.53 Hz, 1H), 5.77 (br. s., 1H), 5.42 (br. s., 1H), 5.06 (s, 2H), 1.45 (s, 9H)
(R)-2-amino-3-methyl-N-(2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo[d]thiazol-6-yl)
butanamide hydrochloride (39)
1
H NMR (400 MHz, MeOD) δ 8.39 (s, 1H), 7.77 (d, J = 8.78 Hz, 1H), 7.61 (d, J = 8.53 Hz, 1H),
7.44 (d, J = 8.03 Hz, 2H), 7.09 (d, J = 8.03 Hz, 2H), 4.32 (s, 2H), 3.97 (br. s., 1H), 2.27 (s, 3H),
1.13 (dd, J = 6.78, 12.80 Hz, 6H); 13C NMR (101 MHz, MeOD) δ 167.8, 166.8, 166.2, 147.6,
135.5, 135.1, 134.0, 129.0, 120.2, 119.9, 119.5, 112.3, 60.9, 59.0, 37.6, 30.4, 19.6, 17.7, 16.6;
HRMS (m/z): [M + Na] calcd for C21H24N4O2S2 Na 451.5601, found 451.1238
(R)-2-amino-N-(2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo[d]thiazol-6-yl)-2-phenyl
acetamide hydrochloride (40)
1
H NMR (400 MHz, MeOD) δ 8.26 - 8.37 (m, 1H), 7.69 (d, J = 8.78 Hz, 1H), 7.65 - 7.67 (m,
1H), 7.64 (br. s., 1H), 7.51 (d, J = 1.76 Hz, 4H), 7.42 (d, J = 8.28 Hz, 2H), 7.09 (d, J = 8.03 Hz,
2H), 5.24 (s, 1H), 4.27 (s, 2H), 2.26 (s, 3H); 13C NMR (101 MHz, MeOD) δ 168.8, 167.8, 167.4,
149.5, 137.0, 136.8, 136.7, 135.5, 134.2, 131.4, 130.7, 130.5, 129.6, 121.8, 121.8, 120.7, 113.6,
58.6, 38.9, 21.1; HRMS (m/z): [M + Na] calcd for C24H22N4ClO2S2Na 521.0298, found
521.0345
(R)-3-methyl-1-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)amino)-1oxobutan-2-aminium chloride (41)
1
H NMR (400 MHz, DMSO-d6) δ 11.36 (br. s., 1H), 8.86 (s, 1H), 8.48 (br. s., 2H), 8.42 (s, 1H),
8.15 (d, J = 8.03 Hz, 1H), 7.98 - 8.09 (m, 3H), 7.60 - 7.76 (m, 3H), 5.23 - 5.36 (m, 2H), 3.99 (br.
s., 1H), 2.15 - 2.33 (m, 1H), 1.01 (d, J = 6.53 Hz, 6H); 13C NMR (101 MHz, DMSO-d6) δ 192.9,
167.0, 164.7, 149.0, 135.5, 135.3, 135.1, 132.7, 132.1, 130.8, 129.7, 129.0, 128.5, 127.8, 127.2,
123.7, 121.2, 118.9, 111.9, 66.4, 58.0, 41.1, 30.0, 18.5, 18.0; HRMS (m/z): [M + Na] calcd for
C24H24 N3ClO2S2Na 508.0311, found 508.0896
(R)-2-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)amino)-2-oxo-1phenylethanaminium chloride (42)
1
H NMR (400 MHz, DMSO-d6) d 11.50 (br. s., 1H), 8.93 (br. s., 3H), 8.86 (br. s., 1H), 8.37 (s,
1H), 8.16 (d, J = 7.78 Hz, 1H), 7.98 - 8.09 (m, 3H), 7.67 - 7.79 (m, 5H), 7.59 - 7.67 (m, 2H),
7.45 (d, J = 7.53 Hz, 3H), 5.28 (s, 2H); 13C NMR (101 MHz, DMSO-d6) d 192.8, 166.1, 149.1,
145.5, 135.5, 135.3, 135.0, 133.7, 132.6, 132.1, 130.7, 129.7, 129.3, 129.0, 128.9, 128.5, 127.9,
127.8, 127.2, 123.7, 121.2, 118.7, 111.8, 66.4, 41.0; HRMS (m/z): [M + Na] calcd for
C27H22N3O2S2Na 507.6017, found 507.1051
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 Application of decision capture protocol to generate easily interpretable graphical views
to visualize the screening tree, most relevant assays and highly profiled compounds for the
project of interest
 Understanding the role of waters in binding affinity of PARP inhibitors.
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Summer Trainee, University of North Carolina, Chapel Hill, NC, June 1st – July 31st, 2009
 Hands on various QSAR approaches such as K-Nearest Neighborhood method, Support
Vector Machine. Mentor: Dr. Alexander Tropsha
Research Assistant, University of Mississippi, Oxford, MS, August 2006-present
 Employed virtual screening to identify drug-like small molecule inhibitors of parasitic
cysteine proteases (malaria, leishmania) using targeted cysteine protease compound library
generated based on soft-electrophiles of interest.
 Carried out substructure/similarity searching to identify the analogs of virtual screening
hits. Structure-based optimization of obtained hits and development of combinatorial
library of selected compounds.
 Solvent thermodynamic analysis Falcipain Ligand binding domain, to gain insight in to
structure-activity relationships of FP-2 hits
 Performed de novo design and docking studies of plasmodial cysteine protease inhibitors of
falcipain-II (malaria), and viral cysteine protease (SARS 3CLpro).
 Performed scoring-based enrichment studies for falcipain-2 (Malarial cysteine protease)
inhibitors.
 Calculation of LUMO density for predicting the most electrophilic centers in the cysteine
protease inhibitors
 Investigate the binding mode of Bcl-xL (anticancer target) inhibitors through steered
molecular dynamics study and conventional molecular dynamics approach.
 Conducted QSAR study of artemisinin analogs (malaria) and arylpiperazines class of 5HT1A receptor antagonists (depression). Developed Multiple Linear Regression (MLR),
Support Vector machine (SVM) and K-Nearest Neighbor (KNN) classification models for
artemisinin and its derivatives.
 Performed pharmacophore modeling of angiotensin-II type-I (AT1) and dual AT1-PPARγ
ligands.
 Developed homology model of 5-HT1A and TXA2 receptor (GPCRs).
 Synthesized (4 step) small molecule library containing benzthizaole scaffold as novel
malarial cysteine protease inhibitors and 2-napthyloxyethylamines derivatives as 5-HT1A
receptor antagonists.
 Design of hypothesis and protocol for the validation of proposed artemisinin mechanism
through inhibition of PfATP6-SERCA.
 Defended Original Research Proposal (NIH, R01) entitled “Targeting Influenza A virus
(H1N1, H3N2, H5N1): Development of Cap-Dependent Endonuclease inhibitors as new
Anti-Influenza therapeutics” as a part of Ph.D. curriculum.
TECHNICAL SKILLS



Structure-based modeling: Homology modeling and refinement, pose-validation,
enrichment, structure-based virtual screening of commercial database, receptor-based
pharmacophore and structure-based drug design,
Ligand-based modeling: 2D/3D QSAR, pharmacophore modeling and screening, clustering,
diversity analysis, similarity/substructure searching, property-based filtration, database
handling, ADME/Toxicity modeling
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Simulation techniques: WaterMap analysis, Conformational analysis, Molecular Dynamics
simulation and Steered Molecular Dynamics simulation
Synthetics: Synthesis of library of small molecules bearing benzthiazole and substituted 2napthyloxyethylamines scaffold, olefination reactions, peptide coupling etc.
Programming skills: shell scripting, scripting languages such as python, ICM reference
language, pilot scripting, SQL

MODELING TOOLS AND SOFTWARE






Pipeline Pilot, Discovery studio, Spotfire
Schrodinger:- Glide, WaterMap, Phase, Canvas, Desmond, Macromodel, Impact, Prime,
Strike, QikProp, Jaguar
ICM:- 4D docking, APF, QSAR modeling
Sybyl, MOE, GOLD, Catalyst
Miscellaneous: NAMD, WEKA, LIBSVM, ISIDA, PYMOL, VMD, ChemOffice Ultra, Enotebook

AWARDS/AFFILIATION
 CCG Excellence Student Travel Award, Fall 2011, ACS meeting at Denver.
 Travel award for Practical Computing Biologist workshop organized by NESCent
Academy at University of North Carolina, Raleigh, June 5th to June 15th, 2011.
 American Chemical Society’s Ole Miss Local Section‟s Graduate Student Research
Award in the Pharmaceutical Sciences for year 2011.
 NIH Pre-Doctoral Fellowship, NIH Center of Biomedical Research Excellence (COBRE),
2009-2010, “Potential of artemisinin and its derivatives in the treatment of brain cancer and
neurological manifestations of Malaria: Design of novel artemisinin derivatives using QSAR
models, prediction of pharmacokinetic properties and insight into the mechanism of the action
of this class of drugs”.
 Research Grant Award, Graduate Student Council, University of Mississippi, 2008-09,
“Design of small molecule reversible inhibitors of cathepsin K for the treatment of
osteoporosis using computer aided drug designing”
 Scholarship for Academic Excellence, Sir Ratan Tata and J. R. D. Tata Trust, Mumbai,
India, 2004-05.
 Junior Research Fellowship, All India Council For Technical Education, 2003-2004
 Professional affiliation: American Chemical Society (COMP, MEDI), Royal Society of
Chemistry (AMRSC), Rho chi chapter at Olemiss, University of Mississippi.
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